<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews - Shepherd, E - 2017 | Cochrane Library</title> <meta content="Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews - Shepherd, E - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012077.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews - Shepherd, E - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012077.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012077.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews" name="citation_title"/> <meta content="Emily Shepherd" name="citation_author"/> <meta content="The University of Adelaide" name="citation_author_institution"/> <meta content="emily.shepherd@adelaide.edu.au" name="citation_author_email"/> <meta content="Rehana A Salam" name="citation_author"/> <meta content="Philippa Middleton" name="citation_author"/> <meta content="Maria Makrides" name="citation_author"/> <meta content="Healthy Mothers, Babies and Children, South Australian Health and Medical Research Institute" name="citation_author_institution"/> <meta content="Sarah McIntyre" name="citation_author"/> <meta content="University of Sydney" name="citation_author_institution"/> <meta content="Nadia Badawi" name="citation_author"/> <meta content="Caroline A Crowther" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD012077.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/08/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012077.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012077.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012077.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Parturition; Antibiotic Prophylaxis; Cerebral Palsy [epidemiology, *prevention &amp; control]; Fetal Distress [therapy]; Hypertension [therapy]; Infant, Premature; Magnesium Sulfate [therapeutic use]; Neuroprotective Agents [therapeutic use]; Pre‐Eclampsia [therapy]; Pregnancy Complications, Cardiovascular [therapy]; Premature Birth [prevention &amp; control]; Prenatal Care [*methods]; Randomized Controlled Trials as Topic; Review Literature as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012077.pub2&amp;doi=10.1002/14651858.CD012077.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="QO4KtYGW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012077\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012077\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012077.pub2",title:"Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews",firstPublishedDate:"Aug 8, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012077.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012077.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012077.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012077.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012077.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012077.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012077.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012077.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012077.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012077.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8045 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012077.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-sec-0067"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-sec-0025"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-sec-0026"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-sec-0061"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/appendices#CD012077-sec-0072"> Search strategies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Overview</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information#CD012077-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Emily Shepherd</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information#CD012077-cr-0003">Rehana A Salam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information#CD012077-cr-0004">Philippa Middleton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information#CD012077-cr-0005">Maria Makrides</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information#CD012077-cr-0006">Sarah McIntyre</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information#CD012077-cr-0007">Nadia Badawi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information#CD012077-cr-0008">Caroline A Crowther</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information/en#CD012077-sec-0076">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 August 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012077.pub2">https://doi.org/10.1002/14651858.CD012077.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012077-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012077-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012077-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012077-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012077-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012077-abs-0001" lang="en"> <section id="CD012077-sec-0001"> <h3 class="title" id="CD012077-sec-0001">Background</h3> <p>Cerebral palsy is an umbrella term encompassing disorders of movement and posture, attributed to non‐progressive disturbances occurring in the developing fetal or infant brain. As there are diverse risk factors and causes, no one strategy will prevent all cerebral palsy. Therefore, there is a need to systematically consider all potentially relevant interventions for their contribution to prevention. </p> </section> <section id="CD012077-sec-0002"> <h3 class="title" id="CD012077-sec-0002">Objectives</h3> <p>To summarise the evidence from Cochrane reviews regarding the effects of antenatal and intrapartum interventions for preventing cerebral palsy. </p> </section> <section id="CD012077-sec-0003"> <h3 class="title" id="CD012077-sec-0003">Methods</h3> <p>We searched the <i>Cochrane Database of Systematic Reviews</i> on 7 August 2016, for reviews of antenatal or intrapartum interventions reporting on cerebral palsy. Two authors assessed reviews for inclusion, extracted data, assessed review quality, using AMSTAR and ROBIS, and quality of the evidence, using the GRADE approach. We organised reviews by topic, and summarised findings in text and tables. We categorised interventions as effective (high‐quality evidence of effectiveness); possibly effective (moderate‐quality evidence of effectiveness); ineffective (high‐quality evidence of harm or of lack of effectiveness); probably ineffective (moderate‐quality evidence of harm or of lack of effectiveness); and no conclusions possible (low‐ to very low‐quality evidence). </p> </section> <section id="CD012077-sec-0004"> <h3 class="title" id="CD012077-sec-0004">Main results</h3> <p>We included 15 Cochrane reviews. A further 62 reviews pre‐specified the outcome cerebral palsy in their methods, but none of the included randomised controlled trials (RCTs) reported this outcome. The included reviews were high quality and at low risk of bias. They included 279 RCTs; data for cerebral palsy were available from 27 (10%) RCTs, involving 32,490 children. They considered interventions for: treating mild to moderate hypertension (two) and pre‐eclampsia (two); diagnosing and preventing fetal compromise in labour (one); preventing preterm birth (four); preterm fetal maturation or neuroprotection (five); and managing preterm fetal compromise (one). Quality of evidence ranged from very low to high. </p> <p><b><i>Effective interventions: high‐quality evidence of effectiveness</i> </b> </p> <p>There was a reduction in cerebral palsy in children born to women at risk of preterm birth who received magnesium sulphate for neuroprotection of the fetus compared with placebo (risk ratio (RR) 0.68, 95% confidence interval (CI) 0.54 to 0.87; five RCTs; 6145 children). </p> <p><b><i>Probably ineffective interventions: moderate‐quality evidence of harm</i> </b> </p> <p>There was an increase in cerebral palsy in children born to mothers in preterm labour with intact membranes who received any prophylactic antibiotics versus no antibiotics (RR 1.82, 95% CI 0.99 to 3.34; one RCT; 3173 children). There was an increase in cerebral palsy in children, who as preterm babies with suspected fetal compromise, were born immediately compared with those for whom birth was deferred (RR 5.88, 95% CI 1.33 to 26.02; one RCT; 507 children). </p> <p><b><i>Probably ineffective interventions: moderate‐quality evidence of lack of effectiveness</i> </b> </p> <p>There was no clear difference in the presence of cerebral palsy in children born to women at risk of preterm birth who received repeat doses of corticosteroids compared with a single course (RR 1.03, 95% CI 0.71 to 1.50; four RCTs; 3800 children). </p> <p><b><i>No conclusions possible: low‐ to very low‐quality evidence</i> </b> </p> <p>Low‐quality evidence found there was a possible reduction in cerebral palsy for children born to women at risk of preterm birth who received antenatal corticosteroids for accelerating fetal lung maturation compared with placebo (RR 0.60, 95% CI 0.34 to 1.03; five RCTs; 904 children). There was no clear difference in the presence of cerebral palsy with interventionist care for severe pre‐eclampsia versus expectant care (RR 6.01, 95% CI 0.75 to 48.14; one RCT; 262 children); magnesium sulphate for pre‐eclampsia versus placebo (RR 0.34, 95% CI 0.09 to 1.26; one RCT; 2895 children); continuous cardiotocography for fetal assessment during labour versus intermittent auscultation (average RR 1.75, 95% CI 0.84 to 3.63; two RCTs; 13,252 children); prenatal progesterone for prevention of preterm birth versus placebo (RR 0.14, 95% CI 0.01 to 3.48; one RCT; 274 children); and betamimetics for inhibiting preterm labour versus placebo (RR 0.19, 95% CI 0.02 to 1.63; one RCT; 246 children). </p> <p>Very low‐quality found no clear difference for the presence of cerebral palsy with any antihypertensive drug (oral beta‐blockers) for treatment of mild to moderate hypertension versus placebo (RR 0.33, 95% CI 0.01 to 8.01; one RCT; 110 children); magnesium sulphate for prevention of preterm birth versus other tocolytic agents (RR 0.13, 95% CI 0.01 to 2.51; one RCT; 106 children); and vitamin K and phenobarbital prior to preterm birth for prevention of neonatal periventricular haemorrhage versus placebo (RR 0.77, 95% CI 0.33 to 1.76; one RCT; 299 children). </p> </section> <section id="CD012077-sec-0005"> <h3 class="title" id="CD012077-sec-0005">Authors' conclusions</h3> <p>This overview summarises evidence from Cochrane reviews on the effects of antenatal and intrapartum interventions on cerebral palsy, and can be used by researchers, funding bodies, policy makers, clinicians and consumers to aid decision‐making and evidence translation. We recommend that readers consult the included Cochrane reviews to formally assess other benefits or harms of included interventions, including impacts on risk factors for cerebral palsy (such as the reduction in intraventricular haemorrhage for preterm babies following exposure to antenatal corticosteroids). </p> <p>Magnesium sulphate for women at risk of preterm birth for fetal neuroprotection can prevent cerebral palsy. Prophylactic antibiotics for women in preterm labour with intact membranes, and immediate rather than deferred birth of preterm babies with suspected fetal compromise, may increase the risk of cerebral palsy. Repeat doses compared with a single course of antenatal corticosteroids for women at risk of preterm birth do not clearly impact the risk of cerebral palsy. </p> <p>Cerebral palsy is rarely diagnosed at birth, has diverse risk factors and causes, and is diagnosed in approximately one in 500 children. To date, only a small proportion of Cochrane reviews assessing antenatal and intrapartum interventions have been able to report on this outcome. There is an urgent need for long‐term follow‐up of RCTs of interventions addressing risk factors for cerebral palsy, and consideration of the use of relatively new interim assessments (including the General Movements Assessment). Such RCTs must be rigorous in their design, and aim for consistency in cerebral palsy outcome measurement and reporting to facilitate pooling of data, to focus research efforts on prevention. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012077-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012077-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012077-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012077-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012077-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012077-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012077-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012077-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012077-abs-0003" lang="en"> <h3>Interventions during pregnancy and childbirth for preventing cerebral palsy: an overview of Cochrane reviews </h3> <p><b>What is the issue?</b> </p> <p>Cerebral palsy is a term that includes a group of conditions affecting people's ability to move, and is the most common physical disability in childhood. Cerebral palsy is usually due to events before, during, or after childbirth that lead to injury in babies' developing brains. There is no single cause of cerebral palsy. For many children, the cause of cerebral palsy is unclear, however, there are many known risk factors. The biggest risk factor is birth before 37 weeks of pregnancy (preterm birth). Other risk factors for mothers include some medical conditions (including thyroid problems), abnormalities of the placenta, pre‐eclampsia (high blood pressure and protein in the urine), and some bacterial and viral infections. For babies, risk factors include congenital and genetic abnormalities, having a low birthweight or growth restricted as a fetus, being a twin or triplet, some infections, and prolonged loss of oxygen during birth. </p> <p><b>Why is this important?</b> </p> <p>As there are different risk factors and causes for cerebral palsy, it is likely that various different interventions (treatments) may be needed to prevent cerebral palsy by reducing risk factors. This overview summarises the evidence about preventing cerebral palsy from Cochrane reviews of interventions during pregnancy and childbirth. </p> <p><b>What evidence did we find?</b> </p> <p>We searched for evidence on 7 August 2016. We identified 15 Cochrane reviews that assessed interventions during pregnancy or childbirth that reported on cerebral palsy, with information from 27 randomised controlled trials involving 32,490 children. The reviews were all high quality, but the quality of the evidence about cerebral palsy ranged from very low to high. </p> <p>The interventions assessed were for treating mild to moderate hypertension (two reviews), treating pre‐eclampsia (two reviews), diagnosing or preventing fetal compromise (when the unborn baby may not be well) during labour (one review), preventing preterm birth (four reviews), maturing or protecting babies' lungs or brains before preterm birth (five reviews), and managing fetal compromise of preterm babies (one review). </p> <p>We found high‐quality evidence that one intervention was effective for cerebral palsy prevention: preterm children born to mothers who received magnesium sulphate before birth were less likely to develop cerebral palsy than children whose mothers received a placebo (five trials, 6145 children). </p> <p>We found moderate‐quality evidence that two interventions were probably ineffective, and could cause harm: (i) children born to mothers who had received antibiotics for preterm labour when their waters had not broken were more likely to develop cerebral palsy than children whose mothers did not receive antibiotics (one trial, 3173 children); and (ii) preterm children who were born immediately when there was suspected fetal compromise were more likely to develop cerebral palsy than those for whom birth was postponed (one trial, 507 children). </p> <p>We found moderate‐quality evidence that there was no clear difference in the chance of children to develop cerebral palsy whether their mothers received one or more courses of corticosteroids before preterm birth (four trials, 3800 children). </p> <p>There was low‐quality evidence as to whether the other interventions prevented, increased, or had no impact on cerebral palsy, although we did find that children born to mothers who received corticosteroids to help mature their lungs before preterm birth were potentially less likely to develop cerebral palsy than those born to mothers who received a placebo (five trials, 904 children). </p> <p><b>What does this mean?</b> </p> <p>We identified one intervention that was effective in preventing cerebral palsy (magnesium sulphate before preterm birth), two that appeared to cause harm (preventive antibiotics for women in preterm labour when their waters have not broken, and immediate birth for preterm babies with suspected compromise), and one that did not appear to make a clear difference (more than one course of corticosteroids before preterm birth). For the other interventions assessed, there was not enough evidence to reach any conclusions. Further good quality randomised controlled trials, assessing interventions that might impact cerebral palsy risk factors, with long‐term follow‐up to measure cerebral palsy, are needed. We identified over 60 other Cochrane reviews that may provide more information in the future. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012077-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012077-sec-0067"></div> <section id="CD012077-sec-0068"> <p> <h5 class="title">Implications for practice</h5> <section id="CD012077-sec-0069"> <p>This overview summarises the evidence from Cochrane reviews of randomised controlled trials regarding the effects of antenatal and intrapartum intervention on cerebral palsy, and can be used by researchers, funding bodies, policy makers, clinicians, and consumers to aid decision‐making and evidence translation. </p> <p>There is high‐quality evidence that magnesium sulphate for neuroprotection of the fetus, given to women at risk of preterm birth, can prevent cerebral palsy better than placebo. Moderate‐quality evidence shows that any prophylactic antibiotics for women in preterm labour with intact membranes may increase the risk of cerebral palsy more than no antibiotics. Moderate‐quality evidence shows that immediate birth of preterm babies with suspected fetal compromise may increase the risk of cerebral palsy more than deferred birth. There is moderate‐quality evidence showing no clear difference in the risk of cerebral palsy between repeat doses of corticosteroids and a single course for women at risk of preterm birth. No conclusions were possible for other interventions assessed in this overview, because of low‐ to very‐low quality evidence. </p> <p>The scope of this overview was limited to the effects of interventions on cerebral palsy, and pre‐specified secondary review outcomes. Consultation of the included Cochrane reviews is required to formally assess additional benefits and harms of these interventions, including impacts on risk factors for cerebral palsy, (such as the reduction in intraventricular haemorrhage for preterm babies following exposure to antenatal corticosteroids). </p> </section> </p> <p> <h5 class="title">Implications for research</h5> <section id="CD012077-sec-0070"> <p>This overview highlights areas where there was insufficient evidence to draw conclusions on the effects of several antenatal and intrapartum interventions on cerebral palsy, and it should be used to generate research questions and priorities. As cerebral palsy is rarely diagnosed at birth, has diverse risk and causal factors, and is diagnosed in approximately one in 500 children, it is a challenging outcome for investigators of such interventions to measure and report. To date, a small proportion of Cochrane reviews assessing antenatal and intrapartum interventions have been able to report on cerebral palsy, which may be due to a number of reasons, including: a lack of primary research (with few randomised trials of antenatal and intrapartum interventions conducting long‐term follow‐up of children), lack of reporting on cerebral palsy by randomised trials, lack of reporting on cerebral palsy by relevant Cochrane reviews (due to not pre‐specifying it as an outcome of interest, not clearly defining long‐term follow‐up results, or not being 'up‐to‐date'), or the absence of Cochrane reviews assessing relevant interventions. </p> <p>With greater understanding of the diverse risk factors and causes of cerebral palsy, there is an urgent need for long‐term follow‐up of interventions addressing risk factors for cerebral palsy, as well as a need to consider the use of relatively new interim assessments (such as the General Movements Assessment), to measure impact on cerebral palsy. Such studies must be rigorous in their design, and aim for consistency in cerebral palsy outcome measurement and reporting to facilitate pooling of outcome data, therefore, informing research efforts aimed at prevention of cerebral palsy. </p> </section> </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012077-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012077-sec-0016"></div> <section id="CD012077-sec-0017"> <h3 class="title" id="CD012077-sec-0017">Description of the condition</h3> <section id="CD012077-sec-0018"> <h4 class="title">Cerebral palsy: definition and prevalence</h4> <p>Cerebral palsy was originally defined by clinical description, at a time when there was little knowledge of causes, risk factors, or pathology. Discussion on the definition and classification was first recorded in English, French, and German medical literature in the nineteenth century; for over 150 years, there has been debate about what the term ‘cerebral palsy’ actually describes (<a href="./references#CD012077-bbs2-0095" title="MorrisC . Definition and classification of cerebral palsy: a historical perspective. Developmental Medicine &amp; Child Neurology2007;49:3‐7. ">Morris 2007</a>). Definitions adopted by international cerebral palsy registries have commonly included those proposed by Bax in the 1960s (<a href="./references#CD012077-bbs2-0054" title="BaxMCO . Terminology and classification of cerebral palsy. Developmental Medicine &amp; Child Neurology1964;6(3):295‐7. ">Bax 1964</a>), Mutch and colleagues in the 1990s (<a href="./references#CD012077-bbs2-0096" title="MutchL , AlbermanE , HagbergB , KodamaK , PeratMV . Cerebral palsy epidemiology: where are we now and where are we going?. Developmental Medicine &amp; Child Neurology1992;34(6):547‐51. ">Mutch 1992</a>), and more recently, by Rosenbaum and colleagues (a revised version of <a href="./references#CD012077-bbs2-0054" title="BaxMCO . Terminology and classification of cerebral palsy. Developmental Medicine &amp; Child Neurology1964;6(3):295‐7. ">Bax 1964</a>): "Cerebral palsy describes a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to non‐progressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cognition, communication, and behaviour, by epilepsy, and by secondary musculoskeletal problems" (<a href="./references#CD012077-bbs2-0110" title="RosenbaumP , PanethN , LevitonA , GoldsteinM , BaxM , DamianoD , et al. A report: the definition and classification of cerebral palsy April 2006. Developmental Medicine and Child Neurology Supplement2007;109:8‐14. ">Rosenbaum 2007</a>). </p> <p>Today, cerebral palsy is still a clinical description, but registries and surveillance programmes, such as those in Australia, the United Kingdom, and Europe, highlight five key elements that reflect the core features of cerebral palsy, provided in definitions, and proposed by the Surveillance of Cerebral Palsy in Europe (SCPE): (i) it is an ‘umbrella term’; (ii) it is permanent but not unchanging; (iii) it involves a disorder of movement, posture, motor function, or a combination; (iv) it is due to a non‐progressive interference, lesion, or abnormality; and (v) the interference, lesion, or abnormality arose in the developing or immature brain (<a href="./references#CD012077-bbs2-0059" title="CansC . Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Developmental Medicine &amp; Child Neurology2000;42(12):816‐24. ">Cans 2000</a>; <a href="./references#CD012077-bbs2-0096" title="MutchL , AlbermanE , HagbergB , KodamaK , PeratMV . Cerebral palsy epidemiology: where are we now and where are we going?. Developmental Medicine &amp; Child Neurology1992;34(6):547‐51. ">Mutch 1992</a>; <a href="./references#CD012077-bbs2-0110" title="RosenbaumP , PanethN , LevitonA , GoldsteinM , BaxM , DamianoD , et al. A report: the definition and classification of cerebral palsy April 2006. Developmental Medicine and Child Neurology Supplement2007;109:8‐14. ">Rosenbaum 2007</a>; <a href="./references#CD012077-bbs2-0118" title="Smithers‐SheedyH , BadawiN , BlairE , CansC , HimmelmannK , Krägeloh‐MannI , et al. What constitutes cerebral palsy in the twenty‐first century?. Developmental Medicine and Child Neurology2014;56:323‐8. ">Smithers‐Sheedy 2014</a>). As cerebral palsy is defined by clinical description, which may change over time, a longer time span for diagnosis is considered useful to confirm that the condition meets the criteria for cerebral palsy, and to accurately describe the motor impairment. Thus, final ascertainment for surveillance programmes across the world range from four to 12 years, with many considering data to be 'complete' at or near five years (<a href="./references#CD012077-bbs2-0118" title="Smithers‐SheedyH , BadawiN , BlairE , CansC , HimmelmannK , Krägeloh‐MannI , et al. What constitutes cerebral palsy in the twenty‐first century?. Developmental Medicine and Child Neurology2014;56:323‐8. ">Smithers‐Sheedy 2014</a>). While average age for diagnosis has been around 18 months, recent evidence has suggested that cerebral palsy may be reliably detected in high‐risk infants as early as three to four months post‐term age, using tests such as Prechtl's General Movements Assessment and medical resonance imaging (<a href="./references#CD012077-bbs2-0058" title="BosanquetM , CopelandL , WareR , BoydR . A systematic review of tests to predict cerebral palsy in young children. Developmental Medicine and Child Neurology2013;55(5):418‐26. ">Bosanquet 2013</a>; <a href="./references#CD012077-bbs2-0093" title="MorganC , CrowleC , GoyenT‐A , HardmanC , JackmanM , NovakI , et al. Sensitivity and specificity of General Movements Assessment for diagnostic accuracy of detecting cerebral palsy early in an Australian context. Journal of Paediatrics and Child Health2016;52(1):54‐9. ">Morgan 2016</a>). </p> <p>Cerebral palsy can be described by its motor type and body parts distribution (topography). Primary and secondary motor types include spasticity, dyskinesia, ataxia, and hypotonia, which are determined by a combination of structured neurological and motor assessments, with observations sometimes corroborated by imaging findings (<a href="https://archie.cochrane.org/sections/documents/view?version=z1506102316117587477552126264219%26format=REVMAN#REF-Cans-2000" target="_blank">Cans 2000</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1506102316117587477552126264219%26format=REVMAN#REF-Rosenbaum-2007" target="_blank">Rosenbaum 2007</a>; <a href="./references#CD012077-bbs2-0112" title="SangerTD , DelgadoMR , Gaebler‐SpiraD , HallettM , MinkJW , Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics2003;111(1):e89‐97. ">Sanger 2003</a>). Spasticity is the predominant primary motor type. Frequently used terms to describe the topography are hemiplegia (unilateral involvement), diplegia (bilateral involvement), with the lower limbs more affected than the upper limbs, and quadriplegia (bilateral involvement), with the upper limbs more or equally involved. Monoplegia and triplegia are occasionally reported as separate entities, or grouped with hemiplegia and quadriplegia, respectively (<a href="./references#CD012077-bbs2-0077" title="HowardJ , SooB , GrahamHK , BoydRN , ReidS , LaniganA , et al. Cerebral palsy in Victoria: motor types, topography and gross motor function. Journal of Paediatrics and Child Health2005;41(9‐10):479‐83. ">Howard 2005</a>; <a href="./references#CD012077-bbs2-0113" title="SankarC , MundkurN . Cerebral palsy‐definition, classification, etiology and early diagnosis. Indian Journal of Pediatrics2005;72(10):865‐8. ">Sankar 2005</a>). </p> <p>Today, the Gross Motor Function Classification System (GMFCS) is used internationally as the principal way to classify gross motor function (<a href="./references#CD012077-bbs2-0094" title="MorrisC , BartlettD . Gross Motor Function Classification System: impact and utility. Developmental Medicine &amp; Child Neurology2004;46:60‐5. ">Morris 2004</a>; <a href="./references#CD012077-bbs2-0104" title="PalisanoR , RosenbaumP , WalterS , RussellD , WoodE , GaluppiB . Development and reliability of a system to classify gross motor function in children with cerebral palsy. Developmental Medicine &amp; Child Neurology1997;39(4):214‐23. ">Palisano 1997</a>; <a href="./references#CD012077-bbs2-0124" title="WoodE , RosenbaumP . The gross motor function classification system for cerebral palsy: a study of reliability and stability over time. Developmental Medicine &amp; Child Neurology2000;42:292‐6. ">Wood 2000</a>). It describes the gross movement ability of children in one of five ordinal levels, and provides descriptions for each level across five age bands: less than two years; two to four years; four to six years; six to 12 years; 12 to 18 years (<a href="./references#CD012077-bbs2-0124" title="WoodE , RosenbaumP . The gross motor function classification system for cerebral palsy: a study of reliability and stability over time. Developmental Medicine &amp; Child Neurology2000;42:292‐6. ">Wood 2000</a>). Unlike classifications based on motor type and topography, the GMFCS has been shown to be a valid, reliable, stable, and clinically relevant method for classification, and in conjunction with the Gross Motor Function Measure (GMFM), for prediction (after the age of two) of motor function in cerebral palsy (<a href="./references#CD012077-bbs2-0104" title="PalisanoR , RosenbaumP , WalterS , RussellD , WoodE , GaluppiB . Development and reliability of a system to classify gross motor function in children with cerebral palsy. Developmental Medicine &amp; Child Neurology1997;39(4):214‐23. ">Palisano 1997</a>; <a href="./references#CD012077-bbs2-0124" title="WoodE , RosenbaumP . The gross motor function classification system for cerebral palsy: a study of reliability and stability over time. Developmental Medicine &amp; Child Neurology2000;42:292‐6. ">Wood 2000</a>). The Manual Ability Classification System (MACS) provides a method analogous to the GMFCS for assessing the ability of children with cerebral palsy to handle objects (<a href="./references#CD012077-bbs2-0067" title="EliassonAC , Krumlinde‐SundholmL , RösbladB , BeckungE , ArnerM , OhrvallAM , et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Developmental Medicine &amp; Child Neurology2006;48:549‐54. ">Eliasson 2006</a>), and the Communication Function Classification System (CFCS) assists in evaluating the communication capacity in real‐life situations for children with cerebral palsy (<a href="./references#CD012077-bbs2-0072" title="HideckerMJC , PanethN , RosenbaumPL , KentRD , LillieJ , EulenbergJB , et al. Developing and validating the Communication Function Classification System for individuals with cerebral palsy. Developmental Medicine &amp; Child Neurology2011;53(8):704‐10. ">Hidecker 2011</a>). One can draw a comprehensive picture of functional performance in daily life for individuals with cerebral palsy by using the GMFCS, MACS, and CFCS together, to inform both research and clinical practice (<a href="./references#CD012077-bbs2-0064" title="CompagnoneE , ManiglioJ , CamposeoS , VespinoT , LositoL , DeRinaldisM , et al. Functional classifications for cerebral palsy: correlations between the gross motor function classification system (GMFCS), the manual ability classification system (MACS) and the communication function classification system (CFCS). Research in Developmental Disabilities2014;35(11):2651‐7. ">Compagnone 2014</a>; <a href="./references#CD012077-bbs2-0073" title="HideckerMJ , HoNT , DodgeN , HurvitzEA , SlaughterJ , Workinger MS, et al. Inter‐relationships of functional status in cerebral palsy: analyzing gross motor function, manual ability, and communication function classification systems in children. Developmental Medicine and Child Neurology2012;54(8):737‐42. ">Hidecker 2012</a>). </p> <p>Despite variation in definitions and classifications of cerebral palsy, there is wide agreement that it is the most common physical disability in childhood. In a recent meta‐analysis of 19 studies, the global pooled birth prevalence was 2.11 per 1000 live births (95% confidence interval 1.98 to 2.25); a cumulative meta‐analysis demonstrated stability in the prevalence over the past 10 years (<a href="./references#CD012077-bbs2-0100" title="OskouiM , CoutinhoF , DykemanJ , JettéN , PringsheimT . An update on the prevalence of cerebral palsy: a systematic review and meta‐analysis. Developmental Medicine &amp; Child Neurology2013;55(6):509‐19. ">Oskoui 2013</a>). Similar trends and relative stability of rates over time have been shown in geographical regions "with CP Registers" that have used consistent methods of ascertainment, with most published estimates of total population birth prevalence around two per 1000 live births (<a href="./references#CD012077-bbs2-0057" title="BlairE , WatsonL . Epidemiology of cerebral palsy. Seminars in Fetal and Neonatal Medicine2006;11:117‐25. ">Blair 2006</a>). In low‐ and middle‐income countries, birth prevalence estimates have tended to be in a similar range, or higher, but it is difficult to meaningfully compare rates, since very few of these countries use registries or surveillance programmes (<a href="./references#CD012077-bbs2-0057" title="BlairE , WatsonL . Epidemiology of cerebral palsy. Seminars in Fetal and Neonatal Medicine2006;11:117‐25. ">Blair 2006</a>; <a href="./references#CD012077-bbs2-0059" title="CansC . Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Developmental Medicine &amp; Child Neurology2000;42(12):816‐24. ">Cans 2000</a>; <a href="./references#CD012077-bbs2-0063" title="ColverA , FairhurstC , PharoahPO . Cerebral palsy. Lancet2014;383:1240‐9. ">Colver 2014</a>). However, there is now emerging evidence, including from Australia and Europe, that birth prevalence and severity of the condition are starting to decline for the first time (<a href="./references#CD012077-bbs2-0106" title="ReidSM , MeehanE , McIntyreS , GoldsmithS , BadawiN , ReddihoughDS , the Australian Cerebral Palsy Register Group. Temporal trends in cerebral palsy by impairment severity and birth gestation. Developmental Medicine and Child Neurology2016;58(Suppl 2):25‐35. ">Reid 2016</a>; <a href="./references#CD012077-bbs2-0115" title="SellierE , PlattMJ , AndersenGL , Krägeloh‐MannI , De LaCruzJ , CansC , et al. Decreasing prevalence in cerebral palsy: a multi‐site European population‐based study, 1980 to 2003. Developmental Medicine and Child Neurology2015;58:85‐92. ">Sellier 2015</a>). Rate variations have also been observed, particularly when stratified by gestational age or birthweight. In the aforementioned meta‐analysis, the prevalence was highest in children weighing 1000 to 1499 g at birth (59.18 per 1000 live births), and for children born before 28 weeks of gestation (111.80 per 1000 live births; <a href="https://archie.cochrane.org/sections/documents/view?version=z1506102316117587477552126264219%26format=REVMAN#REF-Oskoui-2013" target="_blank">Oskoui 2013</a>). </p> </section> <section id="CD012077-sec-0019"> <h4 class="title">Cerebral palsy: causes and risk factors</h4> <p>For approximately 6% of individuals with cerebral palsy, their brain injury is believed to have been acquired during a recognised event at least 28 days after birth and before the age of two to five; commonly, a cerebrovascular accident, spontaneous, associated with surgery or with complications of cardiac defects, or accidental and non‐accidental head injuries (<a href="./references#CD012077-bbs2-0051" title="Australian Cerebral Palsy Register (ACPR) Group. Report of the Australian Cerebral Palsy Register, Birth Years 1993–2006. Sydney: ACPR Group, 2013. ">ACPR Group 2013</a>). For the remaining 94% of individuals with cerebral palsy, their brain injury is believed to have occurred during the antenatal or the neonatal period of infant development, that is, during pregnancy, or within the first 28 days of life (<a href="./references#CD012077-bbs2-0051" title="Australian Cerebral Palsy Register (ACPR) Group. Report of the Australian Cerebral Palsy Register, Birth Years 1993–2006. Sydney: ACPR Group, 2013. ">ACPR Group 2013</a>). </p> <p>The pathogenesis of such brain injury is complex and multifactorial, with interrelated pathways contributing to cellular dysfunction and death, including accumulation of reactive oxygen species, the release of excitatory amino acids, energy depletion, and apoptosis (<a href="./references#CD012077-bbs2-0080" title="InderTE , VolpeJJ . Mechanisms of perinatal brain injury. Seminars in Neonatology2000;5:3‐16. ">Inder 2000</a>; <a href="./references#CD012077-bbs2-0120" title="VexlerZS , FerrieroDM . Molecular and biochemical mechanisms of perinatal brain injury. Seminars in Neonatology2011;6:99‐108. ">Vexler 2001</a>). There are multiple causes of brain injury, including hypoxia‐ischaemia (characterised by reduced oxygen in the blood combined with reduced blood flow to the brain), haemorrhage, infection, maldevelopment, and metabolic derangement (<a href="./references#CD012077-bbs2-0121" title="VolpeJJ . Perinatal brain injury: from pathogenesis to neuroprotection. Mental Retardation and Developmental Disabilities Research Reviews2000;7:56‐64. ">Volpe 2000</a>). Brain hypoxia (deficiency of oxygen) and ischaemia (insufficient blood supply) may lead to different neuropathology in infants born preterm and at term, with cerebral white matter injury predominating in preterm infants, and neuronal cell injury in term infants (<a href="./references#CD012077-bbs2-0121" title="VolpeJJ . Perinatal brain injury: from pathogenesis to neuroprotection. Mental Retardation and Developmental Disabilities Research Reviews2000;7:56‐64. ">Volpe 2000</a>). Injury to the developing brain is known to be associated with long‐term sequelae, including cerebral palsy, as well as hearing, sight, speech, and behavioural disorders, seizures, and intellectual disabilities (<a href="./references#CD012077-bbs2-0120" title="VexlerZS , FerrieroDM . Molecular and biochemical mechanisms of perinatal brain injury. Seminars in Neonatology2011;6:99‐108. ">Vexler 2001</a>). </p> <p>Preterm birth is one of the principal risk factors for cerebral palsy and associated neurosensory disabilities (<a href="./references#CD012077-bbs2-0075" title="HimpensE , Van denBroeckC , OostraA , CaldersP , VanhaesebrouckP . Prevalence, type, distribution, and severity of cerebral palsy in relation to gestational age: a meta‐analytic review. Developmental Medicine and Child Neurology2008;50:334‐40. ">Himpens 2008</a>; <a href="./references#CD012077-bbs2-0100" title="OskouiM , CoutinhoF , DykemanJ , JettéN , PringsheimT . An update on the prevalence of cerebral palsy: a systematic review and meta‐analysis. Developmental Medicine &amp; Child Neurology2013;55(6):509‐19. ">Oskoui 2013</a>). The degree of prematurity is associated with vulnerability of cerebral white matter, and is predictive of an increasing risk of white matter injury (such as periventricular leukomalacia), and intraventricular haemorrhage (<a href="./references#CD012077-bbs2-0086" title="LarroqueB , MarretS , AncelPY , ArnaudC , MarpeauL , SupernantK , et al. White matter damage and intraventricular hemorrhage in very preterm infants: the EPIPAGE study. Journal of Pediatrics2003;143(4):477‐83. ">Larroque 2003</a>), established risk factors for the development of cerebral palsy (<a href="./references#CD012077-bbs2-0111" title="SalibaE , MarretS . Cerebral white matter damage in the preterm infant: pathophysiology and risk factors. Seminars in Neonatology2001;6(2):121‐33. ">Saliba 2001</a>). Although preterm birth is acknowledged as a major risk factor for cerebral palsy, with over 40% of individuals with cerebral palsy being born preterm (compared with approximately 8% of the general population), most individuals with cerebral palsy (50% to 60%) are in fact, born at term (<a href="./references#CD012077-bbs2-0051" title="Australian Cerebral Palsy Register (ACPR) Group. Report of the Australian Cerebral Palsy Register, Birth Years 1993–2006. Sydney: ACPR Group, 2013. ">ACPR Group 2013</a>). </p> <p>Studies on possible risk factors for cerebral palsy for preterm‐ and term‐born individuals are abundant (with some risk factors reported more consistently than others). Evidence now suggests that 70% to 80% of cerebral palsy cases are associated with antenatal factors, with birth asphyxia playing a relatively minor role (<a href="./references#CD012077-bbs2-0055" title="BlairE , StanleyFJ . Intrapartum asphyxia: a rare cause of cerebral palsy. Journal of Pediatrics1988;112(4):515‐9. ">Blair 1988</a>; <a href="./references#CD012077-bbs2-0068" title="EllenbergJH , NelsonKB . The association of cerebral palsy with birth asphyxia: a definitional quagmire. Developmental Medicine &amp; Child Neurology2013;55:210‐6. ">Ellenberg 2013</a>; <a href="./references#CD012077-bbs2-0088" title="MacLennanAH , ThompsonSC , GeczJ . Cerebral palsy: causes, pathways, and the role of genetic variants. American Journal of Obstetrics and Gynecology2015;213(6):779‐88. ">MacLennan 2015</a>). Risk factors, in additional to preterm birth, often reported in the literature include: (a) factors prior to conception, such as: young or advanced maternal age, high parity, nulliparity, a short or long inter‐pregnancy interval, a history of stillbirth, multiple miscarriages, neonatal death, or premature birth, family history of cerebral palsy and other genetic predispositions, low socioeconomic status, and pre‐existing maternal conditions (e.g. intellectual disability, and epilepsy); (b) factors in early pregnancy, such as: male gender, multiple gestation, congenital malformations or birth defects, and infections (i.e. TORCH complex: <b>t</b> oxoplasmosis (parasite), <b>o</b> ther infections, <b>r</b> ubella, <b>c</b> ytomegalovirus, <b>h</b>erpes simplex virus); (c) factors during pregnancy, such as: maternal disease (e.g. thyroid disorders), pregnancy complications (e.g. high blood pressure, pre‐eclampsia, placenta praevia, placental abruption, and other placental abnormalities), intrauterine infection or inflammation and chorioamnionitis, intrauterine growth restriction, and other precursors to preterm birth; and (d) factors around the time of birth and neonatal period, such as: an acute intrapartum hypoxic event, meconium aspiration, stroke, seizures, hypoglycaemia, jaundice, and infection, along with inborn errors of metabolism (such as glucose‐6‐phosphate dehydrogenase deficiency), particular syndromes, or chromosomal abnormalities (<a href="./references#CD012077-bbs2-0082" title="JacobssonB , HagbergG . Antenatal risk factors for cerebral palsy. Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology2004;18(3):425‐36. ">Jacobsson 2004</a>; <a href="./references#CD012077-bbs2-0090" title="McIntyreS , MorganC , WalkerK , NovakI . Cerebral palsy ‐ don't delay. Developmental Disabilities Research Reviews2011;17(2):114‐29. ">McIntyre 2011</a>; <a href="./references#CD012077-bbs2-0091" title="McIntyreS , TaitzD , KeoghJ , GoldsmithS , BadawiN , BlairE . A systematic review of risk factors for cerebral palsy in children born at term in developed countries. Developmental Medicine and Child Neurology2013;55:499‐508. ">McIntyre 2013</a>; <a href="./references#CD012077-bbs2-0098" title="NelsonKB . Causative factors in cerebral palsy. Clinical Obstetrics and Gynecology2008;51(4):749‐62. ">Nelson 2008b</a>; <a href="./references#CD012077-bbs2-0118" title="Smithers‐SheedyH , BadawiN , BlairE , CansC , HimmelmannK , Krägeloh‐MannI , et al. What constitutes cerebral palsy in the twenty‐first century?. Developmental Medicine and Child Neurology2014;56:323‐8. ">Smithers‐Sheedy 2014</a>). </p> <p>In low‐ and middle‐income countries, the causes and risk factors for cerebral palsy are known to differ considerably (<a href="./references#CD012077-bbs2-0057" title="BlairE , WatsonL . Epidemiology of cerebral palsy. Seminars in Fetal and Neonatal Medicine2006;11:117‐25. ">Blair 2006</a>). With few survivors of very preterm birth in such countries, common risk factors are birth asphyxia and maternal Rhesus alloimmunisation, or inherited disorders, such as glucose‐6‐phosphate dehydrogenase deficiency and subsequent bilirubin encephalopathy, and there are much higher proportions of children with postnatally acquired cerebral palsy, particularly associated with postinfectious brain damage following meningitis, septicaemia, and other conditions, such as malaria (<a href="./references#CD012077-bbs2-0057" title="BlairE , WatsonL . Epidemiology of cerebral palsy. Seminars in Fetal and Neonatal Medicine2006;11:117‐25. ">Blair 2006</a>; <a href="./references#CD012077-bbs2-0085" title="LagunjuIA , FatundeOJ . The child with cerebral palsy in a developing country ‐ diagnosis and beyond. Journal of Pediatric Neurology2009;7:375‐9. ">Lagunju 2009</a>). </p> <p>While a great number of potential risk factors for cerebral palsy have been identified, their commonality is that separately, or in combination, they may lead to injury to the developing brain. A growing body of evidence now suggests that genetic abnormalities may also contribute to the development of cerebral palsy (<a href="./references#CD012077-bbs2-0092" title="Moreno‐De‐LucaA , LedbetterDH , MartinCL . Genetic insights into the causes and classification of cerebral palsies. Lancet Neurology2012;11(3):283‐92. ">Moreno‐De‐Luca 2012</a>; <a href="./references#CD012077-bbs2-0101" title="OskouiM , GazzelloneMJ , ThiruvahindrapuramB , ZarreiM , AndersenJ , WeiJ . Clinically relevant copy number variations detected in cerebral palsy. Nature Communications2015;6:7949. ">Oskoui 2015</a>; <a href="./references#CD012077-bbs2-0102" title="O’CallaghanME , MacLennanAH , HaanEA , DekkerG , South Australian Cerebral Palsy Research Group. The genomic basis of cerebral palsy: a HuGE systematic literature review. Human Genetics2009;126(1):149‐72. ">O’Callaghan 2009</a>). Previously, only 1% to 2% of cerebral palsy cases were linked to a causative genetic mutation, but recent studies have shown that up to 14% have single gene mutations and 31% have copy number variations that may be at fault (<a href="./references#CD012077-bbs2-0088" title="MacLennanAH , ThompsonSC , GeczJ . Cerebral palsy: causes, pathways, and the role of genetic variants. American Journal of Obstetrics and Gynecology2015;213(6):779‐88. ">MacLennan 2015</a>). Possible genetic mutations and variants associated with cerebral palsy are likely to be heterogeneous, but they both trigger pathways (either directly, or in the case of genetic susceptibility, when certain risk factors are present), leading to non‐progressive neuropathology associated with motor dysfunction and cerebral palsy (<a href="./references#CD012077-bbs2-0088" title="MacLennanAH , ThompsonSC , GeczJ . Cerebral palsy: causes, pathways, and the role of genetic variants. American Journal of Obstetrics and Gynecology2015;213(6):779‐88. ">MacLennan 2015</a>). Though there is currently no known cure for cerebral palsy, increasing knowledge of risk factors and causal pathways had increased the hope for the development and implementation of primary preventive strategies: “we are on the move… the vision of prevention and cure no longer seems an unattainable goal” (<a href="./references#CD012077-bbs2-0053" title="BadawiN , KeoghJM . Causal pathways in cerebral palsy. Journal of Paediatrics and Child Health2013;49(1):5‐8. ">Badawi 2013</a>)<i>.</i> </p> </section> <section id="CD012077-sec-0020"> <h4 class="title">Cerebral palsy: consequences</h4> <p>Cerebral palsy is the leading cause of physical disability in children. Though traditionally regarded as a paediatric condition, it is now recognised that cerebral palsy is a condition with life‐long impact – a ‘lifespan condition’ – and thus, the outcomes of individuals with cerebral palsy across the life course are considered when planning and directing interventions in childhood (<a href="./references#CD012077-bbs2-0063" title="ColverA , FairhurstC , PharoahPO . Cerebral palsy. Lancet2014;383:1240‐9. ">Colver 2014</a>). </p> <p>Most individuals with cerebral palsy will survive to adulthood, with some studies suggesting life expectancy can be broadly similar to that of the general population if a child reaches adolescence (<a href="./references#CD012077-bbs2-0062" title="ColverA . Outcomes for people with cerebral palsy: life expectancy and quality of life. Paediatrics and Child Health2012;22(9):384‐7. ">Colver 2012</a>). For known cases of antenatally‐ or neonatally‐acquired cerebral palsy, the 20‐year survival rate has been estimated to be approximately 90%, however, strong associations between increasing motor impairment, severe intellectual impairment, number of severe impairments, and early mortality have been shown (<a href="./references#CD012077-bbs2-0056" title="BlairE , WatsonL , BadawiN , StanleyFJ . Life expectancy among people with cerebral palsy in Western Australia. Developmental Medicine &amp; Child Neurology2001;43(8):508‐15. ">Blair 2001</a>; <a href="./references#CD012077-bbs2-0071" title="HemmingK , HuttonJL , ColverA , PlattM‐J . Regional variation in survival of people with cerebral palsy in the United Kingdom. Pediatrics2005;116(6):1383‐90. ">Hemming 2005</a>; <a href="./references#CD012077-bbs2-0105" title="ReidSM , CarlinJB , ReddihoughDS . Survival of individuals with cerebral palsy born in Victoria, Australia, between 1970 and 2004. Developmental Medicine &amp; Child Neurology2012;54(4):353‐60. ">Reid 2012</a>). While a mixed picture in overall survival trends has been presented to date, some improvements in survival have been observed over time for two groups of individuals with cerebral palsy with the most severe disabilities – children who are largely immobile and fed by others, and adults who are dependent on gastrostomy feeding (<a href="./references#CD012077-bbs2-0119" title="StraussD , BrooksJ , RosenbloomL , ShavelleR . Life expectancy in cerebral palsy: an update. Developmental Medicine &amp; Child Neurology2008;50(7):487‐93. ">Strauss 2008</a>). </p> <p>Today's frequently used definitions importantly acknowledge co‐occurring impairments, diseases, and functional limitations, which are common among individuals with cerebral palsy, including hearing, sight, and speech disorders, intellectual disability and epilepsy (<a href="./references#CD012077-bbs2-0110" title="RosenbaumP , PanethN , LevitonA , GoldsteinM , BaxM , DamianoD , et al. A report: the definition and classification of cerebral palsy April 2006. Developmental Medicine and Child Neurology Supplement2007;109:8‐14. ">Rosenbaum 2007</a>). A recent systematic review estimated, for example, that among children with cerebral palsy, “1 in 2 had an intellectual disability… 1 in 4 could not talk; 1 in 4 had epilepsy; 1 in 4 had a behaviour disorder… 1 in 10 were blind… and 1 in 25 were deaf” (<a href="./references#CD012077-bbs2-0099" title="NovakI , HinesM , GoldsmithS , BarclayR . Clinical prognostic messages from a systematic review of cerebral palsy. Paediatrics2012;130(5):e1285‐e1312. ">Novak 2012</a>). </p> <p>Economic studies have estimated lifetime costs of cerebral palsy, including healthcare costs (such as primary health care, hospital care, and pharmaceuticals), social care costs (such as specialised education and housing), and productivity costs (the cost for society when an individual never enters the labour market, or leaves it) as EUR860,000 for men and EUR800,000 for women in Denmark (in 2000; <a href="./references#CD012077-bbs2-0084" title="KruseM , MichelsenSI , FlachsEM , Brønnum‐HansenH , MadsenM , UldallP . Lifetime costs of cerebral palsy. Developmental Medicine &amp; Child Neurology2009;51(8):622‐8. ">Kruse 2009</a>), and USD921,000 for individuals in the United States (in 2003; <a href="./references#CD012077-bbs2-0060" title="Centers for Disease Control and Prevention (CDC). Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment ‐ United States, 2003. MMWR: Morbidity and Mortality Weekly Report2004;53(3):57‐9. ">CDC 2004</a>). In Australia, the financial cost of cerebral palsy was estimated AUD1.47 billion (in 2007); the value of lost well‐being (disability and premature death) was a further AUD2.4 billion (<a href="./references#CD012077-bbs2-0050" title="AccessEconomics . The Economic Impact of Cerebral Palsy in Australia in 2007. Sydney: Cerebral Palsy Australia, 2008. ">Access Economics 2008</a>). </p> <p>The impacts of cerebral palsy are considerable, not only for individuals, but for families, carers, communities, and societies (<a href="./references#CD012077-bbs2-0066" title="DavisE , ShelleyA , WatersE , BoydR , CookK , DavernM . The impact of caring for a child with cerebral palsy: quality of life for mothers and fathers. Child: Care, Health and Development2010;36:63‐73. ">Davis 2010</a>). Accordingly, individuals with cerebral palsy and their families, clinicians and researchers recognise that identification of primary preventive measures continues to be a key priority (<a href="./references#CD012077-bbs2-0089" title="McIntyreS , NovakI , CusickA . Consensus research priorities for cerebral palsy: a Delphi survey of consumers, researchers, and clinicians. Developmental Medicine and Child Neurology2010;52(3):270‐5. ">McIntyre 2010</a>). </p> </section> </section> <section id="CD012077-sec-0021"> <h3 class="title" id="CD012077-sec-0021">Description of the interventions</h3> <section id="CD012077-sec-0022"> <h4 class="title">Antenatal or intrapartum approaches to prevention of cerebral palsy</h4> <p>Research efforts aimed at moving towards a future without cerebral palsy have increasingly focused on understanding the causes of cerebral palsy. As it is now widely recognised that causes differ, for example, by gestational age (i.e. for preterm‐ and term‐born children), and clinical subtype of cerebral palsy (<a href="./references#CD012077-bbs2-0097" title="NelsonKB , ChangT . Is cerebral palsy preventable?. Current Opinion in Neurology2008;21(2):129‐35. ">Nelson 2008</a>), it is reasonable to consider that successful primary preventive interventions may also vary according to different aetiologies and causal factors. For example, spastic diplegia is the most common subtype of cerebral palsy in preterm infants, most often caused by white matter injury initiated by cerebral ischaemia, maternal intrauterine infection, or fetal systemic inflammation; quadriplegic cerebral palsy, especially with dyskinesia, is a subtype of cerebral palsy sometimes related to acute asphyxia during the birth process (<a href="./references#CD012077-bbs2-0097" title="NelsonKB , ChangT . Is cerebral palsy preventable?. Current Opinion in Neurology2008;21(2):129‐35. ">Nelson 2008</a>). </p> <p>Primary preventive interventions may include public health strategies for the general population (e.g. periconceptional folate supplementation to reduce birth defects), strategies directed at preventing distal components on a causal pathway to cerebral palsy (e.g. melatonin for small‐for‐gestational age in pregnancy), and strategies closer to the proximal cause of brain damage (e.g. magnesium sulphate for neuroprotection immediately prior to very preterm birth; <a href="./references#CD012077-bbs2-0079" title="IMPACT for CerebralPalsy . 2011 Summit Report. Availale from impact.cerebralpalsy.org.au/activities/research‐summits/2011‐summit‐report/ (accessed 17 May 2015). ">IMPACT for CP 2011</a>). </p> <p>Therefore, we considered a broad range of antenatal and intrapartum interventions* in this overview, with varying primary aims and indications, which may mediate the risk of cerebral palsy. The examples presented below are not an exhaustive list, but include: </p> <p> <ul id="CD012077-list-0001"> <li> <p>nutrition interventions in pregnancy, e.g. periconceptional folate supplementation; marine oil, and other prostaglandin precursors; vitamins C and E; </p> </li> <li> <p>behaviour or advice interventions in pregnancy, e.g. reducing alcohol and drug consumption; supporting smoking cessation; promoting hand‐washing; </p> </li> <li> <p>interventions for predicting or preventing preterm birth (including subsequent management strategies), e.g. fetal fibronectin testing; cervical assessment by ultrasound; risk‐scoring systems; transfer to a hospital with neonatal intensive care unit facilities; cervical cerclage; cervical pessary; prenatal administration of progesterone; acute tocolytic and maintenance therapy (i.e. magnesium sulphate; calcium channel blockers (nifedipine); oxytocin receptor antagonists (atosiban); betamimetics (terbutaline); cyclo‐oxygenase (COX) inhibitors (indomethacin)); </p> </li> <li> <p>interventions prior to preterm or term birth for fetal neuroprotection, e.g. antenatal corticosteroids; repeat doses of corticosteroids; thyrotropin‐releasing hormone added to corticosteroids; magnesium sulphate; creatine; melatonin; phenobarbital; vitamin K; </p> </li> <li> <p>screening and management of fetal growth and well‐being in pregnancy, e.g. fetal movement counting for assessment of well‐being; symphysial fundal height (SFH) measurement for detecting abnormal fetal growth; ultrasound for fetal assessment in early pregnancy; routine ultrasound in late pregnancy; antenatal cardiotocography for fetal assessment; fetal and umbilical Doppler ultrasound; utero‐placental Doppler ultrasound; interventions for impaired fetal growth; </p> </li> <li> <p>diagnosing and preventing fetal compromise in labour, e.g. intermittent auscultation (IA) of fetal heart rate; continuous cardiotocography (CTG) for electric fetal heart rate monitoring (EFM); fetal electrocardiogram (ECG); fetal pulse oximetry; patient safety programmes; </p> </li> <li> <p>interventions for infection during pregnancy, e.g. TORCH, urinary tract infections, other vaginal infections (i.e. bacterial vaginosis); </p> </li> <li> <p>interventions for preterm and term pre‐labour rupture of membranes, e.g. planned early birth (versus expectant management); antibiotics; tocolytics; </p> </li> <li> <p>other specific interventions for medical problems in pregnancy and labour, e.g. screening and subsequent management for thyroid dysfunction; anti‐D administration for preventing Rhesus alloimmunisation in Rh‐negative women; interventions for the treatment of mild to moderate, or severe hypertension, and for the prevention (i.e. antioxidants; antiplatelet agents) and treatment of pre‐eclampsia or eclampsia (i.e. magnesium sulphate; lytic cocktail; diazepam; phenytoin); interventions for placenta praevia or placental abruption; interventions for uterine rupture or cord prolapse. </p> </li> </ul> </p> <p>*We will not consider interventions in the neonatal period (such as cooling for newborns with hypoxic ischaemic encephalopathy (<a href="./references#CD012077-bbs2-0081" title="JacobsSE , BergM , HuntR , Tarnow‐MordiWO , InderTE , DavisPG . Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003311.pub3] ">Jacobs 2013</a>)), as these interventions will be assessed in a separate overview which will be focused specifically on neonatal interventions for prevention of cerebral palsy (<a href="./references#CD012077-bbs2-0117" title="ShepherdE , MiddletonP , MakridesM , McIntyreSJ , BadawiN , CrowtherCA . Neonatal interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD012409] ">Shepherd 2016</a>). </p> </section> </section> <section id="CD012077-sec-0023"> <h3 class="title" id="CD012077-sec-0023">How the intervention might work</h3> <p>Advances in research into several factors that modify the risk of cerebral palsy in infants suggest many opportunities for prevention, with some of the main strategies focusing on the prevention of preterm birth, or protection of the developing fetal brain through antenatal administration of neuroprotective agents. </p> <p>For example, because preterm birth and neurodevelopmental outcomes are so strongly associated (<a href="./references#CD012077-bbs2-0051" title="Australian Cerebral Palsy Register (ACPR) Group. Report of the Australian Cerebral Palsy Register, Birth Years 1993–2006. Sydney: ACPR Group, 2013. ">ACPR Group 2013</a>; <a href="./references#CD012077-bbs2-0100" title="OskouiM , CoutinhoF , DykemanJ , JettéN , PringsheimT . An update on the prevalence of cerebral palsy: a systematic review and meta‐analysis. Developmental Medicine &amp; Child Neurology2013;55(6):509‐19. ">Oskoui 2013</a>), it is possible that interventions to prolong gestation or reduce the risk of preterm birth will also reduce the risk of cerebral palsy (<a href="./references#CD012077-bbs2-0061" title="ChangE . Preterm birth and the role of neuroprotection. BMJ2015;350:g6661. ">Chang 2015</a>; <a href="./references#CD012077-bbs2-0103" title="O’SheaMT . Diagnosis, treatment and prevention of cerebral palsy in near‐term/term infants. Clinical Obstetrics and Gynaecology2008;51(4):816‐28. ">O’Shea 2008</a>). Specific approaches, supported by high level evidence, for prolonging pregnancy and preventing preterm birth include: interventions for primary prevention of preterm birth (e.g. smoking cessation programmes for the general population); interventions for secondary prevention of indicated preterm birth (e.g. antiplatelet drugs (low‐dose aspirin) for the prevention of pre‐eclampsia); interventions for secondary prevention of spontaneous preterm birth (e.g. progesterone and cervical cerclage for women at increased risk of preterm birth due to a prior preterm birth, or where a short cervix has been identified on ultrasound); and tertiary interventions, for women with immediate risk of preterm birth (e.g. antibiotics for women with preterm rupture of membranes; and calcium channel blockers and an oxytocin antagonist (atosiban) for women with preterm labour; <a href="./references#CD012077-bbs2-0078" title="IamsJD , RomeroR , CulhaneJF , GoldenbergRL . Preterm birth 2 ‐ Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet2008;371(9607):164‐75. ">Iams 2008</a>; <a href="./references#CD012077-bbs2-0103" title="O’SheaMT . Diagnosis, treatment and prevention of cerebral palsy in near‐term/term infants. Clinical Obstetrics and Gynaecology2008;51(4):816‐28. ">O’Shea 2008</a>). </p> <p>For women with immediate risk of preterm birth, it is possible that antenatal interventions aimed at protecting the developing fetal brain from injury will also reduce the risk of cerebral palsy. For example, antenatal corticosteroids to accelerate fetal lung maturation in women at risk of preterm birth have also been shown to be neuroprotective, reducing the risk of intraventricular haemorrhage and periventricular leukomalacia (<a href="./references#CD012077-bbs2-0061" title="ChangE . Preterm birth and the role of neuroprotection. BMJ2015;350:g6661. ">Chang 2015</a>; <a href="./references#CD012077-bbs2-0078" title="IamsJD , RomeroR , CulhaneJF , GoldenbergRL . Preterm birth 2 ‐ Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet2008;371(9607):164‐75. ">Iams 2008</a>; <a href="./references#CD012077-bbs2-0103" title="O’SheaMT . Diagnosis, treatment and prevention of cerebral palsy in near‐term/term infants. Clinical Obstetrics and Gynaecology2008;51(4):816‐28. ">O’Shea 2008</a>). Magnesium sulphate is another drug administered antenatally, with the potential to mediate the risk of cerebral palsy by protecting the developing fetal brain from injury, such as intraventricular haemorrhage (<a href="./references#CD012077-bbs2-0061" title="ChangE . Preterm birth and the role of neuroprotection. BMJ2015;350:g6661. ">Chang 2015</a>; <a href="./references#CD012077-bbs2-0097" title="NelsonKB , ChangT . Is cerebral palsy preventable?. Current Opinion in Neurology2008;21(2):129‐35. ">Nelson 2008</a>; <a href="./references#CD012077-bbs2-0103" title="O’SheaMT . Diagnosis, treatment and prevention of cerebral palsy in near‐term/term infants. Clinical Obstetrics and Gynaecology2008;51(4):816‐28. ">O’Shea 2008</a>). Beyond antenatal corticosteroids and magnesium sulphate, a range of other antenatally administered agents, such as melatonin, creatine, and allopurinol, may enhance the ability of the preterm or term developing fetal brain to withstand brain damage, and in doing so, reduce the risk of cerebral palsy (<a href="./references#CD012077-bbs2-0061" title="ChangE . Preterm birth and the role of neuroprotection. BMJ2015;350:g6661. ">Chang 2015</a>; <a href="./references#CD012077-bbs2-0109" title="RobertsonNJ , TanS , GroenendaalF , VanBelF , JuulSE , BennetL , et al. Which neuroprotective agents are ready for bench to bedside translation in the newborn infant?. Journal of Pediatrics2012;160:544‐52. ">Robertson 2012</a>). </p> <p>There are numerous other antenatal and intrapartum interventions with the potential to contribute to the prevention of cerebral palsy in preterm and term infants by modifying known risk factors for cerebral palsy, for example: identification and subsequent management of maternal thyroid dysfunction (both hypo‐ and hyper‐thyroidism) in pregnancy, identification and treatment of hypertension and pre‐eclampsia in pregnancy, and identification and management of perinatal infections (including chorioamnionitis) in pregnancy. </p> </section> <section id="CD012077-sec-0024"> <h3 class="title" id="CD012077-sec-0024">Why it is important to do this overview</h3> <p>A multitude of individual studies and Cochrane reviews assessing a broad range of antenatal or intrapartum interventions (with varying primary aims and indications) recognise the potential for the interventions of interest to mediate the risk of cerebral palsy. With the acknowledgement that a multiplicity of risk factors impact on the risk of cerebral palsy, and that causes of cerebral palsy differ, there is a need to systematically consider all potentially relevant interventions for their ability to contribute to prevention. To our knowledge, there is no published overview that has assembled and summarised the evidence from Cochrane reviews on interventions for the prevention of cerebral palsy in one coherent document, to be used by researchers, funding bodies, policy makers, clinicians, and consumers to aid decision making and evidence translation. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012077-sec-0025" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012077-sec-0025"></div> <p>The objective of this overview was to summarise the evidence from Cochrane reviews regarding the effects of antenatal and intrapartum interventions for preventing cerebral palsy, and to assess the effects of these interventions on associated outcomes, including severity and type of cerebral palsy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012077-sec-0026" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012077-sec-0026"></div> <section id="CD012077-sec-0027"> <h3 class="title">Criteria for considering reviews for inclusion</h3> <p>In this overview, we included Cochrane reviews of antenatal or intrapartum interventions, where cerebral palsy was reported as a primary or secondary outcome, or as part of a composite outcome, with data reported for cerebral palsy from at least one of the trials included in the review. </p> <p>We identified relevant Cochrane protocols for future inclusion, and classified them as 'Ongoing reviews' (<a href="./appendices#CD012077-sec-0073">Appendix 1</a>). </p> <p>We listed reviews that pre‐specified cerebral palsy as a primary or secondary outcome, but had no data reported from included trials as 'Reviews awaiting further classification', which will be re‐considered in future updates of the overview (<a href="./appendices#CD012077-sec-0074">Appendix 2</a>). </p> <p>We made note of the publication and search dates of the reviews, however, we did not attempt to update the individual reviews. We contacted the Cochrane Pregnancy and Childbirth Editorial Base to identify any relevant new reviews or review updates that were in progress, in order to include the most up‐to‐date versions of the reviews, if and where possible. </p> <section id="CD012077-sec-0028"> <h4 class="title">Participants</h4> <p>We considered reviews assessing interventions in pregnant women.</p> </section> <section id="CD012077-sec-0029"> <h4 class="title">Interventions</h4> <p>We considered all types of interventions used in the antenatal or intrapartum period, compared with placebo, no treatment, or an alternative intervention. </p> <p>We planned to include pharmacological, medical, nutritional, behavioural, and educational interventions (see <a href="#CD012077-sec-0021">Description of the interventions</a> for further descriptions of possible interventions). </p> </section> <section id="CD012077-sec-0030"> <h4 class="title">Outcomes of interest</h4> <section id="CD012077-sec-0031"> <h5 class="title">Primary</h5> <p> <ul id="CD012077-list-0002"> <li> <p>Cerebral palsy (however defined by review authors and trialists).</p> </li> </ul> </p> </section> <section id="CD012077-sec-0032"> <h5 class="title">Secondary</h5> <p> <ul id="CD012077-list-0003"> <li> <p>Cerebral palsy or death (e.g. in early childhood, and at the latest time point measured).</p> </li> <li> <p>Severity of cerebral palsy (e.g. according to: Gross Motor Function Classification System (GMFCS); Manual Ability Classification System (MACS); Communication Function Classification System (CFCS)). </p> </li> <li> <p>Other composite outcomes that included cerebral palsy as a component.</p> </li> <li> <p>Type of cerebral palsy (e.g. according to topography (diplegia; hemiplegia; quadriplegia; monoplegia; triplegia), or motor type (spastic; dyskinetic; ataxic)). </p> </li> <li> <p>Motor dysfunction (e.g. in infancy and early childhood, and at the latest time point measured; however defined by review authors and trialists) </p> </li> </ul> </p> </section> </section> </section> <section id="CD012077-sec-0033"> <h3 class="title">Search methods for identification of reviews</h3> <p>We searched the <i>Cochrane Database of Systematic Reviews,</i> using the term ‘cerebral palsy’, on 7 August 2016. We searched ‘all text’, and did not limit our search to ‘title, abstract, or keywords’. We did not apply any language or date restrictions. No other databases were searched. We managed citations retrieved through the search with Covidence (<a href="./references#CD012077-bbs2-0065" title="Veritas Health Innovation. Covidence. Version accessed 17 May 2015. Melbourne, Australia: Veritas Health Innovation, 2015. ">Covidence 2015</a>). </p> </section> <section id="CD012077-sec-0034"> <h3 class="title" id="CD012077-sec-0034">Data collection and analysis</h3> <p>We followed the methodology for data collection and synthesis from Chapter 22 of the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD012077-bbs2-0074" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). Where appropriate, we prepared the overview using Covidence and Review Manager 5 software (<a href="./references#CD012077-bbs2-0065" title="Veritas Health Innovation. Covidence. Version accessed 17 May 2015. Melbourne, Australia: Veritas Health Innovation, 2015. ">Covidence 2015</a>; <a href="./references#CD012077-bbs2-0107" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <section id="CD012077-sec-0035"> <h4 class="title">Selection of reviews</h4> <p>Two overview authors independently assessed all potential reviews we identified. We resolved any disagreement through discussion, or if required, we consulted a third author. </p> </section> <section id="CD012077-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>Two overview authors independently extracted data from the reviews using a pre‐defined data extraction form. We resolved discrepancies through discussion. Where any information from the reviews was unclear or missing, we accessed the published papers of the individual studies. </p> <p>We extracted information on the following.</p> <p> <ul id="CD012077-list-0004"> <li> <p>Review characteristics:</p> <ul id="CD012077-list-0005"> <li> <p>review title and authors;</p> </li> <li> <p>date that the review was last assessed as up‐to‐date;</p> </li> <li> <p>number of included trials, number of participants (women and infants) in the trials and their characteristics (e.g. countries where the trials were conducted and inclusion criteria for the trials); </p> </li> <li> <p>quality of the included trials (as reported by the review authors; see <a href="#CD012077-sec-0037">Assessment of methodological quality of included reviews</a>); </p> </li> <li> <p>interventions and comparisons relevant to this overview;</p> </li> <li> <p>all pre‐specified outcomes relevant to this overview;</p> </li> <li> <p>any other characteristics required to assess and report on review quality (see <a href="#CD012077-sec-0037">Assessment of methodological quality of included reviews</a>). </p> </li> </ul> </li> <li> <p>Statistical summaries:</p> <ul id="CD012077-list-0006"> <li> <p>the summary intervention effects (including the pooled effects (e.g. risk ratios (RR), odds ratios (OR) or mean differences (MD) as reported in the individual reviews), 95% confidence intervals (CIs), and numbers of studies and participants contributing data to each pooled effect) for outcomes relevant to this overview (N.B. if the summary statistic (RR or OR) has been calculated using a random‐effects analysis, the results are presented as the 'average' treatment effect); </p> </li> <li> <p>information required to assess and report on the quality of the evidence for the intervention effects extracted above (see <a href="#CD012077-sec-0037">Assessment of methodological quality of included reviews</a>); </p> </li> <li> <p>results of any subgroup or sensitivity analyses conducted by the review authors, for our primary outcome. </p> </li> </ul> </li> </ul> </p> <p>If there were no meta‐analyses in a review, and therefore, no statistical summaries, we extracted the narrative text relating to the results for our overview outcomes. </p> <p>When cerebral palsy was reported as part of a composite outcome, we extracted any available data on cerebral palsy. Where it was not possible to extract only the cerebral palsy data, we reported the composite outcome data; however, we reported it separately, as a secondary outcome. </p> </section> <section id="CD012077-sec-0037"> <h4 class="title">Assessment of methodological quality of included reviews</h4> <section id="CD012077-sec-0038"> <h5 class="title">Quality of included reviews</h5> <p>We assessed the methodological quality of each systematic review using the AMSTAR (A Measurement Tool to Assess Reviews) instrument (<a href="./references#CD012077-bbs2-0116" title="SheaBJ , HamelC , WellsGA , BouterLM , KristjansoonE , GrimshawJ , et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. Journal of Clinical Epidemiology2009;62(10):1013‐20. ">Shea 2009</a>). AMSTAR evaluates the methods used in a review against 11 distinct criteria and assesses the degree to which review methods are unbiased. Each item on AMSTAR is rated as yes (clearly done), no (clearly not done), cannot answer, or not applicable. These criteria are as follows. </p> <p> <ol id="CD012077-list-0007"> <li> <p>Was an a priori design provided?</p> </li> <li> <p>Was there duplicate study selection and data extraction?</p> </li> <li> <p>Was a comprehensive literature search performed?</p> </li> <li> <p>Was the status of publication used as an inclusion criterion?</p> </li> <li> <p>Was a list of studies (included and excluded) provided?</p> </li> <li> <p>Were the characteristics of the included studies provided?</p> </li> <li> <p>Was the scientific quality of the included studies assessed and documented?</p> </li> <li> <p>Was the scientific quality of the included studies used appropriately in formulating conclusions? </p> </li> <li> <p>Were the methods used to combine the findings of studies appropriate?</p> </li> <li> <p>Was the likelihood of publication bias assessed?</p> </li> <li> <p>Was the conflict of interest stated?</p> </li> </ol> </p> <p>For all items except item 4, a rating of 'yes' was considered adequate. For item 4, a rating of ‘no’ was considered adequate. A review that adequately met all of the 11 criteria was considered to be a review of the highest quality. For this overview, we considered reviews that achieved scores of between 8 to 11 as high quality; scores of 4 to 7 as medium quality; and scores of 0 to 3 as low quality. </p> <p>To further assess the risk of bias of the systematic reviews, we used the new ROBIS (Risk Of Bias In Systematic reviews) tool (<a href="./references#CD012077-bbs2-0122" title="WhitingP , SavovicJ , HigginsJ , SheaB , ReevesB , CaldwellD , et al. ROBIS: a new tool to assess the risk of bias in a systematic review. Cochrane Colloquium. 2014 September 21‐16; Hyderabad. Hyderabad, India: Cochrane Collaboration. Available from colloquium.cochrane.org/abstracts/robis‐new‐tool‐assess‐risk‐bias‐systematic‐review, 2014. ">Whiting 2014</a>). The tool considers risk of bias across four key domains. </p> <p> <ol id="CD012077-list-0008"> <li> <p>Study eligibility criteria.</p> </li> <li> <p>Identification and selection of studies.</p> </li> <li> <p>Data collection and study appraisal.</p> </li> <li> <p>Synthesis and findings.</p> </li> </ol> </p> <p>A series of questions within each of the domains elicits information about possible limitations of the systematic review, leading to a judgement about the concerns within that domain (low, high, or unclear). Assessors then consider the risk of bias of the review as a whole, with signalling questions and information to support the overall judgement of risk of low, high or unclear bias (<a href="./references#CD012077-bbs2-0122" title="WhitingP , SavovicJ , HigginsJ , SheaB , ReevesB , CaldwellD , et al. ROBIS: a new tool to assess the risk of bias in a systematic review. Cochrane Colloquium. 2014 September 21‐16; Hyderabad. Hyderabad, India: Cochrane Collaboration. Available from colloquium.cochrane.org/abstracts/robis‐new‐tool‐assess‐risk‐bias‐systematic‐review, 2014. ">Whiting 2014</a>). </p> <p>Two overview authors independently assessed the quality of the included reviews; another overview author verified this assessment. We resolved differences through discussion. </p> </section> <section id="CD012077-sec-0039"> <h5 class="title">Quality of included studies within reviews</h5> <p>We did not reassess the quality of included studies within reviews but reported study quality according to the review authors' assessment. When individual studies were included in two or more Cochrane reviews, we reported this, along with any variation in the review authors' assessments of study quality. We collected this information during the data extraction process. </p> </section> <section id="CD012077-sec-0040"> <h5 class="title">Quality of evidence in included reviews</h5> <p>We assessed the quality of the evidence for our primary outcome (cerebral palsy) and secondary review outcomes using the GRADE approach, as outlined in the <i>GRADE Handbook</i> (<a href="./references#CD012077-bbs2-0114" title="SchünemannH , BrożekJ , GuyattG , OxmanA (editors) . GRADE Handbook. The GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html. ">Schünemann 2013</a>). We reported the quality of evidence as assessed by the review authors (who were in the best position to assess quality given their familiarity with the study‐level data), using ‘Summary of findings’ tables from the reviews if provided. Where necessary, we constructed tables using GRADEpro GDT software (<a href="./references#CD012077-bbs2-0070" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>). The GRADE system assesses the following features for the evidence found for important outcomes. </p> <p> <ul id="CD012077-list-0009"> <li> <p>Study limitations (risk of bias): internal validity of the evidence.</p> </li> <li> <p>Inconsistency: heterogeneity or variability in the estimates of effect across studies.</p> </li> <li> <p>Indirectness: degree of differences between population, intervention, comparator, for the intervention and outcome of interest. </p> </li> <li> <p>Imprecision (random error): extent to which confidence in the effect estimate is adequate to support a particular decision. </p> </li> <li> <p>Publication bias: degree of selective publication of studies.</p> </li> </ul> </p> <p>The GRADE system rates the quality of the evidence as:</p> <p> <ul id="CD012077-list-0010"> <li> <p>High (further research is very unlikely to change confidence in the estimate of effect).</p> </li> <li> <p>Moderate (further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate). </p> </li> <li> <p>Low (further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate). </p> </li> <li> <p>Very low (any estimate of effect is very uncertain).</p> </li> </ul> </p> </section> </section> <section id="CD012077-sec-0041"> <h4 class="title">Data synthesis</h4> <p>We used a narrative description of the characteristics of the included Cochrane reviews.</p> <p>We summarised the main results of the included reviews by categorising their findings in the following framework, organised by antenatal or intrapartum intervention, and by intervention topic. This approach was used in previous Cochrane and non‐Cochrane overviews (i.e. <a href="./references#CD012077-bbs2-0069" title="FarquharC , RishworthJR , BrownJ , NelenWLDM , MarjoribanksJ . Assisted reproductive technology: an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD010537.pub4] ">Farquhar 2015</a>; <a href="./references#CD012077-bbs2-0087" title="LassiZS , MiddletonPF , CrowtherC , BhuttaZA . Interventions to improve neonatal health and later survival: an overview of systematic reviews. EBioMedicine2015;2(8):983‐98. ">Lassi 2015</a>). A similar approach was also used in <a href="./references#CD012077-bbs2-0083" title="JonesL , OthmanM , DowswellT , AlfirevicZ , GatesS , NewburnM , et al. Pain management for women in labour: an overview of systematic reviews. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD009234.pub2] ">Jones 2012</a>, in which interventions were categorised as 'what works', 'what may work', and 'insufficient evidence to make a judgement'. </p> <p> <ul id="CD012077-list-0011"> <li> <p>Effective interventions: indicated that the review found high‐quality evidence of effectiveness for an intervention. </p> </li> <li> <p>Possibly effective interventions: indicated that the review found moderate‐quality evidence of effectiveness for an intervention, but more evidence is needed. </p> </li> <li> <p>Ineffective interventions: indicated that the review found high‐quality evidence of lack of effectiveness (or harm) for an intervention. </p> </li> <li> <p>Probably ineffective interventions: indicated that the review found moderate‐quality evidence suggesting lack of effectiveness (or harm) for an intervention, but more evidence is needed. </p> </li> <li> <p>No conclusions possible: indicated that the review found low or very low‐quality evidence, or insufficient evidence to comment on the effectiveness or safety of an intervention. </p> </li> </ul> </p> <p>The choice of category was based on the quality of the evidence for cerebral palsy. We used separate assessments for different comparisons if required (e.g. where one intervention was compared with both placebo (or no treatment) and an alternative intervention). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012077-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012077-sec-0042"></div> <p>Our search of the <i>Cochrane Database of Systematic Reviews</i> identified 500 protocols and reviews. Following our review of titles and abstracts, we excluded 381 protocols and reviews, and assessed the full‐text of 119 protocols and reviews. </p> <p>We excluded 33 reviews that did not pre‐specify cerebral palsy as a primary or secondary review outcome (see <a href="./full#CD012077-tbl-0001">Table 1</a>: Characteristics of excluded studies). </p> <div class="table" id="CD012077-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of excluded reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reason for exclusion</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0016" title="Abou El SenounG , DowswellT , MousaHA . Planned home versus hospital care for preterm prelabour rupture of the membranes (PPROM) prior to 37 weeks' gestation. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD008053.pub3] ">Abou El Senoun 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary neonatal outcomes included:</p> <p> <ul id="CD012077-list-0012"> <li> <p>Disability at time of childhood follow‐up (as defined by authors).</p> </li> <li> <p>Serious disability (as defined by authors) after two years.</p> </li> </ul> </p> <p>No outcome data for these outcomes.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0017" title="BrickerL , MedleyN , PrattJJ . Routine ultrasound in late pregnancy (after 24 weeks' gestation). Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD001451.pub4] ">Bricker 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcomes included:</p> <p> <ul id="CD012077-list-0013"> <li> <p>Neurodevelopment at age two.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0018" title="BuchananSL , CrowtherCA , LevettKM , MiddletonP , MorrisJ . Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. Cochrane Database of Systematic Reviews2010, Issue 3. [DOI: 10.1002/14651858.CD004735.pub3] ">Buchanan 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary neonatal outcomes included:</p> <p> <ul id="CD012077-list-0014"> <li> <p>Disability at time of childhood follow‐up.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0019" title="ChapmanE , ReveizL , IllanesE , Bonfill CospX . Antibiotic regimens for management of intra‐amniotic infection. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD010976.pub2] ">Chapman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0020" title="CrowleyAE , GrivellRM , DoddJM . Sealing procedures for preterm prelabour rupture of membranes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD010218.pub2] ">Crowley 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary infant outcomes included:</p> <p> <ul id="CD012077-list-0015"> <li> <p>Neurodevelopmental delay at 12 months and 24 months.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0021" title="DareMR , MiddletonP , CrowtherCA , FlenadyV , VaratharajuB . Planned early birth versus expectant management (waiting) for prelabour rupture of membranes at term (37 weeks or more). Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD005302.pub2] ">Dare 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>foetal, neonatal, and infant outcomes included:</p> <p> <ul id="CD012077-list-0016"> <li> <p>Disability at time of childhood follow‐up.</p> </li> </ul> </p> <p>No outcome data for this outcome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0022" title="EastCE , BeggL , ColditzPB , LauR . Fetal pulse oximetry for fetal assessment in labour. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD004075.pub4] ">East 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcomes included:</p> <p> <ul id="CD012077-list-0017"> <li> <p>Long‐term neurodevelopmental outcome.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0023" title="GomiH , GotoY , LaopaiboonM , UsuiR , MoriR . Routine blood cultures in the management of pyelonephritis in pregnancy for improving outcomes. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD009216.pub2] ">Gomi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0024" title="HanS , CrowtherCA , MooreV . Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD000940.pub3] ">Han 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcomes included:</p> <p> <ul id="CD012077-list-0018"> <li> <p>Any neurological disability at follow‐up.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0025" title="HofmeyrGJ , BarrettJF , CrowtherCA . Planned caesarean section for women with a twin pregnancy. Cochrane Database of Systematic Reviews2015, Issue 12. [DOI: 10.1002/14651858.CD006553.pub3] ">Hofmeyr 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcomes included:</p> <p> <ul id="CD012077-list-0019"> <li> <p>Perinatal or infant death (excluding fatal anomalies) or disability in childhood.</p> </li> </ul> </p> <p>Secondary long‐term infant outcomes included:</p> <p> <ul id="CD012077-list-0020"> <li> <p>Disability in childhood, as defined by trial authors.</p> </li> </ul> </p> <p>No outcome data for these outcomes.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0026" title="HopkinsL , SmaillFM . Antibiotic regimens for management of intra‐amniotic infection. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD003254] ">Hopkins 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0027" title="KenyonS , BoulvainM , NeilsonJP . Antibiotics for preterm rupture of membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD001058.pub3] ">Kenyon 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary outcome included:</p> <p> <ul id="CD012077-list-0021"> <li> <p>Long‐term health outcomes (as defined by trial authors) after at least two years.</p> </li> </ul> </p> <p>Outcome data only reported for 'Serious childhood disability at seven years'.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0028" title="KhunpraditS , LumbiganonP , LaopaiboonM . Admission tests other than cardiotocography for fetal assessment during labour. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008410.pub2] ">Khunpradit 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary outcomes include:</p> <p> <ul id="CD012077-list-0022"> <li> <p>Neonatal neurodevelopment.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0029" title="KiizaJAK , HofmeyrGJ . Amnioinfusion for chorioamnionitis. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011622] ">Kiiza 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Protocol.</p> <p>Secondary baby outcomes will include:</p> <p> <ul id="CD012077-list-0023"> <li> <p>Long‐term neurodevelopmental outcome.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0030" title="LewinS , Munabi‐BabigumiraS , GlentonC , DanielsK , Bosch‐CapblanchX , VanWykBE , et al. Lay health workers in primary and community health care for maternal and child health and the management of infectious diseases. Cochrane Database of Systematic Reviews2010, Issue 3. [DOI: 10.1002/14651858.CD004015.pub3] ">Lewin 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0031" title="LutomskiJE , MeaneyS , GreeneRA , RyanAC , DevaneD . Expert systems for fetal assessment in labour. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD010708.pub2] ">Lutomski 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0032" title="MackeenAD , Seibel‐SeamonJ , MuhammadJ , BaxterJK , BerghellaV . Tocolytics for preterm premature rupture of membranes. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD007062.pub3] ">Mackeen 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0033" title="NeilsonJP . Interventions for suspected placenta praevia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD001998] ">Neilson 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0034" title="OlsenO , ClausenJA . Planned hospital birth versus planned home birth. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD000352.pub2] ">Olsen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0035" title="OthmanM , AlfirevicZ , NeilsonJP . Probiotics for preventing preterm labour. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD005941.pub2] ">Othman 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0036" title="SangkomkamhangUS , LumbiganonP , PrasertcharoensukW , LaopaiboonM . Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD006178.pub3] ">Sangkomkamhang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0037" title="SayL , GülmezogluAM , HofmeyrGJ . Transcutaneous electrostimulation for suspected placental insufficiency (diagnosed by Doppler studies). Cochrane Database of Systematic Reviews1996, Issue 1. [DOI: 10.1002/14651858.CD000079] ">Say 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0038" title="SayL , GülmezogluAM , HofmeyrGJ . Plasma volume expansion for suspected impaired fetal growth. Cochrane Database of Systematic Reviews1996, Issue 4. [DOI: 10.1002/14651858.CD000167] ">Say 1996a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0039" title="SayL , GülmezogluAM , HofmeyrGJ . Calcium channel blockers for potential impaired fetal growth. Cochrane Database of Systematic Reviews1996, Issue 1. [DOI: 10.1002/14651858.CD000049] ">Say 1996b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0040" title="SayL , GülmezogluAM , HofmeyrGJ . Bed rest in hospital for suspected impaired fetal growth. Cochrane Database of Systematic Reviews1996, Issue 1. [DOI: 10.1002/14651858.CD000034] ">Say 1996c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0041" title="SayL , GülmezogluAM , HofmeyrGJ . Betamimetics for suspected impaired fetal growth. Cochrane Database of Systematic Reviews2001, Issue 4. [DOI: 10.1002/14651858.CD000036] ">Say 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0042" title="SayL , GülmezogluAM , HofmeyrGJ . Maternal oxygen administration for suspected impaired fetal growth. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD000137] ">Say 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0043" title="SayL , GülmezogluAM , HofmeyrGJ . Maternal nutrient supplementation for suspected impaired fetal growth. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD000148] ">Say 2003a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0044" title="SayL , GülmezogluAM , HofmeyrGJ . Hormones for suspected impaired fetal growth. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD000109] ">Say 2003b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0045" title="SiegfriedN , Van derMerweL , BrocklehurstP , SintTT . Antiretrovirals for reducing the risk of mother‐to‐child transmission of HIV infection. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD003510.pub3] ">Siegfried 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0046" title="SiriwachirachaiT , SangkomkamhangUS , LumbiganonP , LaopaiboonM . Antibiotics for meconium‐stained amniotic fluid in labour for preventing maternal and neonatal infections. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD007772.pub3] ">Siriwachirachai 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0047" title="StanCM , BoulvainM , PfisterR , Hirsbrunner‐AlmagbalyP . Hydration for treatment of preterm labour. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD003096.pub2] ">Stan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary outcomes included:</p> <p> <ul id="CD012077-list-0024"> <li> <p>Long‐term sequelae: neurologic impairment and chronic lung disease.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0048" title="ThomasJT , MullerP , WilkinsonCS . Antenatal phenobarbital for reducing neonatal jaundice after red cell isoimmunization. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005541.pub2] ">Thomas 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes included:</p> <p> <ul id="CD012077-list-0025"> <li> <p>Adverse neonatal outcomes in terms of longer‐term neurological outcomes.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> </tbody> </table> </div> <p>We listed 71 protocols and reviews in the appendices.</p> <p> <ul id="CD012077-list-0026"> <li> <p><a href="./appendices#CD012077-sec-0073">Appendix 1</a>, Ongoing reviews, lists nine Cochrane protocols that have pre‐specified cerebral palsy as a primary or secondary outcome, and will be considered for inclusion in future updates of the overview when they are published as full reviews. </p> </li> <li> <p><a href="./appendices#CD012077-sec-0074">Appendix 2</a>, Reviews awaiting further classification, summarises the 62 Cochrane reviews that pre‐specified cerebral palsy as a primary or secondary outcome, but the included trials had no data reported on this outcome; these reviews will again be considered for inclusion in future updates of the overview. </p> </li> </ul> </p> <p>We included 15 reviews in this overview. See <a href="./full#CD012077-fig-0001">Figure 1</a>. Review flow diagram, for details. </p> <div class="figure" id="CD012077-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Review flow diagram." data-id="CD012077-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012077.pub2/media/CDSR/CD012077/image_n/nCD012077-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Review flow diagram.</p> </div> </div> </div> <section id="CD012077-sec-0043"> <h3 class="title" id="CD012077-sec-0043">Description of included reviews</h3> <p>Of the 15 included reviews:</p> <p> <ul id="CD012077-list-0027"> <li> <p>two focused on the treatment of mild to moderate hypertension:</p> <ul id="CD012077-list-0028"> <li> <p>antihypertensive drug therapy for mild to moderate hypertension during pregnancy (<a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a>); </p> </li> <li> <p>oral beta‐blockers for mild to moderate hypertension during pregnancy (<a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a>). </p> </li> </ul> </li> <li> <p>two assessed interventions for the treatment of pre‐eclampsia:</p> <ul id="CD012077-list-0029"> <li> <p>interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation (<a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a>); </p> </li> <li> <p>magnesium sulphate and other anticonvulsants for women with pre‐eclampsia (<a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a>). </p> </li> </ul> </li> </ul> <ul id="CD012077-list-0030"> <li> <p>one focused on interventions for the diagnosis and prevention of fetal compromise in labour: </p> <ul id="CD012077-list-0031"> <li> <p>continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour (<a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a>). </p> </li> </ul> </li> </ul> <ul id="CD012077-list-0032"> <li> <p>four assessed interventions for the prevention of preterm birth:</p> <ul id="CD012077-list-0033"> <li> <p>prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth (<a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a>); </p> </li> <li> <p>prophylactic antibiotics for inhibiting preterm labour with intact membranes (<a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a>); </p> </li> <li> <p>magnesium sulphate for preventing preterm birth in threatened preterm labour (<a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a>); </p> </li> <li> <p>betamimetics for inhibiting preterm labour (<a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a>). </p> </li> </ul> </li> <li> <p>five focused on interventions prior to preterm birth for fetal maturation or neuroprotection:</p> <ul id="CD012077-list-0034"> <li> <p>vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a>); </p> </li> <li> <p>phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a>); </p> </li> <li> <p>magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>); </p> </li> <li> <p>repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes (<a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a>); </p> </li> <li> <p>antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (<a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a>). </p> </li> </ul> </li> <li> <p>one focused on interventions for the management of preterm fetal compromise:</p> <ul id="CD012077-list-0035"> <li> <p>immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes (<a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a>). </p> </li> </ul> </li> </ul> </p> <p>The number of randomised controlled trials (RCT) in the 15 reviews ranged from one (<a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a>) to 49 (<a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a>). The number of women in each RCT ranged from 425 (<a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a>) to 37,715 (<a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a>). In total, there were 279 randomised trials, involving over 101,098 women and their babies. </p> <p>One third (five) of the 15 reviews had conducted searches between August 2013 and August 2016, and were considered up‐to‐date (<a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a>; <a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a>; <a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a>; <a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a>; <a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a>). The other 10 reviews had latest search dates ranging from August 2008 to April 2013. </p> <p>See <a href="#CD012077-tbl-0002">Table 2</a>, Characteristics of included reviews and <a href="#CD012077-tbl-0003">Table 3</a>, Risk of bias assessments from included reviews, for further details of the characteristics of the 15 included reviews. </p> <div class="table" id="CD012077-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included reviews</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Date of search; date assessed as up‐to‐date</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. included trials; countries and years of publication</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. participants in included trials</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion criteria for "Types of participants"</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relevant comparison interventions (no. trials and participants)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overview outcomes for which data were reported (pre‐specified unless stated otherwise)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 April 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 RCTs</p> <p>34 RCTs in industrialised countries (Australia, France, Hong Kong, Ireland, Israel, Italy, Sweden, UK and USA) </p> <p>15 RCTs in low‐ or middle‐income countries (Argentina, Brazil, Caribbean Islands, India, South Africa, Sudan and Venezuela) </p> <p>RCTs published in:</p> <p>1960s: 1</p> <p>1970s: 2</p> <p>1980s: 22</p> <p>1990s: 17</p> <p>2000s: 5</p> <p>2010s; 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4723 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women with mild to moderate hypertension during pregnancy, regardless of whether or not they had proteinuria, previous antihypertensive treatment, or whether the pregnancy was singleton or multiple </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>any antihypertensive drug versus no drugs</p> <p>(29 RCTs, 3350 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary outcome</p> <p>primary outcome was impaired long‐term growth and development in infancy and childhood</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 31 December 2012</p> <p>Up‐to‐date: 31 January 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 RCTs (1 qRCT)</p> <p>No. RCTs in:</p> <p>Australia: 2</p> <p>Denmark: 1</p> <p>Greece: 1</p> <p>India: 1</p> <p>Ireland: 2</p> <p>Pakistan: 1</p> <p>Sweden: 1</p> <p>UK: 1</p> <p>USA: 3</p> <p>RCTs published in:</p> <p>1970s: 4</p> <p>1980s: 6</p> <p>1990s: 2</p> <p>2000s: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37,715 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pregnant women in labour and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>continuous cardiotocography versus intermittent auscultation</p> <p>(12 RCTs, 33,681 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a primary review outcome</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 28 February 2013</p> <p>Up‐to‐date:</p> <p>10 July 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 RCTs</p> <p>No. RCTs in:</p> <p>Egypt: 1</p> <p>Europe: 1</p> <p>South Africa: 1</p> <p>USA: 1</p> <p>RCTs published in:</p> <p>1990s: 2</p> <p>2000s: 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>425 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women with severe pre‐eclampsia, up to and including 34 weeks' gestation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>interventionist care versus expectant (delayed delivery) care</p> <p>(4 RCTs, 425 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary review outcome</p> <p>pre‐specified outcome was 'measures of long‐term growth and development, such as important impairment and cerebral palsy' </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 20 December 2010</p> <p>Up‐to‐date:</p> <p>15 February 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 RCTs Countries of trials not reported</p> <p>RCTs published in:</p> <p>1980s: 4</p> <p>1990s: 3</p> <p>2000s: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>879 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women at risk of imminent very preterm birth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>vitamin K versus control</p> <p>(8 RCTs, 879 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a primary review outcome</p> <p>pre‐specified outcome was long‐term neurodevelopment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 20 December 2010</p> <p>Up‐to‐date: 9 January 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 RCTs</p> <p>Countries of trials not reported</p> <p>RCTs published in:</p> <p>1980s: 4</p> <p>1990s: 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1752 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women at risk of imminent very preterm birth (before 34 weeks' gestation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>phenobarbital versus control</p> <p>(9 RCTs, 1752 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy, motor dysfunction (other neuromotor impairment) reported as primary review outcomes </p> <p>pre‐specified outcome was 'long‐term neurodevelopment'</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 January 2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 RCTs (4 qRCTs)</p> <p>No. RCTs in: China: 3</p> <p>Iran: 5</p> <p>Italy: 1</p> <p>Mexico: 1</p> <p>Thailand: 1</p> <p>Turkey: 1</p> <p>USA: 25</p> <p>RCTs published in:</p> <p>1980s: 7</p> <p>1990s: 18</p> <p>2000s: 10</p> <p>2010s: 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3571 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women considered to be in preterm labour given magnesium sulphate to reduce their risk of preterm birth </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>magnesium sulphate versus placebo, no treatment, or other tocolytic agent</p> <p>(37 RCTs, 3571 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary review outcome</p> <p>primary review outcome was a composite outcome including cerebral palsy, listed as 'serious infant outcome' ("...death or chronic lung disease...grade three or four intraventricular haemorrhage or periventricular leukomalacia, major neurosensory disability (legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy, or developmental delay or intellectual impairment...))" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 January 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 RCTs</p> <p>No. RCTs in:</p> <p>Australia and New Zealand: 1</p> <p>Canada: 1</p> <p>Finland: 1</p> <p>India: 1</p> <p>USA: 5</p> <p>20 countries: 1</p> <p>RCTs published in:</p> <p>2000s: 9</p> <p>2010s: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4733 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women considered to be at risk of preterm birth who had already received a single course of prenatal corticosteroid seven or more days previously </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>repeat doses of prenatal corticosteroids versus placebo or no treatment</p> <p>(10 RCTs, 4733 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary review outcome;</p> <p>composite primary outcomes that included cerebral palsy</p> <p> <ul id="CD012077-list-0036"> <li> <p>survival free of any disability (however defined by authors)</p> </li> </ul> <ul id="CD012077-list-0037"> <li> <p>survival free of major disability (however defined by authors)</p> </li> </ul> <ul id="CD012077-list-0038"> <li> <p>major neurosensory disability (not pre‐specified)</p> </li> </ul> <ul id="CD012077-list-0039"> <li> <p>disability at childhood follow‐up (however defined by authors)</p> </li> </ul> <ul id="CD012077-list-0040"> <li> <p>composite serious outcome (however defined by authors)</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 January 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 RCTs</p> <p>No. RCTs in:</p> <p>Albania: 1</p> <p>Brazil: 1</p> <p>Denmark and Austria: 1</p> <p>Egypt: 3</p> <p>Finland: 1</p> <p>France: 3</p> <p>India: 2</p> <p>Iran: 5</p> <p>Italy: 1</p> <p>Netherlands: 1</p> <p>Spain: 1</p> <p>Turkey: 1</p> <p>UK: 1</p> <p>USA: 11</p> <p>international: 3</p> <p>RCTs published in:</p> <p>1970s: 2</p> <p>1980s: 2</p> <p>2000s: 13</p> <p>2010s: 19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8523 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pregnant women considered to be at increased risk of preterm birth:</p> <p> <ul id="CD012077-list-0041"> <li> <p>Past history of spontaneous preterm birth</p> </li> <li> <p>Multiple pregnancy</p> </li> <li> <p>Ultrasound identified short cervical length</p> </li> <li> <p>fetal fibronectin testing</p> </li> <li> <p>Following acute presentation with symptoms or signs of threatened preterm labour</p> </li> <li> <p>Other reason considered to be at increased risk of preterm birth</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>progesterone versus placebo or no treatment</p> <p>(11 RCTs, 1899)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary review outcome</p> <p>motor dysfunction, pre‐specified as motor impairment, reported as secondary review outcome </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 31 August 2008</p> <p>Up‐to‐date: 5 November 2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 RCTs</p> <p>No. RCTs in: Australia and New Zealand: 1</p> <p>France: 1</p> <p>USA: 2</p> <p>international; 1 (predominately in developing countries)</p> <p>RCTs published in:</p> <p>2000s: 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5560 women and their 6145 babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women considered to be at risk of preterm birth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>magnesium sulphate versus placebo</p> <p>(5 RCTs, 6145 babies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy; cerebral palsy or death; severity of cerebral palsy (mild, moderate, moderate to severe, severe cerebral palsy); composite outcomes including cerebral palsy (any neurologic impairment; major neurological disability; death or any neurologic impairment; death or major neurological disability); motor dysfunction (substantial gross motor dysfunction; death or substantial gross motor dysfunction) reported as primary outcomes </p> <p>pre‐specified outcomes were: neurological impairments (developmental delay or intellectual impairment (developmental quotient or intelligence quotient less than one standard deviation (SD) below the mean), cerebral palsy (abnormality of tone with motor dysfunction), blindness (corrected visual acuity worse than 6/60 in the better eye), or deafness (hearing loss requiring amplification or worse)); neurological disabilities (abnormal neurological function caused by any of the preceding impairments) at follow‐up later in childhood; substantial gross motor dysfunction (motor dysfunction such that the child was not walking at age two years or later, or the inability to grasp and release a small block with both hands); major neurological disability (legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy, developmental delay or intellectual impairment (developmental quotient or intelligence quotient less than two SD below the mean)); paediatric mortality combined with cerebral palsy, substantial gross motor dysfunction, neurological impairment, or major neurological disability (these combined outcomes recognise the competing risks of death or survival with neurological problems) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 4 June 2010</p> <p>Up‐to‐date: 1 September 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 RCTs</p> <p>No. RCTs in: Denmark: 1</p> <p>India; 1</p> <p>Malaysia: 1</p> <p>Mexico: 2</p> <p>South Africa: 2</p> <p>Taiwan: 1</p> <p>USA: 5</p> <p>international: 2 (1 in 33 countries, with 85% recruitment in low‐ and middle‐income countries; 1 in 8 countries) </p> <p>RCTs published in:</p> <p>1990s: 10</p> <p>2000s: 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,570 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>any women with pre‐eclampsia, regardless of whether: before or after delivery, a singleton or multiple pregnancy, or whether an anticonvulsant had been given before trial entry </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>magnesium sulphate versus placebo or no anticonvulsant</p> <p>(6 RCTs, 11,444 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>severe cerebral palsy; other composite outcomes including cerebral palsy (neurosensory disability; death or neurosensory disability) were all reported as secondary review outcomes </p> <p>pre‐specified outcomes were 'long‐term growth and development: blindness, deafness, seizures, poor growth, neurodevelopmental delay and cerebral palsy' </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 31 August 2013</p> <p>Up‐to‐date: 3 October 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 RCTs</p> <p>No. RCTs in:</p> <p>Canada: 1</p> <p>Chile: 1</p> <p>Denmark: 1</p> <p>Germany: 1</p> <p>Iran: 1</p> <p>South Africa: 1</p> <p>Uruguay: 1</p> <p>USA: 6</p> <p>international: 1</p> <p>RCTs published in:</p> <p>1980s: 1</p> <p>1990s: 10</p> <p>2000s: 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7837 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women thought to be in preterm labour with intact membranes, between 20 and 36 completed weeks of gestation </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>any antibiotics versus no antibiotics</p> <p>(14 RCTs, 7837 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a primary review outcome</p> <p>pre‐specified outcome was 'major long‐term infant neurosensory impairment'</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search:</p> <p>4 July 2012 (r<i>esults added to Studies awaiting classification</i>) </p> <p>Up‐to‐date: 30 January 2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 RCTs</p> <p>No. RCTs in:</p> <p>Argentina: 1</p> <p>Australia: 2</p> <p>Brazil: 1</p> <p>England: 5</p> <p>Fr Caribbean: 1</p> <p>France: 3</p> <p>Hong Kong: 1</p> <p>India: 1</p> <p>Israel: 4</p> <p>Scotland: 4</p> <p>Sweden: 3</p> <p>USA: 2</p> <p>Venezuela: 1</p> <p>RCTs published in:</p> <p>1970s: 1</p> <p>1980s: 17</p> <p>1990s: 11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2548 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women with mild to moderate hypertension during pregnancy, however defined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>beta‐blockers versus placebo or no beta‐blocker</p> <p>(13 RCTs, 1480 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy reported as a review outcome, rather than primary or secondary</p> <p>pre‐specified outcome was 'measures of long‐term health and development such as cerebral palsy' </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 RCTs (20 RCTs contributed data)</p> <p>No. RCTs in:</p> <p>Australia: 1</p> <p>Canada: 1</p> <p>Europe: 6</p> <p>Iran: 1</p> <p>Italy: 1</p> <p>Japan: 1</p> <p>Sweden: 1</p> <p>USA: 10</p> <p>not reported: 6</p> <p>RCTs published in:</p> <p>1960s: 1</p> <p>1970s: 5</p> <p>1980s: 18</p> <p>1990s: 3</p> <p>2010s: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2715 women and their babies in 20 RCTs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pregnant women assessed as being in spontaneous preterm labour and considered suitable for tocolytic agents </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>betamimetics versus placebo</p> <p>(12 RCTs, 1367 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy reported as a primary review outcome</p> <p>pre‐specified outcome was 'abnormal long‐term neurodevelopmental status at more than 12 months corrected age (moderate to severe developmental delay, cerebral palsy, sensory impairment, for example, blind and deaf, or a combination)' </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 30 April 2010 (added the search to Studies awaiting classification)</p> <p>Up‐to‐date:</p> <p>15 May 2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 RCTs</p> <p>No. RCTs in:</p> <p>Brazil: 1</p> <p>Canada: 1</p> <p>Finland: 2</p> <p>Jordan: 1 RCT</p> <p>Netherlands: 1</p> <p>New Zealand: 1</p> <p>South Africa: 1</p> <p>Spain: 1</p> <p>Tunisia: 1</p> <p>UK: 1</p> <p>USA: 10</p> <p>RCTs published in:</p> <p>1970s: 3</p> <p>1980s: 8</p> <p>1990s: 8</p> <p>2000s: 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>over 3999 women (data available for 3885 women and their babies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women with a singleton or multiple pregnancy, expected to deliver preterm as a result of either spontaneous preterm labour, preterm pre‐labour rupture of the membranes, or elective preterm delivery </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>antenatal corticosteroids versus placebo or no treatment</p> <p>(21 RCTs, 3885 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary review outcome</p> <p>other composite outcome including cerebral palsy (neurodevelopmental delay) reported as a primary review outcome </p> <p>pre‐specified primary outcome was 'neurodevelopmental disability' at follow‐up (blindness, deafness, moderate/severe cerebral palsy (however defined by authors), or development delay or intellectual impairment (defined as developmental quotient or intelligence quotient less than 2 SD below population mean))' </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 April 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 RCT</p> <p>1 RCT in Belgium, Cyprus, Czech Republic, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Saudi Arabia, Slovenia, United Kingdom </p> <p>RCT published in 2000s</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>548 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pregnant women at less than 36 weeks' gestation in whom there was clinical suspicion of fetal compromise as defined by trialists </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immediate delivery versus deferred delivery</p> <p>(1 RCT, 548 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary outcome</p> <p>other composite outcomes including cerebral palsy (death or disability at or after two years of age) reported as a primary review outcome </p> <p>'neurodevelopmental impairment at or after two years of age' reported as a secondary outcome </p> <p>'death or severe disability in childhood' reported but not pre‐specified</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviation: RCT: randomised controlled trial</p> </div> </div> <div class="table" id="CD012077-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of bias assessments from included reviews</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Summary of trial limitations (risk of bias)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 12 RCTs low risk; 35 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Allocation concealment:</b> 17 RCTs low risk; 32 RCTs unclear risk </p> <p><b>Blinding (participants and personnel):</b> 10 RCTs low risk; 1 RCT unclear risk; 38 RCTs high risk </p> <p><b>Blinding (outcome assessors):</b> 10 RCTs low risk; 2 RCTs unclear risk; 37 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 45 RCTs low risk; 4 RCTs high risk </p> <p><b>Selective reporting:</b> 9 RCTs low risk; 40 RCTs unclear risk </p> <p><b>Other:</b> 23 RCTs low risk; 24 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Overall:</b> "Overall, the quality of the studies included in this review is moderate to poor" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 3 RCTs low risk; 8 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Allocation concealment:</b> 3 RCTs low risk; 6 RCTs unclear risk; 4 RCTs high risk </p> <p><b>Blinding (participants and personnel):</b> 13 RCTs high risk </p> <p><b>Blinding (outcome assessors):</b> 12 RCTs unclear risk; 1 RCT high risk </p> <p><b>Incomplete outcome data:</b> 8 RCTs low risk; 3 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Selective reporting:</b> 13 RCTs high risk </p> <p><b>Other:</b> 13 RCTs low risk </p> <p><b>Overall:</b> Only 2 RCTs were judged to be of high quality. </p> <p>"The overall quality of the evidence can best be described as low to moderate"</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 3 RCTs low risk; 1 RCT unclear risk </p> <p><b>Allocation concealment:</b> 3 RCTs low risk; 1 RCT unclear risk </p> <p><b>Blinding (participants and personnel):</b> 1 RCT low risk; 3 RCTs unclear risk </p> <p><b>Blinding (outcome assessors):</b> 1 RCT low risk; 3 RCTs unclear risk </p> <p><b>Incomplete outcome data:</b> 1 RCT low risk; 2 RCTs unclear risk; 1 RCT high risk </p> <p><b>Selective reporting:</b> 4 RCTs low risk </p> <p><b>Other:</b> 1 RCT low risk; 2 RCTs unclear; 1 RCT high risk </p> <p><b>Overall:</b> "Overall, two trials were judged to have a low risk of bias, one was unclear and one a high risk of bias" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 2 RCTs low risk; 4 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Allocation concealment:</b> 7 RCTs unclear risk; 1 RCT high risk </p> <p><b>Blinding:</b> 2 RCTs low risk; 1 RCT unclear risk; 5 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 3 RCTs low risk; 4 RCTs unclear risk; 1 RCT high risk </p> <p><b>Selective reporting:</b> 6 RCTs low risk; 2 RCTs unclear risk </p> <p><b>Other:</b> 5 RCTs low risk; 2 RCTs unclear risk; 1 RCT high risk </p> <p><b>Overall:</b> "The trials were of variable quality." </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 1 RCT low risk; 4 RCTs unclear risk; 4 RCTs high risk </p> <p><b>Allocation concealment:</b> 7 RCTs unclear risk; 1 RCT high risk; 1 RCT: not reported </p> <p><b>Blinding:</b> 4 RCTs low risk; 1 RCT unclear risk; 4 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 1 RCT low risk; 5 RCTs unclear risk; 3 RCTs high risk </p> <p><b>Selective reporting:</b> 9 RCTs low risk </p> <p><b>Other:</b> 6 RCTs low risk; 1 RCT unclear risk; 2 RCTs high risk </p> <p><b>Overall:</b> "Poor‐quality trials contribute excessively to the weight in the overall analysis due to the higher rate of adverse outcomes in those trials" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 15 RCTs low risk; 18 RCTs unclear risk; 4 RCTs high risk </p> <p><b>Allocation concealment:</b> 6 RCTs low risk; 27 RCTs unclear risk; 4 RCTs high risk </p> <p><b>Blinding (participants and personnel):</b> 4 RCTs low risk; 7 RCTs unclear risk; 26 RCTs high risk </p> <p><b>Blinding (outcome assessors):</b> 1 RCT low risk; 35 RCTs unclear risk; 1 RCT high risk </p> <p><b>Incomplete outcome data:</b> 20 RCTs low risk; 15 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Selective reporting:</b> 11 RCTs low risk; 19 RCTs unclear risk; 7 RCTs high risk </p> <p><b>Other:</b> 17 RCTs low risk; 20 RCTs unclear risk </p> <p><b>Overall: "</b>Overall, we judged the included trials to be of moderate to high risk of bias" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 8 RCTs low risk; 2 RCTs unclear risk </p> <p><b>Allocation concealment:</b> 10 RCTs low risk </p> <p><b>Blinding (participants and personnel):</b> 9 RCTs low risk; 1 RCT high risk </p> <p><b>Blinding (outcome assessors):</b> 4 RCTs low risk; 6 RCTs unclear risk </p> <p><b>Incomplete outcome data:</b> 7 RCTs low risk; 3 RCTs unclear risk </p> <p><b>Selective reporting:</b> 9 RCTs low risk; 1 RCT unclear risk </p> <p><b>Other:</b> 7 RCTs low risk; 3 RCTs high risk </p> <p><b>Overall:</b> "Overall, the included trials were assessed as having a low to moderate risk of bias" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 23 RCTs low risk; 13 RCTs unclear risk </p> <p><b>Allocation concealment:</b> 23 RCTs low risk; 13 RCTs unclear risk </p> <p><b>Blinding (participants and personnel):</b> 24 RCTs low risk; 7 RCTs unclear risk; 4 RCTs high risk </p> <p><b>Blinding (outcome assessors):</b> 15 RCTs low risk; 17 RCTs unclear risk; 4 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 31 RCTs low risk; 5 RCTs unclear risk </p> <p><b>Selective reporting:</b> 25 RCTs low risk; 10 RCTs unclear risk; 1 RCT high risk </p> <p><b>Other:</b> 21 RCTs low risk; 15 RCTs unclear risk </p> <p><b>Overall:</b> "The overall quality of the included trials varied from good to fair" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 4 RCTs low risk; 1 RCT unclear risk </p> <p><b>Allocation concealment:</b> 4 RCTs low risk; 1 RCT unclear risk </p> <p><b>Blinding:</b> 3 RCTs low risk; 2 RCT unclear risk </p> <p><b>Incomplete outcome data:</b> 2 RCTs low risk; 3 RCT unclear risk </p> <p><b>Selective reporting:</b> 4 RCTs low risk; 1 RCT unclear risk </p> <p><b>Overall:</b> "Overall, the methodological quality of the trials was relatively good, with a low risk of bias. However, the quality was better, and the risk of bias lower, in some studies compared with others" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 6 RCTs low risk; 9 RCTs unclear risk </p> <p><b>Allocation concealment:</b> 5 RCTs low risk; 9 RCTs unclear risk; 1 RCT high risk </p> <p><b>Blinding:</b> 4 RCTs low risk; 3 RCTs unclear risk; 8 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 7 RCTs low risk; 3 RCTs unclear risk; 5 RCTs high risk </p> <p><b>Overall:</b> "The quality of the studies included in this review ranged from excellent to poor. However, most of the poor quality studies were small. The large study comparing magnesium sulphate with placebo was of high quality" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 7 RCTs low risk; 7 RCTs unclear risk </p> <p><b>Allocation concealment:</b> 9 RCTs low risk; 5 RCTs unclear risk </p> <p><b>Blinding (participants and personnel):</b> 12 RCTs low risk; 2 RCTs high risk </p> <p><b>Blinding (outcome assessors):</b> 12 RCTs low risk; 2 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 13 RCTs low risk; 1 RCT unclear risk (long‐term: 1 RCT low risk; 13 RCTs unclear risk) </p> <p><b>Selective reporting:</b> 12 RCTs low risk; 2 RCTs unclear risk </p> <p><b>Other:</b> 13 RCTs low risk; 1 RCT unclear risk </p> <p><b>Overall:</b> "Overall the quality of the included trials was good" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Allocation concealment:</b> adequate in 5 RCT </p> <p><b>Double blinding (of physicians and patients) for outcome assessment:</b> 7 RCTs </p> <p><b>For maternal and pregnancy outcomes, follow up of greater than 90%:</b> 20 RCTs </p> <p><b>Overall:</b> "The quality of these trials was poor" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 12 RCTs low risk; 16 RCTs unclear risk </p> <p><b>Allocation concealment:</b> 7 RCTs low risk; 21 RCTs unclear risk </p> <p><b>Blinding (participants and personnel):</b> 15 RCTs low risk; 1 RCTs unclear risk; 12 RCTs high risk </p> <p><b>Blinding (outcome assessors):</b> 9 RCTs low risk; 8 RCTs unclear risk; 11 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 16 RCTs low risk; 10 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Selective reporting:</b> 1 RCT low risk; 26 RCTs unclear risk; 1 RCT high risk </p> <p><b>Other:</b> 8 RCTs low risk; 19 RCTs unclear risk; 1 RCT high risk </p> <p><b>Overall:</b> not detailed </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Allocation concealment:</b> 8 RCTs: A (adequate); 12 RCTs: B (unclear); 1 RCT: C (inadequate) </p> <p><b>Overall:</b> not detailed </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 1 RCT low risk </p> <p><b>Allocation concealment:</b> 1 RCT low risk </p> <p><b>Blinding (participants and personnel):</b> 1 RCT high risk </p> <p><b>Blinding (outcome assessors):</b> 1 RCT low risk </p> <p><b>Incomplete outcome data:</b> 1 RCT low risk (high for childhood outcomes) </p> <p><b>Selective reporting:</b> 1 RCT low risk </p> <p><b>Other:</b> 1 RCT high risk </p> <p><b>Overall:</b> "large study of good quality" </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviation: RCT: randomised controlled trial</p> </div> </div> </section> <section id="CD012077-sec-0044"> <h3 class="title" id="CD012077-sec-0044">Methodological quality of included reviews</h3> <p>According to AMSTAR criteria:</p> <p> <ol id="CD012077-list-0042"> <li> <p>all reviews pre‐specified their design;</p> </li> <li> <p>all reviews reported duplicate study selection and data extraction;</p> </li> <li> <p>all reviews performed a comprehensive literature search;</p> </li> <li> <p>all reviews considered grey literature;</p> </li> <li> <p>all reviews provided lists of included and excluded studies;</p> </li> <li> <p>all reviews provided the characteristics of the included studies;</p> </li> <li> <p>all reviews assessed and documented the scientific quality of the included studies;</p> </li> <li> <p>all reviews used scientific quality of the included studies appropriately in formulating conclusions; </p> </li> <li> <p>11 reviews combined the findings of studies using appropriate methods; in three reviews, fixed‐effect meta‐analyses were used despite the presence of substantial statistical heterogeneity; one review had only one included trial; </p> </li> <li> <p>11 reviews assessed the likelihood of publication bias (or pre‐specified which methods they would use if 10 or more trials were included in a meta‐analysis); </p> </li> <li> <p>three reviews clearly reported conflict of interests or potential sources of support for both the review and included studies. </p> </li> </ol> </p> <p>See <a href="#CD012077-tbl-0004">Table 4</a>: AMSTAR assessments for included reviews, for further details. </p> <div class="table" id="CD012077-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">AMSTAR assessments for included reviews</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Review ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p><b>AMSTAR criteria</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Total score</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>A priori design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duplicate selection and extraction</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comprehensive search</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grey literature considered</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Included and excluded studies lists</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Characteristics of included studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality assessed and documented</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality considered for conclusions</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Methods for combining studies appropriate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Publication bias considered or assessed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conflicts stated</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/10</p> <p>HIGH QUALITY</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>✓: item adequately addressed; ?: unclear whether item addressed; ✗: item not adequately addressed </p> </div> </div> <p>When assessed against the ROBIS domains, all reviews were considered at low risk of bias across the study eligibility criteria, identification and selection of studies, and data collection and study appraisal domains. Three of the reviews received an unclear risk of bias rating for the synthesis and findings domain (based on use of fixed‐effect meta‐analyses in the presence of substantial statistical heterogeneity). See <a href="#CD012077-tbl-0005">Table 5</a>: ROBIS assessments for included reviews, for further details. </p> <div class="table" id="CD012077-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROBIS assessments for included reviews</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Review ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>ROBIS domains</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study eligibility criteria</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Identification and selection of studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Data collection and study appraisal</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Synthesis and findings</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> </tbody> </table> </div> <p>Overall, all 15 included reviews were judged to be of high quality according to AMSTAR criteria, with scores ranging from 8 to 11, and at a low risk of bias, according to ROBIS domains. </p> </section> <section id="CD012077-sec-0045"> <h3 class="title" id="CD012077-sec-0045">Effect of interventions</h3> <p>We have summarised the main results of the included reviews below. They are organised by intervention topic and categorised in the framework discussed under <a href="#CD012077-sec-0041">Data synthesis</a>, based on the quality of the evidence for the presence of cerebral palsy, the primary outcome. </p> <p>For further details and 'Summary of findings' tables for the outcomes of interest, see <a href="#CD012077-tbl-0006">Table 6</a>, All comparisons measuring cerebral palsy; <a href="#CD012077-tbl-0007">Table 7</a>, Subgroup or sensitivity analyses of select comparisons for cerebral palsy; <a href="#CD012077-tbl-0008">Table 8</a>, All comparisons measuring cerebral palsy or death; <a href="#CD012077-tbl-0009">Table 9</a>, All comparisons measuring severity of cerebral palsy; <a href="#CD012077-tbl-0010">Table 10</a>, All comparisons measuring other composite outcomes that include cerebral palsy as a component; and <a href="#CD012077-tbl-0011">Table 11</a>, All comparisons measuring motor dysfunction. </p> <div class="table" id="CD012077-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Summary of findings: all comparisons measuring cerebral palsy</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention and comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the treatment of mild to moderate hypertension</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any antihypertensive drug versus placebo for mild to moderate hypertension during pregnancy (<a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a>) </p> <p>and</p> <p>Oral beta‐blockers versus placebo for mild to moderate hypertension during pregnancy (<a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 1 year (definition not clear; one child with 'spastic quadriparesis with a severe pseudo‐bulbar palsy') assessed by clinical evaluation </p> <p>(assessment method taken from RCT manuscript as not detailed in reviews)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> <p>(1/55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000 (0 to 146)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33 (95% CI 0.01 to 8.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VERY LOW</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear sequence generation, allocation concealment, and selective reporting </p> <p>Imprecision (‐2): Wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the treatment of pre‐eclampsia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventionist care versus expectant (delayed delivery) care for severe pre‐eclampsia (<a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cerebral palsy at 2 years (definition not clear) assessed by family practitioner or paediatrician using short questionnaire </p> <p>(assessment method taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> <p>(1/121)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000 (6 to 398)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 6.01 (95% CI 0.75 to 48.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulphate versus placebo for women with pre‐eclampsia (<a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe cerebral palsy at 18 months defined as 'not walking or unlikely to walk unaided by 24 months; children screened with Ages and Stages Questionnaires; screen‐positive and a sample of screen‐negative children had clinical and neurodevelopmental assessments (using Bayley Scales of Infant Development; Griffiths Tests, or other); if this was not possible, clinical history and examination (using the Health Status Questionnaire) </p> <p>(definition and assessment method taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> <p>(9/1464)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (1 to 8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.34 (95% CI 0.09 to 1.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2895 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of attrition bias for this outcome (2895 of 6922 children included in original RCT ) </p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the diagnosis and prevention of fetal compromise in labour</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous cardiotocography (CTG) versus intermittent auscultation (IA) for fetal assessment during labour (<a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months to 4 years</p> <p> <ul id="CD012077-list-0043"> <li> <p>1 RCT: defined as 'non‐progressive disorder of movement or posture due to a defect in or damage to the developing brain'; a developmental paediatrician performed neurological examinations at 18 months </p> </li> <li> <p>1 RCT: definition not clear; children with abnormal neurological signs in the neonatal period underwent a general physical and detailed neurological examination by a paediatrician at 4 years; other cases identified from records of specialist remedial clinics </p> </li> </ul> </p> <p>(definitions and assessment methods taken from RCT manuscripts as not detailed in review) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> <p>(17/6643)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 (2 to 9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>average RR 1.75 (95% 0.84 to 3.63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,252 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>quality of evidence (GRADE), taken from published review:</p> <p>"study limitations (‐1): most of the pooled effect provided by studies "B" or "C" without a substantial proportion (i.e. &lt; 40% (actual 0% weight) from studies "C" </p> <p>imprecision (‐1): 95% confidence interval around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable benefit favouring IA" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the prevention of preterm birth</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prenatal administration of progesterone versus placebo for preventing preterm birth in women with a previous history spontaneous preterm birth (singletons) (<a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 4 years, definition not clear; assessed by general physical examination by paediatrician or nurse practitioner, or from chart abstraction </p> <p>(age and assessment method taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> <p>(1/82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (0 to 42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.14 (95% 0.01 to 3.48)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any prophylactic antibiotics versus no antibiotics for inhibiting preterm labour with intact membranes (<a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 7 years, definition not clear; measured using proxy information provided by parents through a postal questionnaire (or by telephone in a small number) using validated tools </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> <p>(12/770)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000 (15 to 52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.82 (95% CI 0.99 to 3.34)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3173 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐1): wide confidence interval crossing the line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Betamimetics versus placebo for inhibiting preterm labour (<a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months, definition not clear; assessed by paediatrician examination</p> <p>(assessment method taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> <p>(5/121)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000 (1 to 67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.19 (95% CI 0.02 to 1.63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study limitations (‐1): 1 RCT at unclear risk of attrition bias for this outcome</p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect; 1 small RCT</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulphate versus other tocolytic agents for preventing preterm birth in threatened preterm labour (<a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months, definition not clear; assessed by neurodevelopment examinations at 4, 8, 12, and 18 months, with diagnoses made or verified by developmental paediatrician after 18 month examination </p> <p>(assessment method taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> <p>(3/51)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000 (1 to 148)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.13 (95% CI 0.01 to 2.51)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VERY LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of selection, attrition, and reporting bias, and high risk of performance bias </p> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions prior to preterm birth for fetalmaturation or neuroprotection</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenobarbital versus placebo or no treatment prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months to 3 years</p> <p> <ul id="CD012077-list-0044"> <li> <p>1 RCT: defined as presence of hypertonicity, hyperreflexia, and dystonic or spastic movement quality in the affected extremity (including diplegia, hemiplegia, triplegia, or quadriplegia); assessed by certified examiners trained to perform neurologic examinations at 18 months </p> </li> <li> <p>1 RCT: described as cerebral palsy associated with motor delay (diplegia, monoplegia, quadriplegia, and hemiplegia); assessed by trained nurse practitioner using detailed physical and neurologic examination at 3 years </p> </li> </ul> </p> <p>(definitions and assessment methods taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> <p>(23/252)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000 (37 to 117)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71 (95% CI 0.40 to 1.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 2 RCTs with limitations: 1 with high risk of selection bias, bias due to lack of blinding and attrition bias; 2 with unclear risk of selection bias </p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin K versus placebo prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a>) </p> <p><i>and</i> </p> <p>Phenobarbital versus placebo prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 7 years, definition not clear; method of assessment not clear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> <p>(12/151)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000 (26 to 140)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77 (95% CI 0.33 to 1.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VERY LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of selection bias, and high risk of attrition bias </p> <p>indirectness (‐1): dual intervention of vitamin K and phenobarbital</p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulphate versus placebo for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months to 2 years</p> <p> <ul id="CD012077-list-0045"> <li> <p>1 RCT: defined as abnormalities of tone and loss of motor function; assessed by developmental paediatrician at 2 years </p> </li> <li> <p>1 RCT: defined severe cerebral palsy as not walking or unlikely to walk unaided by 2 years; children screened with Ages and Stages Questionnaires; screen‐positive and a sample of screen‐negative children had clinical and neurodevelopmental assessments at 18 months (using Bayley Scales of Infant Development; Griffiths Tests; or other); if this was not possible, clinical history and examination (using the Health Status Questionnaire) was used </p> </li> <li> <p>1 RCT: used the European Cerebral Palsy Network definition; paediatricians evaluated motor function at 2 years; if examination was not possible, parent telephone interview was used </p> </li> <li> <p>1 RCT: definition not provided; assessed by neurodevelopment examinations at 4, 8, 12, and 18 months, with diagnoses made or verified by developmental paediatrician after the 18 month examination </p> </li> <li> <p>1 RCT: defined as presenting with 2 or more of the following three features: a delay of 30% or more in gross motor developmental milestones; abnormality in muscle tone, 4+ or absent deep tendon reflexes, or movement abnormality; or persistence of primitive reflexes or absence of protective reflexes; assessed by paediatrician or paediatric neurologist at 2 years </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> <p>(154/3093)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 per 1000 (27 to 43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68 (95% CI 0.54 to 0.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6145 (5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antenatal corticosteroids versus placebo for accelerating fetal lung maturation for women at risk of preterm birth (<a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 2 to 6 years</p> <p> <ul id="CD012077-list-0046"> <li> <p>1 RCT: defined as any of hemiparesis, diplegia, tetra‐, quadriplegia; assessed using detailed physical and neurologic examination (including of motor co‐ordination) at 3 years </p> </li> <li> <p>1 RCT: defined as pathological muscle tonus, pre‐existing primitive reflexes and delay in motor coordination; assessed using neurological examination by trial author (including evaluation of gross and fine motor) at 2 years </p> </li> <li> <p>3 RCTs: definition not clear</p> </li> </ul> </p> <p>(definitions and assessment methods taken, where possible, from RCT manuscripts as not detailed in review) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 per 1000</p> <p>(28/414)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000 (23 to 70)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.60 (95% CI 0.34 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>904 (5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 2 RCTs with unclear and 1 RCT with inadequate allocation concealment</p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Repeat doses of corticosteroids versus single course for women at risk of preterm birth (<a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months to 3 years</p> <p> <ul id="CD012077-list-0047"> <li> <p>1 RCT: defined as abnormalities of muscle tone as well as loss of motor function; assessed by developmental paediatrician using neurological examinations at 2 years </p> </li> <li> <p>1 RCT: defined as non‐progressive motor impairment characterised by abnormal muscle tone and decreased range of movements; assessed (by neonatologists, general paediatricians, developmental paediatricians, and trained nurses) using a standardised neurological assessment at 18 months to 2 years </p> </li> <li> <p>1 RCT: definition as described by <a href="./references#CD012077-bbs2-0110" title="RosenbaumP , PanethN , LevitonA , GoldsteinM , BaxM , DamianoD , et al. A report: the definition and classification of cerebral palsy April 2006. Developmental Medicine and Child Neurology Supplement2007;109:8‐14. ">Rosenbaum 2007</a>; assessed by paediatric neurologist or paediatrician using specific neurological examination at 2 years </p> </li> <li> <p>1 RCT: defined as severe delay in gross motor milestones, failure to walk by 17 months of corrected age; abnormality of tone or reflexes; and aberration of primitive reflexes or postural reactions; assessed by paediatricians or paediatric neurologists using neurologic examination between 2 and 3 years </p> </li> </ul> </p> <p>(definitions and assessment methods taken from RCT manuscripts as not all detailed in review) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> <p>(52/1891)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000 (20 to 41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03 (95% CI 0.71 to 1.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3800 (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the management of preterm fetalcompromise</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immediate versus deferred delivery of the preterm baby with suspected fetal compromise (<a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at or after 2 years</p> <p>definition not clear; assessed by family practitioner or paediatrician using short questionnaire </p> <p>(assessment method taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> <p>(2/251)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1000 (11 to 207)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.88 ( CI 95% 1.33 to 26.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT at high risk of performance bias and other bias (did not account for non‐independence of data for twin pregnancies) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence intervals; IA: intermittent auscultation; RCT: randomised controlled trial; RR: risk ratio; CI: confidence interval </p> </div> </div> <div class="table" id="CD012077-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Summary of findings: subgroup or sensitivity analyses of select comparisons for cerebral palsy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention and comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Subgroup or sensitivity analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk with intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants (trials)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test for subgroup differences</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b> Interventions for the diagnosis and prevention of fetalcompromise in labour</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>Continuous cardiotocography (CTG) versus intermittent auscultation (IA) for fetal assessment during labour (<a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>Cerebral palsy at 18 months to 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pregnancy risk status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195 per 1000 (85 to 451)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.54 (95% CI 1.10 to 5.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 1.52, df = 1 (P = 0.22), I² = 34%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed or not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20 (95% CI 0.52 to 2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13079 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Onset of labour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 (2 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.74 (95% CI 0.97 to 3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,252 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gestational age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Preterm labour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195 per 1000 (85 to 451)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.54 (95% CI 1.10 to 5.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 1.52, df = 1 (P = 0.22), I² = 34%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both or gestation not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20 (95% CI 0.52 to 2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,079 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of babies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195 per 1000 (85 to 451)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.54 (95% CI 1.10 to 5.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 1.52, df = 1 (P = 0.22), I² =34%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both or not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20 (95% CI 0.52 to 2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,079 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Access to fetal blood sampling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 (2 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.74 (95% CI 0.97 to 3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,252 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both or not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 (2 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.74 (95% CI 0.97 to 3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,252 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20 (95% CI 0.52 to 2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,079 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 1.52, df = 1 (P = 0.22), I² = 34%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195 per 1000 (85 to 451)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.54 (95% CI 1.10 to 5.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b> Interventions for the prevention of preterm birth</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prenatal administration of progesterone versus placebo for preventing preterm birth in women with a previous history spontaneous preterm birth (singletons) (<a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Route of administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (0 to 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.14 (95% CI 0.01 to 3.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Prophylactic antibiotics versus no antibiotics for inhibiting preterm labour with intact membranes (<a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Cerebral palsy at 7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Type of antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta‐lactam antibiotics alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1000 (6 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 1.22 (95% CI 0.41 to 3.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1049 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Chi² = 1.41, df = 2 (P = 0.49), I² = 0.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Macrolide antibiotics alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 per 1000 (7 to 65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 1.42 (95% CI 0.48 to 4.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1073 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Macrolide and beta‐lactam antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 per 1000 (16 to 123)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 2.83 (95% CI 1.02 to 7.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1052 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any macrolide versus no macrolide for inhibiting preterm labour with intact membranes (<a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Any macrolide versus no macrolide antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1000 (21 to 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.90 (95% CI 1.20 to 3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3173 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any beta‐lactam versus no beta‐lactam for inhibiting preterm labour with intact membranes (<a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Any beta‐lactam versus no beta‐lactam antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000 (20 to 49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.67 (95% CI 1.06 to 2.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3173 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b> Interventions prior to preterm birth for fetal maturation or neuroprotection</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenobarbital versus placebo prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Excluding trials with non‐concealment at randomisation (C quality)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000 (37 to 117)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71 (95% CI 0.40 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin K versus placebo prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a>) </p> <p>and</p> <p>Phenobarbital versus placebo prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Excluding trials with inadequate concealment of allocation of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000 (26 to 140)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77 (95% CI 0.33 to 1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="20" valign="top"> <p>Magnesium sulphate versus placebo for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="20" valign="top"> <p>Cerebral palsy between 18 and 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>neuroprotective intent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 per 1000 (36 to 59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71 (95% CI 0.55 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4446 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Chi² = 1.69, df = 2 (P = 0.43), I² = 0%</p> <p>(Performed by overview authors)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maternal neuroprotective (pre‐eclampsia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000 (1 to 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.40 (95% CI 0.08 to 2.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1593 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tocolytic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000 (1 to 148)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.13 (95% CI 0.01 to 2.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single or multiple pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 per 1000 (16 to 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.92 (95% CI 0.57 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2321 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 1.28, df = 1 (P = 0.26), I² = 22.1%</p> <p>(Performed by overview authors)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000 (11 to 67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.52 (95% CI 0.21 to 1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>527 (2 RCTs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gestational age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less than 34 weeks at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 per 1000 (30 to 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.69 (95% CI 0.54 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5357 (5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not applicable (subgroups not exclusive)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less than 30 weeks at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000 (31 to 73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.86 (95% CI 0.56 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1537 (2 RCTs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Loading dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 g (any or no maintenance)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 per 1000 (24 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.79 (95% CI 0.56 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3595 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 1.33, df = 1 (P = 0.25), I² = 24.6%</p> <p><i>(Performed by overview authors)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 g (any or no maintenance)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000 (24 to 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.59 (95% CI 0.40 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2444 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No maintenance (any loading)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113 per 1000 (15 to 879)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.37 (95% CI 0.18 to 10.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>747 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 0.44, df = 1 (P = 0.51), I² = 0%</p> <p><i>(Performed by overview authors)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any maintenance (any loading)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 per 1000 (23 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68 (95% CI</p> <p>0.51 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5292 (3 RCTs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Loading and maintenance dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loading dose (4 g) and no maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113 per 1000 (15 to 879)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>average RR 1.37 (0.18, 10.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>747 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Chi² = 2.94, df = 3 (P = 0.40), I² = 0%</p> <p><i>(Performed by overview authors)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loading dose (4 g) and lower‐dose maintenance (1 g/hour)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 per 1000 (18 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>average RR 0.81 (95% CI 0.54 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2848 (2 RCTs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loading dose (4 g) and higher‐dose maintenance (2 to 3 g/hour)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000 (1 to 148)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.13 (95% CI 0.01 to 2.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loading dose (6 g) and higher‐dose maintenance (2 to 3 g/hour)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000 (24 to 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.59 (95% CI 0.40 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2444 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Retreatment permitted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000 (24 to 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.59 (95% CI 0.40 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2444 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Chi² = 1.26, df = 2 (P = 0.53), I² = 0%</p> <p><i>(Performed by overview authors)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1000 (24 to 46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.76 (95% CI 0.55 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3536 (3 RCTs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000 (8 to 170)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94 (95% CI 0.20 to 4.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High antenatal corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 per 1000 (35 to 56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67 (95% CI 0.53 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4493 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Studies with lowest risk of bias only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 per 1000 (32 to 56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68 (95% CI 0.52 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3699 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Antenatal corticosteroids versus placebo for accelerating fetal lung maturation for women at risk of preterm birth (<a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Cerebral palsy at 2 to 6 years</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>In babies born from pregnancies complicated by hypertension syndromes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000 (2 to 177)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.28 (95% CI 0.03 to 3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Main decade of recruitment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In babies from trials conducted in 1970s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 per 1000 (7 to 97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95 (95% CI 0.26 to 3.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Chi² = 1.05, df = 2 (P = 0.59), I² = 0%</p> <p>(Performed by overview authors)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In babies from trials conducted in 1980s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 per 1000 (20 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.62 (95% CI 0.28 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In babies from trials conducted in 1990s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 1000 (22 to 149)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.42 (95% CI 0.16 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176 (2 RCTs)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence intervals; RCT: randomised controlled trial; RR: risk ratio </p> </div> </div> <div class="table" id="CD012077-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Summary of findings: all comparisons measuring cerebral palsy or death</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention and comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions prior to preterm birth for fetalmaturation or neuroprotection</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulphate versus placebo for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or cerebral palsy between 18 months and 2 years (as above under cerebral palsy)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> <p>(583/3093)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177 per 1000 (147 to 211)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 0.94 (95% CI 0.78 to 1.12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6145 (5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence intervals; RCT: randomised controlled trial; RR: risk ratio </p> </div> </div> <div class="table" id="CD012077-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Summary of findings: all comparisons measuring severity of cerebral palsy</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention and comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the treatment of pre‐eclampsia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulphate versus placebo for women with pre‐eclampsia (<a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe cerebral palsy at 18 months (definition: not walking or unlikely to walk unaided by 24 months) </p> <p>(definition taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> <p>(9/1464)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (1 to 8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.34 (95% CI 0.09 to 1.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2895 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of attrition bias for this outcome (2895 of 6922 children in original RCT included) </p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions prior to preterm birth for fetalmaturation or neuroprotection</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Magnesium sulphate (neuroprotective intent) versus placebo for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild cerebral palsy at 2 years</p> <p> <ul id="CD012077-list-0048"> <li> <p>1 RCT: definition: walking at 2 years; assessed by developmental paediatrician at 2 years </p> </li> <li> <p>1 RCT: definition: Gross Motor Function Classification System of level 1; assessed by paediatrician or paediatric neurologist at 2 years </p> </li> <li> <p>1 RCT: definition not clear; paediatricians evaluated motor function at 2 years; if examination was not possible, parent telephone interview was used </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> <p>(74/2218)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 per 1000 (17 to 35)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.74 (95% CI 0.52 to 1.04)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4387 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate cerebral palsy at 2 years</p> <p> <ul id="CD012077-list-0049"> <li> <p>1 RCT: definition: not walking at 2 years but likely to do so; assessed by developmental paediatrician at 2 years </p> </li> <li> <p>1 RCT: definition not clear; paediatricians evaluated motor function at 2 years; if examination was not possible, parent telephone interview was used </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> <p>(21/962)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 per 1000 (7 to 28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.66 (95% CI 0.34 to 1.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1943 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe cerebral palsy at 2 years</p> <p> <ul id="CD012077-list-0050"> <li> <p>1 RCT: definition: not walking at 2 years but likely to do so (moderate); not likely to walk (severe); assessed by developmental paediatrician at 2 years </p> </li> <li> <p>1 RCT: definition: Gross Motor Function Classification System level of 2 or 3 (moderate), or level 4 or 5 (severe); assessed by paediatrician or paediatric neurologist at 2 years </p> </li> <li> <p>1 RCT: definition not clear; paediatricians evaluated motor function at 2 years; if examination was not possible, parent telephone interview was used </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> <p>(72/2218)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 per 1000 (14 to 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64 (95% CI 0.44 to 0.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4387 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe cerebral palsy at 2 years</p> <p> <ul id="CD012077-list-0051"> <li> <p>1 RCT: definition: not likely to walk; assessed by developmental paediatrician at 2 years </p> </li> <li> <p>1 RCT: definition not clear; paediatricians evaluated motor function a 2 years; if examination was not possible, parent telephone interview was used </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> <p>(13/962)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 (5 to 25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.82 (95% CI 0.37 to 1.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1943 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence intervals; RCT: randomised controlled trial; RR: risk ratio </p> </div> </div> <div class="table" id="CD012077-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Summary of findings: all comparisons measuring other composite outcomes that include cerebral palsy as a component</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention and comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the treatment of pre‐eclampsia</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Magnesium sulphate versus placebo for women with pre‐eclampsia (<a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurosensory disability at 18 months (definition: functional blindness (binocular visual acuity &lt; 6/60), deafness (severe enough to need a hearing aid), severe cerebral palsy, or DQ &lt; 2 SD below the mean) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> <p>(17/1648)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000 (4 to 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77 (95% CI 0.38 to 1.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3283 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of attrition bias for this outcome (3283 of 6922 children in original RCT included) </p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or neurosensory disability at 18 months (definition as above for 'neursensory disability at 18 months') </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 per 1000</p> <p>(233/1648)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 per 1000 (127 to 177)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06 (95% CI 0.90 to 1.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3283 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of attrition bias for this outcome (3283 of 6922 children in original RCT included) </p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b> Interventions for the prevention of preterm birth</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulphate versus other tocolytic agents for preventing preterm birth in threatened preterm labour (<a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious infant outcome (definition: total perinatal and infant mortality; IVH 3/4 or PVL; cerebral palsy at 18 months; assessment method as above under 'cerebral palsy') </p> <p>(1 RCT included cerebral palsy in composite outcome)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> <p>(3/51)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 per 1000 (41 to 518)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.47 (95% CI 0.69 to 8.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VERY LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of selection, attrition, and reporting bias and high risk of performance bias </p> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b> Interventions prior to preterm birth for fetalmaturation or neuroprotection</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Magnesium sulphate versus placebo for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any neurologic impairment at 18 months or 2 years (definition: any of cerebral palsy, blindness, deafness, or developmental delay or intellectual impairment (DQ or IQ less than 1 SD below the mean)) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 per 1000</p> <p>(200/1421)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 per 1000 (121 to 167)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01 (95% CI 0.86 to 1.19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2848 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major neurological disability at 18 months or 2 years (definition: any of moderate or severe cerebral palsy, blindness, deafness, or an MDI less than 70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 per 1000</p> <p>(91/1421)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 per 1000 (53 to 90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07 (95% CI 0.82 to 1.40)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2848 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐1): wide confidence intervals crossing the line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or any neurologic impairment at 18 months or 2 years (definition as above for 'any neurological impairment') </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348 per 1000</p> <p>(495/1421)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348 per 1000 (317 to 387)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (95% CI 0.91 to 1.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2848 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or major neurological disability at 18 months or 2 years (definition as above for 'major neurological disability') </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272 per 1000</p> <p>(386/1421)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277 per 1000 (244 to 312)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02 (95% CI 0.90 to 1.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2848 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antenatal corticosteroids versus placebo for accelerating fetal lung maturation for women at risk of preterm birth (<a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurodevelopmental delay at 2 years (definition: severe disability: tetraplegic cerebral palsy and/or mental retardation (Bayley's mental index &lt; 70)) </p> <p>(definition taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> <p>(3/32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 per 1000 (13 to 279)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64 (95% CI 0.14 to 2.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VERY LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear allocation concealment</p> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Repeat doses of corticosteroids versus single course for women at risk of preterm birth (<a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Survival free of any disability 18 months to 2 years, defined as:</p> <p> <ul id="CD012077-list-0052"> <li> <p>1 RCT: definition: survival free of severe, moderate or mild neurosensory disability: severe neurosensory disability defined as severe cerebral palsy (child considered permanently non‐ambulant), severe developmental delay (MDI score, &gt; 3 SD below the mean), or blindness; moderate disability defined as moderate cerebral palsy (child non‐ambulant at 2 years but likely to walk), moderate developmental delay (MDI score, &gt; 2 SD to 3 SD below the mean), or deafness; mild disability defined as either mild cerebral palsy (walking at 2 years) or mild developmental delay (MDI score, &gt; 1 SD to 2 SD below the mean) </p> </li> <li> <p>1 RCT: definition: survival free of neurological impairment (cerebral palsy or cognitive delay (2 SD below the normative value)) </p> </li> </ul> </p> <p>(definitions taken from RCT manuscripts as not clearly detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>773 per 1000</p> <p>(1215/1571)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>781 per 1000 (750 to 812)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01 (95% CI 0.97 to 1.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3155 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Survival free of major neurosensory disability at 2 to 3 years, defined as:</p> <p> <ul id="CD012077-list-0053"> <li> <p>1 RCT: definition: survival being ambulant by 2 years of age and not having blindness, deafness, a developmental index score of more than 2 SD below the mean, or cerebral palsy </p> </li> <li> <p>1 RCT: definition: survival without severe neurodevelopmental impairment (cerebral palsy, MDI &lt; 70, DQ &lt; 70, deafness, or blindness) </p> </li> </ul> </p> <p>(definitions taken from RCT manuscripts as not clearly detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>847 per 1000</p> <p>(572/675)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>856 per 1000 (780 to 941)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 1.01 (95% CI 0.92 to 1.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1317 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of selection bias, attrition bias and high risk of other bias </p> <p>inconsistency (‐1): substantial heterogeneity (I² = 88%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major neurosensory disability at 2 to 3 years, defined as:</p> <p> <ul id="CD012077-list-0054"> <li> <p>1 RCT: definition: severe or moderate neurosensory disability: severe neurosensory disability defined as severe cerebral palsy (child considered permanently non‐ambulant), severe developmental delay (MDI score &gt; 3 SD below the mean), or blindness; moderate disability defined as moderate cerebral palsy (child non‐ambulant at 2 years but likely to walk), moderate developmental delay (MDI score &gt; 2 SD to 3 SD below the mean), or deafness </p> </li> <li> <p>1 RCT: definition: severe neurodevelopmental impairment (cerebral palsy, MDI &lt; 70, DQ &lt; 70, deafness, or blindness) </p> </li> </ul> </p> <p>(definitions taken from RCT manuscripts as not clearly detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 per 1000 (71/643)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 per 1000 (34 to 415)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 1.08 (95% CI 0.31 to 3.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1256 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of selection bias, attrition bias, and high risk of other bias </p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability at 2 years, defined as:</p> <p> <ul id="CD012077-list-0055"> <li> <p>1 RCT: definition: severe, moderate, or mild neurosensory disability: severe neurosensory disability defined as severe cerebral palsy (child considered permanently non‐ambulant), severe developmental delay (MDI score &gt; 3 SD below the mean), or blindness; moderate disability defined as moderate cerebral palsy (child non‐ambulant at 2 years but likely to walk), moderate developmental delay (MDI score &gt; 2 SD to 3 SD below the mean), or deafness; mild disability was defined as either mild cerebral palsy (walking at 2 years) or mild developmental delay (MDI score &gt; 1 SD to 2 SD below the mean) </p> </li> </ul> </p> <p>(definition taken from RCT manuscript as not clearly detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361 per 1000 (182/504)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354 per 1000 (300 to 419)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98 (95% CI 0.83 to 1.16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>999 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Composite serious outcome at 18 months to 2 years, defined as:</p> <p> <ul id="CD012077-list-0056"> <li> <p>1 RCT: definition: death or any neurosensory disability: severe, moderate or mild neurosensory disability: severe neurosensory disability defined as severe cerebral palsy (child considered permanently non‐ambulant), severe developmental delay (MDI score &gt; 3 SD below the mean), or blindness; moderate disability defined as moderate cerebral palsy (child non‐ambulant at 2 years but likely to walk), moderate developmental delay (MDI score &gt; 2 SD to 3 SD below the mean), or deafness; mild disability defined as either mild cerebral palsy (walking at 2 years) or mild developmental delay (MDI score &gt; 1 SD to 2 SD below the mean) </p> </li> <li> <p>1 RCT: definition: death or neurologic impairment (cerebral palsy or cognitive delay (cognitive delay was defined as 2 SD below the normative value)) </p> </li> </ul> </p> <p>(definitions taken from RCT manuscripts as not clearly detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 per 1000</p> <p>(356/1571)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224 per 1000 (197 to 254)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99 (95% CI 0.87 to 1.12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3164 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the management of preterm fetalcompromise</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Immediate versus deferred delivery of the preterm baby with suspected fetal compromise (<a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or disability at or after 2 years (definition: cerebral palsy, little or no vision, requirement for hearing aid, or Griffiths DQ of 70 or less) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155 per 1000</p> <p>(44/283)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190 per 1000 (132 to 272)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.22 (95% CI 0.85 to 1.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>573 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study limitations (‐1): 1 RCT at high risk of performance bias and other bias (did not account for non‐independence of data for twin pregnancies) </p> <p>imprecision (‐1): wide intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurodevelopmental impairment at or after 2 years (definition: cerebral palsy, little or no vision, requirement for hearing aid, or Griffiths DQ of 70 or less) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> <p>(12/251)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 per 1000 (41 to 163)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.72 (95% CI 0.86 to 3.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study limitations (‐1): 1 RCT at high risk of performance bias and other bias (did not account for non‐independence of data for twin pregnancies) </p> <p>imprecision (‐1): wide intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or severe disability at 6 to 13 years (definition: classified severe blindness, severe deafness, cerebral palsy, or Kaufman Mental Processing Component &lt; 70 points) </p> <p>(definition taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168 per 1000</p> <p>(25/149)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 per 1000 (81 to 235)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.82 (95% CI 0.48 to 1.40)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>302 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study limitations (‐1): 1 RCT at high risk of performance, attrition and other bias</p> <p>imprecision (‐1): wide intervals crossing line of no effect</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence intervals; DQ: developmental quotient; IQ: intelligence quotient; IVH: intraventricular haemorrhage; MDI: mental development index; PVL: periventricular leukomalacia; RCT: randomised controlled trial; RR: risk ratio; SD: standard deviation </p> </div> </div> <div class="table" id="CD012077-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Summary of findings: all comparisons measuring motor dysfunction</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention and comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk with intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants (trials)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of the evidence (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the prevention of preterm birth</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prenatal administration of progesterone versus placebo for preventing preterm birth in women with a previous history spontaneous preterm birth (singletons) (<a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Motor impairment at 4 years (definition: overall activity problems or co‐ordination problems) </p> <p>(age and definition taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> <p>(2/82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000 (3 to 92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64 (95% CI 0.11 to 3.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; one small RCT with few events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions prior to preterm birth for fetal maturation or neuroprotection</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenobarbital versus control prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other neuromotor impairment at 3 years (definition: tonal abnormalities with no delay in ambulation or other motor milestones) </p> <p>(definition taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> <p>(4/55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 per 1000 (9 to 254)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67 (95% CI 0.13 to 3.49)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VERY LOW</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study limitations (‐2): 1 RCT with high risk of selection bias, bias due to lack of blinding, and attrition bias </p> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Magnesium sulphate versus no placebo for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Substantial gross motor dysfunction between 18 months and 2 years (definition: motor dysfunction such that the child was not walking at age 2 years or later, or the inability to grasp and release a small block with both hands) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> <p>(94/3013)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1000 (14 to 27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61 (95% CI 0.44 to 0.85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5980 (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or substantial gross motor dysfunction between 18 months and 2 years (definition as above for 'substantial gross motor dysfunction') </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174 per 1000</p> <p>(523/3013)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 per 1000 (130 to 194)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 0.92 (95% CI 0.75 to 1.12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5980 (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>inconsistency (‐1): substantial heterogeneity (I² = 65%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence intervals; RCT: randomised controlled trial; RR: risk ratio </p> </div> </div> <section id="CD012077-sec-0046"> <h4 class="title">Interventions for the treatment of mild to moderate hypertension</h4> <section id="CD012077-sec-0047"> <h5 class="title">No conclusions possible: very low‐quality evidence</h5> <p>Very low‐quality evidence in both the <a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a> and <a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a> reviews showed no clear difference for the presence of cerebral palsy at one year when any antihypertensive drug was compared with a placebo (<a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a>), or when an oral beta‐blocker was compared with placebo (<a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a>), in the treatment of mild to moderate hypertension during pregnancy (risk ratio (RR) 0.33, 95% confidence interval (CI) 0.01 to 8.01; one trial; 110 children; <a href="#CD012077-tbl-0006">Table 6</a>). The two reviews included the same trial, and made similar judgements regarding trial quality. </p> </section> </section> <section id="CD012077-sec-0048"> <h4 class="title">Interventions for the treatment of pre‐eclampsia</h4> <section id="CD012077-sec-0049"> <h5 class="title">No conclusions possible: low‐quality evidence</h5> <p>Low‐quality evidence in the <a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a> review showed no clear difference for the presence of cerebral palsy at two years when interventionist care was compared with expectant (delayed delivery) care for severe pre‐eclampsia between 24 and 34 weeks' gestation (RR 6.01, 95% CI 0.75 to 48.14; one trial; 262 children; <a href="#CD012077-tbl-0006">Table 6</a>). </p> <p>Low‐quality evidence in the <a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a> review showed no clear difference for the presence of severe cerebral palsy at 18 months when magnesium sulphate was compared with placebo for women with pre‐eclampsia (RR 0.34, 95% CI 0.09 to 1.26; one trial; 2895 children; <a href="#CD012077-tbl-0006">Table 6</a>; <a href="#CD012077-tbl-0009">Table 9</a>). </p> <p>Low‐quality evidence in the <a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a> review also showed no clear difference in neurosensory disability (composite outcome that included cerebral palsy) at 18 months (RR 0.77, 95% CI 0.38 to 1.58; one trial; 3283 children; <a href="#CD012077-tbl-0010">Table 10</a>), or in death or neurosensory disability at 18 months (RR 1.06, 95% CI 0.90 to 1.25; one trial; 3283 children; <a href="#CD012077-tbl-0010">Table 10</a>) when magnesium sulphate was compared with placebo for women with pre‐eclampsia. </p> </section> </section> <section id="CD012077-sec-0050"> <h4 class="title">Interventions for the diagnosis and prevention of fetal compromise in labour</h4> <section id="CD012077-sec-0051"> <h5 class="title">No conclusions possible: low‐quality evidence</h5> <p>Low‐quality evidence in the <a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a> review showed no clear difference for the presence of cerebral palsy in early childhood (between 18 months and four years) when continuous cardiotocography was compared with intermittent auscultation for fetal assessment during labour (average RR 1.75, 95% CI 0.84 to 3.63; two trials; 13,252 children; <a href="#CD012077-tbl-0006">Table 6</a>). </p> <p><a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a> conducted subgroup analyses for the presence of cerebral palsy, based on pregnancy risk status, onset of labour, gestational age, number of babies, access to fetal blood sampling, parity, and and only high quality trials, however, did not identify any clear subgroup differences (<a href="#CD012077-tbl-0007">Table 7</a>). </p> </section> </section> <section id="CD012077-sec-0052"> <h4 class="title">Interventions for the prevention of preterm birth</h4> <section id="CD012077-sec-0053"> <h5 class="title">Probably ineffective interventions: moderate‐quality evidence of harm</h5> <p>Moderate‐quality evidence in the <a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a> review showed an increase in cerebral palsy in mid‐childhood (at seven years) for children born to mothers who received any prophylactic antibiotics versus no antibiotics for inhibiting preterm labour with intact membranes (RR 1.82, 95% CI 0.99 to 3.34; one trial; 3173 children; <a href="#CD012077-tbl-0006">Table 6</a>). </p> <p>Subgroup analysis for this outcome, based on type of antibiotic did not reveal clear subgroup differences (<a href="#CD012077-tbl-0007">Table 7</a>). Additional analyses were conducted for this outcome, comparing (i) any macrolide antibiotics (including macrolide antibiotics used as a single agent or in combination with other types of antibiotics) versus no macrolide antibiotics (including use of any non‐macrolide antibiotics or no antibiotics), and (ii) any beta‐lactam antibiotics (including beta‐lactam antibiotics used as a single agent or in combination with other types of antibiotics) versus no beta‐lactam antibiotics (including use of any non‐beta‐lactam antibiotics or no antibiotics). An increase in cerebral palsy in mid‐childhood (at seven years) was observed for children born to mothers who received any macrolide versus no macrolide antibiotics, and any beta‐lactam versus no beta‐lactam antibiotics (<a href="#CD012077-tbl-0007">Table 7</a>). </p> </section> <section id="CD012077-sec-0054"> <h5 class="title">No conclusions possible: low‐ to very low‐quality evidence</h5> <p>Low‐quality evidence in the <a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a> review showed no clear difference for the presence of cerebral palsy at four years when prenatal administration of progesterone was compared with placebo for preventing preterm birth in women with a previous history of spontaneous preterm birth (RR 0.14, 95% CI 0.01 to 3.48; one trial; 274 children; <a href="#CD012077-tbl-0006">Table 6</a>). A subgroup analysis was planned for this outcome based on route of administration, however, only one trial was included, which used intramuscular administration (<a href="#CD012077-tbl-0007">Table 7</a>). </p> <p>Low‐quality evidence in the <a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a> review showed no clear difference for the presence of cerebral palsy in children at 18 months when betamimetics were compared with placebo for inhibiting preterm labour (RR 0.19, 95% CI 0.02 to 1.63; one trial; 246 children; <a href="#CD012077-tbl-0006">Table 6</a>). </p> <p>Very‐low quality evidence in the <a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a> review showed no clear difference for the presence of cerebral palsy in children at 18 months when magnesium sulphate was compared with other tocolytic agents for preventing preterm birth in threatened preterm labour (RR 0.13, 95% CI 0.01 to 2.51; one trial; 106 children; <a href="#CD012077-tbl-0006">Table 6</a>). </p> <p>Very low‐quality evidence in the <a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a> review also showed no clear difference for serious infant outcomes (including cerebral palsy) when magnesium sulphate was compared with other tocolytic agents for preventing preterm birth in threatened preterm labour (RR 2.47, 95% CI 0.69 to 8.81; one trial; 106 children; <a href="#CD012077-tbl-0010">Table 10</a>). </p> <p>There was also low‐quality evidence in the <a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a> review showing no clear difference in motor impairment for children at four years when prenatal administration of progesterone was compared with placebo for preventing preterm birth in women with a previous history of spontaneous preterm birth (RR 0.64, 95% CI 0.11 to 3.76; one trial; 274 children; <a href="#CD012077-tbl-0011">Table 11</a>). </p> </section> </section> <section id="CD012077-sec-0055"> <h4 class="title">Interventions prior to preterm birth for fetal maturation or neuroprotection</h4> <section id="CD012077-sec-0056"> <h5 class="title">Effective interventions: high‐quality evidence of effectiveness</h5> <p>High‐quality evidence in the <a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a> review showed a reduction in cerebral palsy at 18 months to two years for children born to women at risk of preterm birth who received magnesium sulphate compared with placebo for neuroprotection of the fetus (RR 0.68, 95% CI 0.54 to 0.87; five trials; 6145 children; <a href="#CD012077-tbl-0006">Table 6</a>). Subgroup analyses for cerebral palsy based on intent (neuroprotective, pre‐eclampsia, tocolytic), single or multiple pregnancy, gestational age at randomisation, loading dose, maintenance dose, and whether re‐treatment was permitted, showed no clear subgroup differences (<a href="#CD012077-tbl-0007">Table 7</a>); the results did not substantially change when they only included studies with high antenatal corticosteroid use, nor when they performed a sensitivity analysis based on trial quality (<a href="#CD012077-tbl-0007">Table 7</a>). </p> <p>High‐quality evidence from <a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a> review also showed a reduction in moderate to severe cerebral palsy at two years (RR 0.64, 95% CI 0.44 to 0.92; three trials; 4387 children; <a href="#CD012077-tbl-0009">Table 9</a>), and in substantial gross motor dysfunction at 18 months to two years (RR 0.61, 95% CI 0.44 to 0.85; four trials; 5980 children; <a href="#CD012077-tbl-0011">Table 11</a>); though no clear differences were shown for death or cerebral palsy at 18 months to two years (average RR 0.94, 95% CI 0.78 to 1.12; five trials; 6145 children; <a href="#CD012077-tbl-0008">Table 8</a>), any neurologic impairment at 18 months to two years (RR 1.01, 95% CI 0.86 to 1.19; two trials; 2848 children; <a href="#CD012077-tbl-0010">Table 10</a>), death or any neurologic impairment (composite outcomes that included cerebral palsy) at 18 months to two years (RR 1.00, 95% CI 0.91 to 1.11; two trials; 2848 children; <a href="#CD012077-tbl-0010">Table 10</a>), or death or major neurological disability at 18 months to two years (RR 1.02, 95% CI 0.90 to 1.15; two trials; 2848 children; <a href="#CD012077-tbl-0010">Table 10</a>). </p> <p>Moderate‐quality evidence from <a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a> showed no clear differences for mild cerebral palsy at two years (RR 0.74, 95% CI 0.52 to 1.04; three trials; 4387 children; <a href="#CD012077-tbl-0009">Table 9</a>), moderate cerebral palsy at two years (RR 0.66, 95% CI 0.34 to 1.28; two trials; 1943 children; <a href="#CD012077-tbl-0009">Table 9</a>), severe cerebral palsy at two years (RR 0.82, 95% CI 0.37 to 1.82; two trials; 1943 children; <a href="#CD012077-tbl-0009">Table 9</a>), major neurological disability at 18 months or two years (RR 1.07; 95% CI 0.82 to 1.40; two trials, 2848 children) (<a href="#CD012077-tbl-0010">Table 10</a>), or death or substantial gross motor dysfunction for children at 18 months to two years (average RR 0.92, 95% CI 0.75 to 1.12; four trials; 5980 children; <a href="#CD012077-tbl-0011">Table 11</a>) when magnesium sulphate was compared with placebo for women at risk of preterm birth for neuroprotection of the fetus. </p> </section> <section id="CD012077-sec-0057"> <h5 class="title">Probably ineffective interventions: moderate‐quality evidence of lack of effectiveness</h5> <p>Moderate‐quality evidence in the <a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a> review showed no clear difference in cerebral palsy at 18 months to three years when repeat doses of corticosteroids were compared with a single course for women at risk of preterm birth (RR 1.03, 95% CI 0.71 to 1.50; four trials; 3800 children; <a href="#CD012077-tbl-0006">Table 6</a>). </p> <p>High‐quality evidence from the <a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a> review also showed no clear differences for survival free of any disability at 18 months to two years (RR 1.01, 95% CI 0.97 to 1.05; two trials; 3155 children; <a href="#CD012077-tbl-0010">Table 10</a>), disability at two years (RR 0.98, 95% CI 0.83 to 1.16; one trial; 999 children; <a href="#CD012077-tbl-0010">Table 10</a>), or composite serious outcome at 18 months to two years (RR 0.99, 95% CI 0.87 to 1.12; two trials; 3164 children; <a href="#CD012077-tbl-0010">Table 10</a>) when repeat doses of corticosteroids were compared with a single course for women at risk of preterm birth; </p> <p>Low‐quality evidence from <a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a> showed no clear differences for survival free of major neurosensory disability (a composite outcome that included cerebral palsy) for children at two to three years (average RR 1.01, 95% CI 0.92 to 1.11; two trials; 1317 children; <a href="#CD012077-tbl-0010">Table 10</a>) and major neurosensory disability at two to three years (average RR 1.08, 95% CI 0.31, 3.76; two trials; 1256 children; <a href="#CD012077-tbl-0010">Table 10</a>) when repeat doses of corticosteroids were compared with a single course for women at risk of preterm birth. </p> </section> <section id="CD012077-sec-0058"> <h5 class="title">No conclusions possible: low‐ to very low‐quality evidence</h5> <p>Low‐quality evidence in the <a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a> review, showed no clear difference in the presence of cerebral palsy in early childhood (between 18 months and three years) when phenobarbital was compared with placebo or no treatment, and given prior to preterm birth to prevent neonatal periventricular haemorrhage (RR 0.71, 95% CI 0.40 to 1.28; two trials; 517 children; <a href="#CD012077-tbl-0006">Table 6</a>). <a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a> had planned to conduct a sensitivity analysis, excluding trials with inadequate concealment of allocation of treatment; the results did not change as the one included trial was retained in the analysis (<a href="#CD012077-tbl-0007">Table 7</a>). </p> <p>Very low‐quality evidence in the <a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a> review also showed no clear difference in other neuromotor impairment for children at three years when phenobarbital was compared with no treatment prior to preterm birth for preventing neonatal periventricular haemorrhage (RR 0.67, 95% CI 0.13 to 3.49; one trial; 96 children; <a href="#CD012077-tbl-0011">Table 11</a>). </p> <p>Very low‐quality evidence from two reviews, showed no clear difference in the presence of cerebral palsy in mid‐childhood (at seven years) when vitamin K was compared with placebo prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a>), and when phenobarbital was compared with placebo prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a>; RR 0.77, 95% CI 0.33 to 1.76; one trial; 299 children; <a href="#CD012077-tbl-0006">Table 6</a>). These two reviews included the same trial (which assessed a combination intervention), and made similar judgements regarding trial quality. Both reviews planned to conduct a sensitivity analysis excluding trials with inadequate concealment of allocation of treatment; the results did not change as the one included trial was retained in the analysis (<a href="#CD012077-tbl-0007">Table 7</a>). </p> <p>Low‐quality evidence in the <a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a> review showed a possible reduction in cerebral palsy between two and six years for children born to women at risk of preterm birth who received antenatal corticosteroids compared with placebo for accelerating fetal lung maturation (RR 0.60;,95% CI 0.34 to 1.03; five trials; 904 children; <a href="#CD012077-tbl-0006">Table 6</a>). A subgroup analysis for cerebral palsy, based on decade of recruitment, revealed no clear subgroup differences (<a href="#CD012077-tbl-0007">Table 7</a>). </p> <p>Very low‐quality evidence from <a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a> review also showed no clear difference in neurodevelopmental delay at two years when antenatal corticosteroids were compared with placebo for accelerating fetal lung maturation for women at risk of preterm birth (RR 0.64, 95% CI 0.14 to 2.98; one trial; 82 children; <a href="#CD012077-tbl-0010">Table 10</a>). </p> </section> </section> <section id="CD012077-sec-0059"> <h4 class="title">Interventions for the management of preterm fetal compromise</h4> <section id="CD012077-sec-0060"> <h5 class="title">Probably ineffective interventions: moderate‐quality evidence of harm</h5> <p>Moderate‐quality evidence in the <a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a> review showed an increase in cerebral palsy at or after two years for children, who as preterm babies with suspected fetal compromise,were born immediately, compared with those for whom birth was deferred (RR 5.88, 95% CI 1.33 to 26.02; one trial; 507 children; <a href="#CD012077-tbl-0006">Table 6</a>). </p> <p>Low‐quality evidence from the <a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a> review also showed no clear differences in death or disability at or after two years (RR 1.22, 95% CI 0.85 to 1.75; one trial; 573 children; <a href="#CD012077-tbl-0010">Table 10</a>), neurodevelopmental impairment at or after two years (RR 1.72, 95% CI 0.86 to 3.41; one trial; 507 children; <a href="#CD012077-tbl-0010">Table 10</a>), or death or severe disability at six to 13 years (RR 0.82, 95% CI 0.48 to 1.40; one trial; 302 children; <a href="#CD012077-tbl-0010">Table 10</a>) when immediate delivery of the preterm baby with suspected fetal compromise was compared with deferred delivery. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012077-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012077-sec-0061"></div> <section id="CD012077-sec-0062"> <h3 class="title" id="CD012077-sec-0062">Summary of main results</h3> <p>This overview included 15 Cochrane reviews, involving 279 randomised controlled trials and 101,098 children. Data for cerebral palsy were available from 27 (10%) randomised controlled trials involving 32,490 (32%) children. </p> <p><b>Effective interventions: high‐quality evidence of effectiveness:</b> high‐quality evidence showed a reduction in cerebral palsy for children born to women at risk of preterm birth who received magnesium sulphate compared with placebo for neuroprotection of the fetus. </p> <p><b>Probably ineffective interventions: moderate‐quality evidence of harm:</b> moderate‐quality evidence showed an increase in cerebral palsy for children born to mothers who received any prophylactic antibiotics versus no antibiotics for inhibiting preterm labour with intact membranes. Moderate‐quality evidence also showed an increase in cerebral palsy for children who, as preterm babies with suspected fetal compromise, were born immediately compared with those for whom birth was deferred. </p> <p><b>Probably ineffective interventions: moderate‐quality evidence of lack of effectiveness:</b> moderate‐quality evidence showed no clear difference in cerebral palsy when repeat doses of corticosteroids were compared with a single course for women at risk of preterm birth. </p> <p><b>No conclusions possible: low‐ to very low‐quality evidence:</b> </p> <p> <ul id="CD012077-list-0057"> <li> <p>Low‐quality evidence showed a possible reduction in cerebral palsy for children born to women at risk of preterm birth who received antenatal corticosteroids compared with placebo for accelerating fetal lung maturation. </p> </li> <li> <p>Low‐quality evidence showed no clear difference for cerebral palsy with interventionist care versus expectant care for severe pre‐eclampsia; magnesium sulphate versus placebo for pre‐eclampsia; continuous cardiotocography versus intermittent auscultation for fetal assessment during labour; prenatal progesterone versus placebo for preventing preterm birth; and betamimetics versus placebo for inhibiting preterm labour. </p> </li> <li> <p>Very low‐quality evidence showed no clear difference for cerebral palsy with any antihypertensive drug versus placebo, or with an oral beta‐blocker versus placebo for mild to moderate hypertension; with magnesium sulphate versus other tocolytic agents for preventing preterm birth; and with vitamin K and phenobarbital versus placebo prior to preterm birth for preventing neonatal periventricular haemorrhage. </p> </li> </ul> </p> </section> <section id="CD012077-sec-0063"> <h3 class="title" id="CD012077-sec-0063">Overall completeness and applicability of evidence</h3> <p>This overview summarises published Cochrane reviews assessing antenatal and intrapartum interventions and their effects on cerebral palsy. Interventions in the neonatal period are the focus of a companion overview (<a href="./references#CD012077-bbs2-0117" title="ShepherdE , MiddletonP , MakridesM , McIntyreSJ , BadawiN , CrowtherCA . Neonatal interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD012409] ">Shepherd 2016</a>). </p> <p>We were only able to include 15 reviews (representing less than 3% of the 546 Pregnancy and Childbirth reviews in the <i>Cochrane Database of Systematic Reviews</i>), which reported data on our primary outcome, cerebral palsy. We identified an additional nine protocols that have pre‐specified cerebral palsy as a primary or secondary outcome and will be considered for inclusion in future updates of the overview when they are published as full reviews. These protocols plan to assess a variety of interventions including: interventions for treating hypertension (guided imagery), preventing (with melatonin) or treating pre‐eclampsia (melatonin; epidural therapy; planned caesarean section versus planned vaginal delivery), for preventing preterm labour or birth (progestogens for multiple pregnancy; hypnosis), for diagnosing and preventing fetal compromise in labour (intermittent auscultation of fetal heart rate in labour), and for induction of labour (amniotomy plus intravenous oxytocin). See <a href="./appendices#CD012077-sec-0073">Appendix 1</a>, Ongoing reviews. We were unable to include an additional 62 reviews assessing a wide range of antenatal and intrapartum interventions, because although they recognised the potential impact of the interventions of interest on cerebral palsy (through pre‐specifying cerebral palsy as a review outcome), none of the included trials within these reviews reported on this outcome. We have summarised the main conclusions of these reviews in <a href="./appendices#CD012077-sec-0074">Appendix 2</a>, Reviews awaiting further classification, and will again consider them for inclusion in future updates of the overview. </p> <p>Although the 15 reviews in this overview included 279 randomised trials, involving over 101,098 women and their babies, the body of evidence for our review was substantially reduced because the included reviews (and trials) did not report on our outcomes of interest. For our primary outcome, cerebral palsy, we have included data from all 15 reviews, but from 27 randomised trials, or only 10% of the trials within the included reviews. </p> <p>The body of evidence for our secondary outcomes was further reduced, with six reviews reporting data on a composite outcome including cerebral palsy, three on motor dysfunction, two on severity of cerebral palsy, and one of the 15 reviews reporting data on cerebral palsy or death. None of our included reviews reported specifically on the type of cerebral palsy. For the majority of our outcomes, data were reported in the reviews by only one or two trials, up to a maximum of five trials, for the majority of interventions assessed. Thus, there were too few data to reach firm conclusions on the effects on cerebral palsy and our secondary outcomes. Unsurprisingly, for the majority of the reviews, data related to cerebral palsy was commonly shorter‐term (reported at one to two years of age), with longer‐term follow up less commonly reported (only three reviews reported on cerebral palsy at seven years). Definitions or criteria for a diagnosis of cerebral palsy, where reported, and assessment methods, varied substantially between and within trials; often this information was not reported in the reviews. </p> <p>We did not attempt to make indirect comparisons in order to address questions concerning the relative performance of difference antenatal or intrapartum interventions. This would not have been appropriate, due to the variety of interventions (and control conditions) assessed in different populations, for various indications. Rather, we aimed to systematically consider all potentially relevant interventions for their ability to contribute to the prevention of cerebral palsy. Within this overview, we have not attempted to duplicate details of participants, interventions (and control conditions) in individual trials. Consulting the individual reviews and trials is encouraged to obtain more information on these factors. </p> <p>The scope of this overview was limited to effects of interventions on cerebral palsy, and a restricted number of pre‐specified secondary outcomes, including the composite outcome 'cerebral palsy or death', in recognition of the competing risks of death and survival with neurosensory disability. In order to assess the effects (benefits or harms) of the included interventions on other outcomes (including perinatal death), readers are encouraged to refer to the included Cochrane reviews themselves. For example, while this overview showed low‐quality evidence of a possible reduction in cerebral palsy for children born to women at risk of preterm birth who received antenatal corticosteroids for accelerating fetal lung maturation, the recently updated <a href="./references#CD012077-bbs2-0108" title="RobertsD , BrownJ , MedleyN , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2017, Issue 3. [DOI: 10.1002/14651858.CD004454.pub3] ">Roberts 2017</a> review assessed additional outcomes, and has revealed reductions in perinatal death, neonatal death, respiratory distress syndrome, moderate to severe respiratory distress syndrome, intraventricular haemorrhage, necrotising enterocolitis, need for mechanical ventilation, and systemic infections in the first 48 hours of life. The review concluded that the findings support "the continued use of a single course of antenatal corticosteroids to accelerate fetal lung maturation in women at risk of preterm birth" (<a href="./references#CD012077-bbs2-0108" title="RobertsD , BrownJ , MedleyN , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2017, Issue 3. [DOI: 10.1002/14651858.CD004454.pub3] ">Roberts 2017</a>). </p> </section> <section id="CD012077-sec-0064"> <h3 class="title" id="CD012077-sec-0064">Quality of the evidence</h3> <p>All of the included reviews were assessed to be of high quality and at low risk of bias with the AMSTAR and ROBIS tools (<a href="#CD012077-tbl-0004">Table 4</a>; <a href="#CD012077-tbl-0005">Table 5</a>). Although the two tools differ in their approaches to assessing review quality or risk of bias, they led to similar assessments. All of the reviews assessed the risk of bias of the included randomised trials, the majority using current guidance as outlined in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012077-bbs2-0074" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). The quality of the randomised trials was variable within and between the reviews (<a href="#CD012077-tbl-0003">Table 3</a>). </p> <p>Two of the 15 reviews used the GRADE approach to assess the quality of evidence for review outcomes (<a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a>; <a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a>). For the other reviews, we used the GRADE system to rate the quality of evidence, incorporating the assessments of study limitations (risk of bias) reported by the review authors. For our primary outcome, cerebral palsy, the quality of the evidence ranged from very low to high, similarly for our secondary outcomes. Downgrading of the quality was most commonly due to study limitations (risk of bias), and imprecision (small sample sizes, low number of events, and wide confidence intervals). As our overview outcomes were assessed through longer‐term follow‐up of antenatal or intrapartum interventions, the potential for bias relating to attrition (which could occur due to children lost to follow‐up differing systematically from those followed‐up), was an important consideration when rating the quality of evidence. The summary of findings for the quality of evidence for each outcome are set out in <a href="#CD012077-tbl-0006">Table 6</a>: Cerebral palsy; <a href="#CD012077-tbl-0008">Table 8</a>: Cerebral palsy or death; <a href="#CD012077-tbl-0009">Table 9</a>: Severity of cerebral palsy; <a href="#CD012077-tbl-0010">Table 10</a>: Other composite outcomes that include cerebral palsy as a component; and <a href="#CD012077-tbl-0011">Table 11</a>: Motor dysfunction. </p> </section> <section id="CD012077-sec-0065"> <h3 class="title" id="CD012077-sec-0065">Potential biases in the overview process</h3> <p>We were aware that there were risks of introducing bias at all stages of the overview process, and took a number of steps to minimise this. All included Cochrane reviews used a protocol that aimed to minimise bias; we also developed a protocol for our overview. At least two overview authors independently assessed reviews for inclusion, carried out data extraction and quality assessment, and assessed the quality of the evidence using the GRADE approach. One potential source of bias relates to authors of this overview being authors of some of the included reviews. As pre‐specified in our protocol, data extraction and quality assessment for these reviews were carried out by two overview authors who were not authors of the individual reviews. </p> <p>We undertook a comprehensive search of the <i>Cochrane Database of Systematic Reviews</i> without language or date restrictions, and identified published reviews, as well as planned and ongoing reviews (protocols). We did not search other databases, and thus it is possible that non‐Cochrane systematic reviews assessing antenatal and intrapartum interventions, and reporting on cerebral palsy, have been conducted but not identified. It is also possible that Cochrane reviews assessing interventions that could have potential to impact cerebral palsy risk (see <a href="#CD012077-sec-0021">Description of the interventions</a> for further discussion of various interventions) may not have acknowledged this by including cerebral palsy as a review outcome. Thus, data from relevant randomised trials assessing these interventions would not have been identified and included in this overview. Based on our search strategy, even Cochrane reviews that pre‐specified outcomes such as 'impaired long‐term growth and development in infancy and childhood' (e.g. <a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a>), but subsequently reported specifically on 'cerebral palsy' have been captured in our search, and included. However, reviews that reported on long‐term neurodevelopmental outcomes without any mention of 'cerebral palsy' would not have been identified, which highlights the need for all Cochrane reviews to provide clear definitions accompanying any outcome measures reported. </p> <p>While our included reviews were judged to be of high methodological quality and at low risk of bias, not all were considered 'up‐to‐date', with only one third conducting searches in the past four years; similarly, not all of the 'Reviews awaiting further classification' were 'up‐to‐date'. Thus, it is possible that additional trials assessing antenatal and intrapartum interventions and reporting on cerebral palsy have been published, but not yet included in the relevant Cochrane reviews; it is also possible that additional trials have been conducted but are not yet published. If and when such trials are included in the relevant Cochrane review, they will be incorporated into this overview. </p> </section> <section id="CD012077-sec-0066"> <h3 class="title" id="CD012077-sec-0066">Agreements and disagreements with other studies or reviews</h3> <p>We did not identify any other overviews or systematic reviews specifically designed to assess antenatal and intrapartum interventions for preventing cerebral palsy. </p> <p>In regards to cerebral palsy prevention for children born preterm, World Health Organization (WHO) recommendations focused on improving the outcomes of preterm birth have recently been released, based on up‐to‐date systematic reviews for priority questions (<a href="./references#CD012077-bbs2-0123" title="World Health Organization (WHO). WHO recommendations on interventions to improve preterm birth outcomes. Available from who.int/reproductivehealth/publications/maternal_perinatal_health/preterm‐birth‐guideline/en2015; Vol. (accessed 20 August 2016). ">WHO 2015</a>). These guidelines assessed a number of interventions that were included in this review, and reached similar conclusions. Specifically, a strong recommendation was made for the use of magnesium sulphate for women at risk of imminent preterm birth before 32 weeks of gestation for prevention of cerebral palsy in the infant and child, which was based on which was based on high quality evidence for cerebral palsy. A strong recommendation was also made against the use of routine antibiotic administration for women in preterm labour with intact amniotic membranes and no clinical signs of infection, based on moderate‐quality evidence for cerebral palsy (<a href="./references#CD012077-bbs2-0123" title="World Health Organization (WHO). WHO recommendations on interventions to improve preterm birth outcomes. Available from who.int/reproductivehealth/publications/maternal_perinatal_health/preterm‐birth‐guideline/en2015; Vol. (accessed 20 August 2016). ">WHO 2015</a>). </p> <p><a href="./references#CD012077-bbs2-0091" title="McIntyreS , TaitzD , KeoghJ , GoldsmithS , BadawiN , BlairE . A systematic review of risk factors for cerebral palsy in children born at term in developed countries. Developmental Medicine and Child Neurology2013;55:499‐508. ">McIntyre 2013</a> conducted a systematic review of cohort and case‐control studies focused on identifying risk factors for cerebral palsy in children born at term, with an aim to assess whether the potential for prevention of these risk factors has been adequately explored. They identified antenatal risk factors that included placental dysfunction or abnormalities, major and minor birth defects and low birthweight, while intrapartum risk factors were meconium aspiration, caesarean section, vacuum or breech delivery. Strategies for possible prevention of cerebral palsy in children born at term were only recognised to currently exist for two of these risk factors: reducing low birthweight (reducing heavy alcohol consumption during pregnancy), and reducing meconium aspiration (amnioinfusion in settings with limited perinatal surveillance; curtailment of post‐term pregnancy). This review highlighted that prevention strategies for cerebral palsy in term born infants are urgently required, and called for heightened efforts focused on preventing identified risk factors, and thus, interrupting pathways to cerebral palsy. </p> <p>A systematic review by <a href="./references#CD012077-bbs2-0076" title="HinesM , SwinburnK , McIntyreS , NovakI , BadawiN . Infants at risk of cerebral palsy: a systematic review of outcomes used in Cochrane studies of pregnancy, childbirth and neonatology. Journal of Maternal‐Fetal &amp; Neonatal Medicine2015;28(16):1871‐83. ">Hines 2015</a> was designed to systematically review meta‐analyses and randomised trials of interventions for infants at risk of cerebral palsy, to determine if consensus existed in study endpoints. The review identified that of the 685 Cochrane Pregnancy and Childbirth or Neonatal reviews published at the time, 177 addressed acknowledged risk factors for cerebral palsy (such as preterm birth, pre‐eclampsia, or neonatal infection). A sample of 22 reviews, with 165 included randomised trials were selected, which addressed interventions such as fetal monitoring during labour; preventing preterm labour, hypertension, and pre‐eclampsia; timing of umbilical cord clamping; maternal or neonatal infection, or both; minimising permanent brain injury; infant respiratory function; and glutamine supplementation. <a href="./references#CD012077-bbs2-0076" title="HinesM , SwinburnK , McIntyreS , NovakI , BadawiN . Infants at risk of cerebral palsy: a systematic review of outcomes used in Cochrane studies of pregnancy, childbirth and neonatology. Journal of Maternal‐Fetal &amp; Neonatal Medicine2015;28(16):1871‐83. ">Hines 2015</a> identified that of the 22 reviews, 18 specified neurodevelopmental outcomes, such as cerebral palsy, blindness, deafness, or intellectual impairment, but of the 203 relevant randomised trials in those reviews, only 22 (11%) contributed data to meta‐analyses for these outcomes. Similar to our overview, <a href="./references#CD012077-bbs2-0076" title="HinesM , SwinburnK , McIntyreS , NovakI , BadawiN . Infants at risk of cerebral palsy: a systematic review of outcomes used in Cochrane studies of pregnancy, childbirth and neonatology. Journal of Maternal‐Fetal &amp; Neonatal Medicine2015;28(16):1871‐83. ">Hines 2015</a> identified an urgent need for long‐term follow‐up after such antenatal and intrapartum interventions, and concluded that "Variation in outcome measurement and long‐term follow‐up has hampered the ability of RCTs to contribute data on important outcomes for CP, resulting in lost opportunities to measure the impact of maternal and neonatal interventions". </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012077-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/media/CDSR/CD012077/urn:x-wiley:14651858:media:CD012077:CD012077-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/media/CDSR/CD012077/image_t/tCD012077-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Review flow diagram." data-id="CD012077-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012077.pub2/media/CDSR/CD012077/image_n/nCD012077-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Review flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/media/CDSR/CD012077/image_n/nCD012077-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD012077-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of excluded reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reason for exclusion</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0016" title="Abou El SenounG , DowswellT , MousaHA . Planned home versus hospital care for preterm prelabour rupture of the membranes (PPROM) prior to 37 weeks' gestation. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD008053.pub3] ">Abou El Senoun 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary neonatal outcomes included:</p> <p> <ul id="CD012077-list-0012"> <li> <p>Disability at time of childhood follow‐up (as defined by authors).</p> </li> <li> <p>Serious disability (as defined by authors) after two years.</p> </li> </ul> </p> <p>No outcome data for these outcomes.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0017" title="BrickerL , MedleyN , PrattJJ . Routine ultrasound in late pregnancy (after 24 weeks' gestation). Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD001451.pub4] ">Bricker 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcomes included:</p> <p> <ul id="CD012077-list-0013"> <li> <p>Neurodevelopment at age two.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0018" title="BuchananSL , CrowtherCA , LevettKM , MiddletonP , MorrisJ . Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. Cochrane Database of Systematic Reviews2010, Issue 3. [DOI: 10.1002/14651858.CD004735.pub3] ">Buchanan 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary neonatal outcomes included:</p> <p> <ul id="CD012077-list-0014"> <li> <p>Disability at time of childhood follow‐up.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0019" title="ChapmanE , ReveizL , IllanesE , Bonfill CospX . Antibiotic regimens for management of intra‐amniotic infection. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD010976.pub2] ">Chapman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0020" title="CrowleyAE , GrivellRM , DoddJM . Sealing procedures for preterm prelabour rupture of membranes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD010218.pub2] ">Crowley 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary infant outcomes included:</p> <p> <ul id="CD012077-list-0015"> <li> <p>Neurodevelopmental delay at 12 months and 24 months.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0021" title="DareMR , MiddletonP , CrowtherCA , FlenadyV , VaratharajuB . Planned early birth versus expectant management (waiting) for prelabour rupture of membranes at term (37 weeks or more). Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD005302.pub2] ">Dare 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>foetal, neonatal, and infant outcomes included:</p> <p> <ul id="CD012077-list-0016"> <li> <p>Disability at time of childhood follow‐up.</p> </li> </ul> </p> <p>No outcome data for this outcome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0022" title="EastCE , BeggL , ColditzPB , LauR . Fetal pulse oximetry for fetal assessment in labour. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD004075.pub4] ">East 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcomes included:</p> <p> <ul id="CD012077-list-0017"> <li> <p>Long‐term neurodevelopmental outcome.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0023" title="GomiH , GotoY , LaopaiboonM , UsuiR , MoriR . Routine blood cultures in the management of pyelonephritis in pregnancy for improving outcomes. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD009216.pub2] ">Gomi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0024" title="HanS , CrowtherCA , MooreV . Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD000940.pub3] ">Han 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcomes included:</p> <p> <ul id="CD012077-list-0018"> <li> <p>Any neurological disability at follow‐up.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0025" title="HofmeyrGJ , BarrettJF , CrowtherCA . Planned caesarean section for women with a twin pregnancy. Cochrane Database of Systematic Reviews2015, Issue 12. [DOI: 10.1002/14651858.CD006553.pub3] ">Hofmeyr 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcomes included:</p> <p> <ul id="CD012077-list-0019"> <li> <p>Perinatal or infant death (excluding fatal anomalies) or disability in childhood.</p> </li> </ul> </p> <p>Secondary long‐term infant outcomes included:</p> <p> <ul id="CD012077-list-0020"> <li> <p>Disability in childhood, as defined by trial authors.</p> </li> </ul> </p> <p>No outcome data for these outcomes.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0026" title="HopkinsL , SmaillFM . Antibiotic regimens for management of intra‐amniotic infection. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD003254] ">Hopkins 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0027" title="KenyonS , BoulvainM , NeilsonJP . Antibiotics for preterm rupture of membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD001058.pub3] ">Kenyon 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary outcome included:</p> <p> <ul id="CD012077-list-0021"> <li> <p>Long‐term health outcomes (as defined by trial authors) after at least two years.</p> </li> </ul> </p> <p>Outcome data only reported for 'Serious childhood disability at seven years'.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0028" title="KhunpraditS , LumbiganonP , LaopaiboonM . Admission tests other than cardiotocography for fetal assessment during labour. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008410.pub2] ">Khunpradit 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary outcomes include:</p> <p> <ul id="CD012077-list-0022"> <li> <p>Neonatal neurodevelopment.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0029" title="KiizaJAK , HofmeyrGJ . Amnioinfusion for chorioamnionitis. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011622] ">Kiiza 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Protocol.</p> <p>Secondary baby outcomes will include:</p> <p> <ul id="CD012077-list-0023"> <li> <p>Long‐term neurodevelopmental outcome.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0030" title="LewinS , Munabi‐BabigumiraS , GlentonC , DanielsK , Bosch‐CapblanchX , VanWykBE , et al. Lay health workers in primary and community health care for maternal and child health and the management of infectious diseases. Cochrane Database of Systematic Reviews2010, Issue 3. [DOI: 10.1002/14651858.CD004015.pub3] ">Lewin 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0031" title="LutomskiJE , MeaneyS , GreeneRA , RyanAC , DevaneD . Expert systems for fetal assessment in labour. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD010708.pub2] ">Lutomski 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0032" title="MackeenAD , Seibel‐SeamonJ , MuhammadJ , BaxterJK , BerghellaV . Tocolytics for preterm premature rupture of membranes. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD007062.pub3] ">Mackeen 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0033" title="NeilsonJP . Interventions for suspected placenta praevia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD001998] ">Neilson 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0034" title="OlsenO , ClausenJA . Planned hospital birth versus planned home birth. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD000352.pub2] ">Olsen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0035" title="OthmanM , AlfirevicZ , NeilsonJP . Probiotics for preventing preterm labour. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD005941.pub2] ">Othman 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0036" title="SangkomkamhangUS , LumbiganonP , PrasertcharoensukW , LaopaiboonM . Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD006178.pub3] ">Sangkomkamhang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0037" title="SayL , GülmezogluAM , HofmeyrGJ . Transcutaneous electrostimulation for suspected placental insufficiency (diagnosed by Doppler studies). Cochrane Database of Systematic Reviews1996, Issue 1. [DOI: 10.1002/14651858.CD000079] ">Say 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0038" title="SayL , GülmezogluAM , HofmeyrGJ . Plasma volume expansion for suspected impaired fetal growth. Cochrane Database of Systematic Reviews1996, Issue 4. [DOI: 10.1002/14651858.CD000167] ">Say 1996a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0039" title="SayL , GülmezogluAM , HofmeyrGJ . Calcium channel blockers for potential impaired fetal growth. Cochrane Database of Systematic Reviews1996, Issue 1. [DOI: 10.1002/14651858.CD000049] ">Say 1996b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0040" title="SayL , GülmezogluAM , HofmeyrGJ . Bed rest in hospital for suspected impaired fetal growth. Cochrane Database of Systematic Reviews1996, Issue 1. [DOI: 10.1002/14651858.CD000034] ">Say 1996c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0041" title="SayL , GülmezogluAM , HofmeyrGJ . Betamimetics for suspected impaired fetal growth. Cochrane Database of Systematic Reviews2001, Issue 4. [DOI: 10.1002/14651858.CD000036] ">Say 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0042" title="SayL , GülmezogluAM , HofmeyrGJ . Maternal oxygen administration for suspected impaired fetal growth. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD000137] ">Say 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0043" title="SayL , GülmezogluAM , HofmeyrGJ . Maternal nutrient supplementation for suspected impaired fetal growth. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD000148] ">Say 2003a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0044" title="SayL , GülmezogluAM , HofmeyrGJ . Hormones for suspected impaired fetal growth. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD000109] ">Say 2003b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0045" title="SiegfriedN , Van derMerweL , BrocklehurstP , SintTT . Antiretrovirals for reducing the risk of mother‐to‐child transmission of HIV infection. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD003510.pub3] ">Siegfried 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0046" title="SiriwachirachaiT , SangkomkamhangUS , LumbiganonP , LaopaiboonM . Antibiotics for meconium‐stained amniotic fluid in labour for preventing maternal and neonatal infections. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD007772.pub3] ">Siriwachirachai 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No outcomes focused on development or disability at follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0047" title="StanCM , BoulvainM , PfisterR , Hirsbrunner‐AlmagbalyP . Hydration for treatment of preterm labour. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD003096.pub2] ">Stan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary outcomes included:</p> <p> <ul id="CD012077-list-0024"> <li> <p>Long‐term sequelae: neurologic impairment and chronic lung disease.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0048" title="ThomasJT , MullerP , WilkinsonCS . Antenatal phenobarbital for reducing neonatal jaundice after red cell isoimmunization. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005541.pub2] ">Thomas 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes included:</p> <p> <ul id="CD012077-list-0025"> <li> <p>Adverse neonatal outcomes in terms of longer‐term neurological outcomes.</p> </li> </ul> </p> <p>No outcome data for this outcome.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of excluded reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012077-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included reviews</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Date of search; date assessed as up‐to‐date</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. included trials; countries and years of publication</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. participants in included trials</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion criteria for "Types of participants"</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relevant comparison interventions (no. trials and participants)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overview outcomes for which data were reported (pre‐specified unless stated otherwise)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 April 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 RCTs</p> <p>34 RCTs in industrialised countries (Australia, France, Hong Kong, Ireland, Israel, Italy, Sweden, UK and USA) </p> <p>15 RCTs in low‐ or middle‐income countries (Argentina, Brazil, Caribbean Islands, India, South Africa, Sudan and Venezuela) </p> <p>RCTs published in:</p> <p>1960s: 1</p> <p>1970s: 2</p> <p>1980s: 22</p> <p>1990s: 17</p> <p>2000s: 5</p> <p>2010s; 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4723 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women with mild to moderate hypertension during pregnancy, regardless of whether or not they had proteinuria, previous antihypertensive treatment, or whether the pregnancy was singleton or multiple </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>any antihypertensive drug versus no drugs</p> <p>(29 RCTs, 3350 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary outcome</p> <p>primary outcome was impaired long‐term growth and development in infancy and childhood</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 31 December 2012</p> <p>Up‐to‐date: 31 January 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 RCTs (1 qRCT)</p> <p>No. RCTs in:</p> <p>Australia: 2</p> <p>Denmark: 1</p> <p>Greece: 1</p> <p>India: 1</p> <p>Ireland: 2</p> <p>Pakistan: 1</p> <p>Sweden: 1</p> <p>UK: 1</p> <p>USA: 3</p> <p>RCTs published in:</p> <p>1970s: 4</p> <p>1980s: 6</p> <p>1990s: 2</p> <p>2000s: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37,715 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pregnant women in labour and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>continuous cardiotocography versus intermittent auscultation</p> <p>(12 RCTs, 33,681 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a primary review outcome</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 28 February 2013</p> <p>Up‐to‐date:</p> <p>10 July 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 RCTs</p> <p>No. RCTs in:</p> <p>Egypt: 1</p> <p>Europe: 1</p> <p>South Africa: 1</p> <p>USA: 1</p> <p>RCTs published in:</p> <p>1990s: 2</p> <p>2000s: 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>425 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women with severe pre‐eclampsia, up to and including 34 weeks' gestation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>interventionist care versus expectant (delayed delivery) care</p> <p>(4 RCTs, 425 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary review outcome</p> <p>pre‐specified outcome was 'measures of long‐term growth and development, such as important impairment and cerebral palsy' </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 20 December 2010</p> <p>Up‐to‐date:</p> <p>15 February 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 RCTs Countries of trials not reported</p> <p>RCTs published in:</p> <p>1980s: 4</p> <p>1990s: 3</p> <p>2000s: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>879 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women at risk of imminent very preterm birth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>vitamin K versus control</p> <p>(8 RCTs, 879 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a primary review outcome</p> <p>pre‐specified outcome was long‐term neurodevelopment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 20 December 2010</p> <p>Up‐to‐date: 9 January 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 RCTs</p> <p>Countries of trials not reported</p> <p>RCTs published in:</p> <p>1980s: 4</p> <p>1990s: 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1752 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women at risk of imminent very preterm birth (before 34 weeks' gestation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>phenobarbital versus control</p> <p>(9 RCTs, 1752 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy, motor dysfunction (other neuromotor impairment) reported as primary review outcomes </p> <p>pre‐specified outcome was 'long‐term neurodevelopment'</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 January 2014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 RCTs (4 qRCTs)</p> <p>No. RCTs in: China: 3</p> <p>Iran: 5</p> <p>Italy: 1</p> <p>Mexico: 1</p> <p>Thailand: 1</p> <p>Turkey: 1</p> <p>USA: 25</p> <p>RCTs published in:</p> <p>1980s: 7</p> <p>1990s: 18</p> <p>2000s: 10</p> <p>2010s: 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3571 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women considered to be in preterm labour given magnesium sulphate to reduce their risk of preterm birth </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>magnesium sulphate versus placebo, no treatment, or other tocolytic agent</p> <p>(37 RCTs, 3571 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary review outcome</p> <p>primary review outcome was a composite outcome including cerebral palsy, listed as 'serious infant outcome' ("...death or chronic lung disease...grade three or four intraventricular haemorrhage or periventricular leukomalacia, major neurosensory disability (legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy, or developmental delay or intellectual impairment...))" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 January 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 RCTs</p> <p>No. RCTs in:</p> <p>Australia and New Zealand: 1</p> <p>Canada: 1</p> <p>Finland: 1</p> <p>India: 1</p> <p>USA: 5</p> <p>20 countries: 1</p> <p>RCTs published in:</p> <p>2000s: 9</p> <p>2010s: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4733 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women considered to be at risk of preterm birth who had already received a single course of prenatal corticosteroid seven or more days previously </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>repeat doses of prenatal corticosteroids versus placebo or no treatment</p> <p>(10 RCTs, 4733 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary review outcome;</p> <p>composite primary outcomes that included cerebral palsy</p> <p> <ul id="CD012077-list-0036"> <li> <p>survival free of any disability (however defined by authors)</p> </li> </ul> <ul id="CD012077-list-0037"> <li> <p>survival free of major disability (however defined by authors)</p> </li> </ul> <ul id="CD012077-list-0038"> <li> <p>major neurosensory disability (not pre‐specified)</p> </li> </ul> <ul id="CD012077-list-0039"> <li> <p>disability at childhood follow‐up (however defined by authors)</p> </li> </ul> <ul id="CD012077-list-0040"> <li> <p>composite serious outcome (however defined by authors)</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 January 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 RCTs</p> <p>No. RCTs in:</p> <p>Albania: 1</p> <p>Brazil: 1</p> <p>Denmark and Austria: 1</p> <p>Egypt: 3</p> <p>Finland: 1</p> <p>France: 3</p> <p>India: 2</p> <p>Iran: 5</p> <p>Italy: 1</p> <p>Netherlands: 1</p> <p>Spain: 1</p> <p>Turkey: 1</p> <p>UK: 1</p> <p>USA: 11</p> <p>international: 3</p> <p>RCTs published in:</p> <p>1970s: 2</p> <p>1980s: 2</p> <p>2000s: 13</p> <p>2010s: 19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8523 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pregnant women considered to be at increased risk of preterm birth:</p> <p> <ul id="CD012077-list-0041"> <li> <p>Past history of spontaneous preterm birth</p> </li> <li> <p>Multiple pregnancy</p> </li> <li> <p>Ultrasound identified short cervical length</p> </li> <li> <p>fetal fibronectin testing</p> </li> <li> <p>Following acute presentation with symptoms or signs of threatened preterm labour</p> </li> <li> <p>Other reason considered to be at increased risk of preterm birth</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>progesterone versus placebo or no treatment</p> <p>(11 RCTs, 1899)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary review outcome</p> <p>motor dysfunction, pre‐specified as motor impairment, reported as secondary review outcome </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 31 August 2008</p> <p>Up‐to‐date: 5 November 2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 RCTs</p> <p>No. RCTs in: Australia and New Zealand: 1</p> <p>France: 1</p> <p>USA: 2</p> <p>international; 1 (predominately in developing countries)</p> <p>RCTs published in:</p> <p>2000s: 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5560 women and their 6145 babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women considered to be at risk of preterm birth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>magnesium sulphate versus placebo</p> <p>(5 RCTs, 6145 babies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy; cerebral palsy or death; severity of cerebral palsy (mild, moderate, moderate to severe, severe cerebral palsy); composite outcomes including cerebral palsy (any neurologic impairment; major neurological disability; death or any neurologic impairment; death or major neurological disability); motor dysfunction (substantial gross motor dysfunction; death or substantial gross motor dysfunction) reported as primary outcomes </p> <p>pre‐specified outcomes were: neurological impairments (developmental delay or intellectual impairment (developmental quotient or intelligence quotient less than one standard deviation (SD) below the mean), cerebral palsy (abnormality of tone with motor dysfunction), blindness (corrected visual acuity worse than 6/60 in the better eye), or deafness (hearing loss requiring amplification or worse)); neurological disabilities (abnormal neurological function caused by any of the preceding impairments) at follow‐up later in childhood; substantial gross motor dysfunction (motor dysfunction such that the child was not walking at age two years or later, or the inability to grasp and release a small block with both hands); major neurological disability (legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy, developmental delay or intellectual impairment (developmental quotient or intelligence quotient less than two SD below the mean)); paediatric mortality combined with cerebral palsy, substantial gross motor dysfunction, neurological impairment, or major neurological disability (these combined outcomes recognise the competing risks of death or survival with neurological problems) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 4 June 2010</p> <p>Up‐to‐date: 1 September 2010</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 RCTs</p> <p>No. RCTs in: Denmark: 1</p> <p>India; 1</p> <p>Malaysia: 1</p> <p>Mexico: 2</p> <p>South Africa: 2</p> <p>Taiwan: 1</p> <p>USA: 5</p> <p>international: 2 (1 in 33 countries, with 85% recruitment in low‐ and middle‐income countries; 1 in 8 countries) </p> <p>RCTs published in:</p> <p>1990s: 10</p> <p>2000s: 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,570 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>any women with pre‐eclampsia, regardless of whether: before or after delivery, a singleton or multiple pregnancy, or whether an anticonvulsant had been given before trial entry </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>magnesium sulphate versus placebo or no anticonvulsant</p> <p>(6 RCTs, 11,444 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>severe cerebral palsy; other composite outcomes including cerebral palsy (neurosensory disability; death or neurosensory disability) were all reported as secondary review outcomes </p> <p>pre‐specified outcomes were 'long‐term growth and development: blindness, deafness, seizures, poor growth, neurodevelopmental delay and cerebral palsy' </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 31 August 2013</p> <p>Up‐to‐date: 3 October 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 RCTs</p> <p>No. RCTs in:</p> <p>Canada: 1</p> <p>Chile: 1</p> <p>Denmark: 1</p> <p>Germany: 1</p> <p>Iran: 1</p> <p>South Africa: 1</p> <p>Uruguay: 1</p> <p>USA: 6</p> <p>international: 1</p> <p>RCTs published in:</p> <p>1980s: 1</p> <p>1990s: 10</p> <p>2000s: 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7837 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women thought to be in preterm labour with intact membranes, between 20 and 36 completed weeks of gestation </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>any antibiotics versus no antibiotics</p> <p>(14 RCTs, 7837 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a primary review outcome</p> <p>pre‐specified outcome was 'major long‐term infant neurosensory impairment'</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search:</p> <p>4 July 2012 (r<i>esults added to Studies awaiting classification</i>) </p> <p>Up‐to‐date: 30 January 2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 RCTs</p> <p>No. RCTs in:</p> <p>Argentina: 1</p> <p>Australia: 2</p> <p>Brazil: 1</p> <p>England: 5</p> <p>Fr Caribbean: 1</p> <p>France: 3</p> <p>Hong Kong: 1</p> <p>India: 1</p> <p>Israel: 4</p> <p>Scotland: 4</p> <p>Sweden: 3</p> <p>USA: 2</p> <p>Venezuela: 1</p> <p>RCTs published in:</p> <p>1970s: 1</p> <p>1980s: 17</p> <p>1990s: 11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2548 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women with mild to moderate hypertension during pregnancy, however defined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>beta‐blockers versus placebo or no beta‐blocker</p> <p>(13 RCTs, 1480 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy reported as a review outcome, rather than primary or secondary</p> <p>pre‐specified outcome was 'measures of long‐term health and development such as cerebral palsy' </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2013</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 RCTs (20 RCTs contributed data)</p> <p>No. RCTs in:</p> <p>Australia: 1</p> <p>Canada: 1</p> <p>Europe: 6</p> <p>Iran: 1</p> <p>Italy: 1</p> <p>Japan: 1</p> <p>Sweden: 1</p> <p>USA: 10</p> <p>not reported: 6</p> <p>RCTs published in:</p> <p>1960s: 1</p> <p>1970s: 5</p> <p>1980s: 18</p> <p>1990s: 3</p> <p>2010s: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2715 women and their babies in 20 RCTs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pregnant women assessed as being in spontaneous preterm labour and considered suitable for tocolytic agents </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>betamimetics versus placebo</p> <p>(12 RCTs, 1367 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy reported as a primary review outcome</p> <p>pre‐specified outcome was 'abnormal long‐term neurodevelopmental status at more than 12 months corrected age (moderate to severe developmental delay, cerebral palsy, sensory impairment, for example, blind and deaf, or a combination)' </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search: 30 April 2010 (added the search to Studies awaiting classification)</p> <p>Up‐to‐date:</p> <p>15 May 2006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 RCTs</p> <p>No. RCTs in:</p> <p>Brazil: 1</p> <p>Canada: 1</p> <p>Finland: 2</p> <p>Jordan: 1 RCT</p> <p>Netherlands: 1</p> <p>New Zealand: 1</p> <p>South Africa: 1</p> <p>Spain: 1</p> <p>Tunisia: 1</p> <p>UK: 1</p> <p>USA: 10</p> <p>RCTs published in:</p> <p>1970s: 3</p> <p>1980s: 8</p> <p>1990s: 8</p> <p>2000s: 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>over 3999 women (data available for 3885 women and their babies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>women with a singleton or multiple pregnancy, expected to deliver preterm as a result of either spontaneous preterm labour, preterm pre‐labour rupture of the membranes, or elective preterm delivery </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>antenatal corticosteroids versus placebo or no treatment</p> <p>(21 RCTs, 3885 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary review outcome</p> <p>other composite outcome including cerebral palsy (neurodevelopmental delay) reported as a primary review outcome </p> <p>pre‐specified primary outcome was 'neurodevelopmental disability' at follow‐up (blindness, deafness, moderate/severe cerebral palsy (however defined by authors), or development delay or intellectual impairment (defined as developmental quotient or intelligence quotient less than 2 SD below population mean))' </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 April 2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 RCT</p> <p>1 RCT in Belgium, Cyprus, Czech Republic, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Saudi Arabia, Slovenia, United Kingdom </p> <p>RCT published in 2000s</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>548 women and their babies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pregnant women at less than 36 weeks' gestation in whom there was clinical suspicion of fetal compromise as defined by trialists </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immediate delivery versus deferred delivery</p> <p>(1 RCT, 548 women)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cerebral palsy reported as a secondary outcome</p> <p>other composite outcomes including cerebral palsy (death or disability at or after two years of age) reported as a primary review outcome </p> <p>'neurodevelopmental impairment at or after two years of age' reported as a secondary outcome </p> <p>'death or severe disability in childhood' reported but not pre‐specified</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Abbreviation: RCT: randomised controlled trial</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012077-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of bias assessments from included reviews</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Summary of trial limitations (risk of bias)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 12 RCTs low risk; 35 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Allocation concealment:</b> 17 RCTs low risk; 32 RCTs unclear risk </p> <p><b>Blinding (participants and personnel):</b> 10 RCTs low risk; 1 RCT unclear risk; 38 RCTs high risk </p> <p><b>Blinding (outcome assessors):</b> 10 RCTs low risk; 2 RCTs unclear risk; 37 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 45 RCTs low risk; 4 RCTs high risk </p> <p><b>Selective reporting:</b> 9 RCTs low risk; 40 RCTs unclear risk </p> <p><b>Other:</b> 23 RCTs low risk; 24 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Overall:</b> "Overall, the quality of the studies included in this review is moderate to poor" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 3 RCTs low risk; 8 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Allocation concealment:</b> 3 RCTs low risk; 6 RCTs unclear risk; 4 RCTs high risk </p> <p><b>Blinding (participants and personnel):</b> 13 RCTs high risk </p> <p><b>Blinding (outcome assessors):</b> 12 RCTs unclear risk; 1 RCT high risk </p> <p><b>Incomplete outcome data:</b> 8 RCTs low risk; 3 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Selective reporting:</b> 13 RCTs high risk </p> <p><b>Other:</b> 13 RCTs low risk </p> <p><b>Overall:</b> Only 2 RCTs were judged to be of high quality. </p> <p>"The overall quality of the evidence can best be described as low to moderate"</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 3 RCTs low risk; 1 RCT unclear risk </p> <p><b>Allocation concealment:</b> 3 RCTs low risk; 1 RCT unclear risk </p> <p><b>Blinding (participants and personnel):</b> 1 RCT low risk; 3 RCTs unclear risk </p> <p><b>Blinding (outcome assessors):</b> 1 RCT low risk; 3 RCTs unclear risk </p> <p><b>Incomplete outcome data:</b> 1 RCT low risk; 2 RCTs unclear risk; 1 RCT high risk </p> <p><b>Selective reporting:</b> 4 RCTs low risk </p> <p><b>Other:</b> 1 RCT low risk; 2 RCTs unclear; 1 RCT high risk </p> <p><b>Overall:</b> "Overall, two trials were judged to have a low risk of bias, one was unclear and one a high risk of bias" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 2 RCTs low risk; 4 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Allocation concealment:</b> 7 RCTs unclear risk; 1 RCT high risk </p> <p><b>Blinding:</b> 2 RCTs low risk; 1 RCT unclear risk; 5 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 3 RCTs low risk; 4 RCTs unclear risk; 1 RCT high risk </p> <p><b>Selective reporting:</b> 6 RCTs low risk; 2 RCTs unclear risk </p> <p><b>Other:</b> 5 RCTs low risk; 2 RCTs unclear risk; 1 RCT high risk </p> <p><b>Overall:</b> "The trials were of variable quality." </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 1 RCT low risk; 4 RCTs unclear risk; 4 RCTs high risk </p> <p><b>Allocation concealment:</b> 7 RCTs unclear risk; 1 RCT high risk; 1 RCT: not reported </p> <p><b>Blinding:</b> 4 RCTs low risk; 1 RCT unclear risk; 4 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 1 RCT low risk; 5 RCTs unclear risk; 3 RCTs high risk </p> <p><b>Selective reporting:</b> 9 RCTs low risk </p> <p><b>Other:</b> 6 RCTs low risk; 1 RCT unclear risk; 2 RCTs high risk </p> <p><b>Overall:</b> "Poor‐quality trials contribute excessively to the weight in the overall analysis due to the higher rate of adverse outcomes in those trials" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 15 RCTs low risk; 18 RCTs unclear risk; 4 RCTs high risk </p> <p><b>Allocation concealment:</b> 6 RCTs low risk; 27 RCTs unclear risk; 4 RCTs high risk </p> <p><b>Blinding (participants and personnel):</b> 4 RCTs low risk; 7 RCTs unclear risk; 26 RCTs high risk </p> <p><b>Blinding (outcome assessors):</b> 1 RCT low risk; 35 RCTs unclear risk; 1 RCT high risk </p> <p><b>Incomplete outcome data:</b> 20 RCTs low risk; 15 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Selective reporting:</b> 11 RCTs low risk; 19 RCTs unclear risk; 7 RCTs high risk </p> <p><b>Other:</b> 17 RCTs low risk; 20 RCTs unclear risk </p> <p><b>Overall: "</b>Overall, we judged the included trials to be of moderate to high risk of bias" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 8 RCTs low risk; 2 RCTs unclear risk </p> <p><b>Allocation concealment:</b> 10 RCTs low risk </p> <p><b>Blinding (participants and personnel):</b> 9 RCTs low risk; 1 RCT high risk </p> <p><b>Blinding (outcome assessors):</b> 4 RCTs low risk; 6 RCTs unclear risk </p> <p><b>Incomplete outcome data:</b> 7 RCTs low risk; 3 RCTs unclear risk </p> <p><b>Selective reporting:</b> 9 RCTs low risk; 1 RCT unclear risk </p> <p><b>Other:</b> 7 RCTs low risk; 3 RCTs high risk </p> <p><b>Overall:</b> "Overall, the included trials were assessed as having a low to moderate risk of bias" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 23 RCTs low risk; 13 RCTs unclear risk </p> <p><b>Allocation concealment:</b> 23 RCTs low risk; 13 RCTs unclear risk </p> <p><b>Blinding (participants and personnel):</b> 24 RCTs low risk; 7 RCTs unclear risk; 4 RCTs high risk </p> <p><b>Blinding (outcome assessors):</b> 15 RCTs low risk; 17 RCTs unclear risk; 4 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 31 RCTs low risk; 5 RCTs unclear risk </p> <p><b>Selective reporting:</b> 25 RCTs low risk; 10 RCTs unclear risk; 1 RCT high risk </p> <p><b>Other:</b> 21 RCTs low risk; 15 RCTs unclear risk </p> <p><b>Overall:</b> "The overall quality of the included trials varied from good to fair" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 4 RCTs low risk; 1 RCT unclear risk </p> <p><b>Allocation concealment:</b> 4 RCTs low risk; 1 RCT unclear risk </p> <p><b>Blinding:</b> 3 RCTs low risk; 2 RCT unclear risk </p> <p><b>Incomplete outcome data:</b> 2 RCTs low risk; 3 RCT unclear risk </p> <p><b>Selective reporting:</b> 4 RCTs low risk; 1 RCT unclear risk </p> <p><b>Overall:</b> "Overall, the methodological quality of the trials was relatively good, with a low risk of bias. However, the quality was better, and the risk of bias lower, in some studies compared with others" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 6 RCTs low risk; 9 RCTs unclear risk </p> <p><b>Allocation concealment:</b> 5 RCTs low risk; 9 RCTs unclear risk; 1 RCT high risk </p> <p><b>Blinding:</b> 4 RCTs low risk; 3 RCTs unclear risk; 8 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 7 RCTs low risk; 3 RCTs unclear risk; 5 RCTs high risk </p> <p><b>Overall:</b> "The quality of the studies included in this review ranged from excellent to poor. However, most of the poor quality studies were small. The large study comparing magnesium sulphate with placebo was of high quality" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 7 RCTs low risk; 7 RCTs unclear risk </p> <p><b>Allocation concealment:</b> 9 RCTs low risk; 5 RCTs unclear risk </p> <p><b>Blinding (participants and personnel):</b> 12 RCTs low risk; 2 RCTs high risk </p> <p><b>Blinding (outcome assessors):</b> 12 RCTs low risk; 2 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 13 RCTs low risk; 1 RCT unclear risk (long‐term: 1 RCT low risk; 13 RCTs unclear risk) </p> <p><b>Selective reporting:</b> 12 RCTs low risk; 2 RCTs unclear risk </p> <p><b>Other:</b> 13 RCTs low risk; 1 RCT unclear risk </p> <p><b>Overall:</b> "Overall the quality of the included trials was good" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Allocation concealment:</b> adequate in 5 RCT </p> <p><b>Double blinding (of physicians and patients) for outcome assessment:</b> 7 RCTs </p> <p><b>For maternal and pregnancy outcomes, follow up of greater than 90%:</b> 20 RCTs </p> <p><b>Overall:</b> "The quality of these trials was poor" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 12 RCTs low risk; 16 RCTs unclear risk </p> <p><b>Allocation concealment:</b> 7 RCTs low risk; 21 RCTs unclear risk </p> <p><b>Blinding (participants and personnel):</b> 15 RCTs low risk; 1 RCTs unclear risk; 12 RCTs high risk </p> <p><b>Blinding (outcome assessors):</b> 9 RCTs low risk; 8 RCTs unclear risk; 11 RCTs high risk </p> <p><b>Incomplete outcome data:</b> 16 RCTs low risk; 10 RCTs unclear risk; 2 RCTs high risk </p> <p><b>Selective reporting:</b> 1 RCT low risk; 26 RCTs unclear risk; 1 RCT high risk </p> <p><b>Other:</b> 8 RCTs low risk; 19 RCTs unclear risk; 1 RCT high risk </p> <p><b>Overall:</b> not detailed </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Allocation concealment:</b> 8 RCTs: A (adequate); 12 RCTs: B (unclear); 1 RCT: C (inadequate) </p> <p><b>Overall:</b> not detailed </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation:</b> 1 RCT low risk </p> <p><b>Allocation concealment:</b> 1 RCT low risk </p> <p><b>Blinding (participants and personnel):</b> 1 RCT high risk </p> <p><b>Blinding (outcome assessors):</b> 1 RCT low risk </p> <p><b>Incomplete outcome data:</b> 1 RCT low risk (high for childhood outcomes) </p> <p><b>Selective reporting:</b> 1 RCT low risk </p> <p><b>Other:</b> 1 RCT high risk </p> <p><b>Overall:</b> "large study of good quality" </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>Abbreviation: RCT: randomised controlled trial</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of bias assessments from included reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012077-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">AMSTAR assessments for included reviews</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Review ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="11" rowspan="1" valign="top"> <p><b>AMSTAR criteria</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Total score</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>A priori design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duplicate selection and extraction</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comprehensive search</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grey literature considered</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Included and excluded studies lists</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Characteristics of included studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality assessed and documented</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality considered for conclusions</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Methods for combining studies appropriate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Publication bias considered or assessed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conflicts stated</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/11</p> <p>HIGH QUALITY</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✗</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/10</p> <p>HIGH QUALITY</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p>✓: item adequately addressed; ?: unclear whether item addressed; ✗: item not adequately addressed </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">AMSTAR assessments for included reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012077-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROBIS assessments for included reviews</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Review ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>ROBIS domains</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study eligibility criteria</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Identification and selection of studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Data collection and study appraisal</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Synthesis and findings</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW RISK</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROBIS assessments for included reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012077-tbl-0006"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Summary of findings: all comparisons measuring cerebral palsy</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention and comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the treatment of mild to moderate hypertension</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any antihypertensive drug versus placebo for mild to moderate hypertension during pregnancy (<a href="./references#CD012077-bbs2-0001" title="AbalosE , DuleyL , SteynDW . Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD002252.pub3] ">Abalos 2014</a>) </p> <p>and</p> <p>Oral beta‐blockers versus placebo for mild to moderate hypertension during pregnancy (<a href="./references#CD012077-bbs2-0012" title="MageeL , DuleyL . Oral beta‐blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002863] ">Magee 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 1 year (definition not clear; one child with 'spastic quadriparesis with a severe pseudo‐bulbar palsy') assessed by clinical evaluation </p> <p>(assessment method taken from RCT manuscript as not detailed in reviews)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> <p>(1/55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000 (0 to 146)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33 (95% CI 0.01 to 8.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VERY LOW</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear sequence generation, allocation concealment, and selective reporting </p> <p>Imprecision (‐2): Wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the treatment of pre‐eclampsia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventionist care versus expectant (delayed delivery) care for severe pre‐eclampsia (<a href="./references#CD012077-bbs2-0003" title="ChurchillD , DuleyL , ThorntonJG , JonesL . Interventionist versus expectant care for severe pre‐eclampsia between 24 and 34 weeks' gestation. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2] ">Churchill 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cerebral palsy at 2 years (definition not clear) assessed by family practitioner or paediatrician using short questionnaire </p> <p>(assessment method taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> <p>(1/121)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000 (6 to 398)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 6.01 (95% CI 0.75 to 48.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulphate versus placebo for women with pre‐eclampsia (<a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe cerebral palsy at 18 months defined as 'not walking or unlikely to walk unaided by 24 months; children screened with Ages and Stages Questionnaires; screen‐positive and a sample of screen‐negative children had clinical and neurodevelopmental assessments (using Bayley Scales of Infant Development; Griffiths Tests, or other); if this was not possible, clinical history and examination (using the Health Status Questionnaire) </p> <p>(definition and assessment method taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> <p>(9/1464)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (1 to 8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.34 (95% CI 0.09 to 1.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2895 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of attrition bias for this outcome (2895 of 6922 children included in original RCT ) </p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the diagnosis and prevention of fetal compromise in labour</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous cardiotocography (CTG) versus intermittent auscultation (IA) for fetal assessment during labour (<a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months to 4 years</p> <p> <ul id="CD012077-list-0043"> <li> <p>1 RCT: defined as 'non‐progressive disorder of movement or posture due to a defect in or damage to the developing brain'; a developmental paediatrician performed neurological examinations at 18 months </p> </li> <li> <p>1 RCT: definition not clear; children with abnormal neurological signs in the neonatal period underwent a general physical and detailed neurological examination by a paediatrician at 4 years; other cases identified from records of specialist remedial clinics </p> </li> </ul> </p> <p>(definitions and assessment methods taken from RCT manuscripts as not detailed in review) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> <p>(17/6643)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 (2 to 9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>average RR 1.75 (95% 0.84 to 3.63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,252 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>quality of evidence (GRADE), taken from published review:</p> <p>"study limitations (‐1): most of the pooled effect provided by studies "B" or "C" without a substantial proportion (i.e. &lt; 40% (actual 0% weight) from studies "C" </p> <p>imprecision (‐1): 95% confidence interval around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable benefit favouring IA" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the prevention of preterm birth</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prenatal administration of progesterone versus placebo for preventing preterm birth in women with a previous history spontaneous preterm birth (singletons) (<a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 4 years, definition not clear; assessed by general physical examination by paediatrician or nurse practitioner, or from chart abstraction </p> <p>(age and assessment method taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> <p>(1/82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (0 to 42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.14 (95% 0.01 to 3.48)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any prophylactic antibiotics versus no antibiotics for inhibiting preterm labour with intact membranes (<a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 7 years, definition not clear; measured using proxy information provided by parents through a postal questionnaire (or by telephone in a small number) using validated tools </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> <p>(12/770)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000 (15 to 52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.82 (95% CI 0.99 to 3.34)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3173 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐1): wide confidence interval crossing the line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Betamimetics versus placebo for inhibiting preterm labour (<a href="./references#CD012077-bbs2-0013" title="NeilsonJP , WestHM , DowswellT . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD004352.pub3] ">Neilson 2014</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months, definition not clear; assessed by paediatrician examination</p> <p>(assessment method taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> <p>(5/121)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000 (1 to 67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.19 (95% CI 0.02 to 1.63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study limitations (‐1): 1 RCT at unclear risk of attrition bias for this outcome</p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect; 1 small RCT</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulphate versus other tocolytic agents for preventing preterm birth in threatened preterm labour (<a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months, definition not clear; assessed by neurodevelopment examinations at 4, 8, 12, and 18 months, with diagnoses made or verified by developmental paediatrician after 18 month examination </p> <p>(assessment method taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> <p>(3/51)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000 (1 to 148)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.13 (95% CI 0.01 to 2.51)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VERY LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of selection, attrition, and reporting bias, and high risk of performance bias </p> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions prior to preterm birth for fetalmaturation or neuroprotection</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenobarbital versus placebo or no treatment prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months to 3 years</p> <p> <ul id="CD012077-list-0044"> <li> <p>1 RCT: defined as presence of hypertonicity, hyperreflexia, and dystonic or spastic movement quality in the affected extremity (including diplegia, hemiplegia, triplegia, or quadriplegia); assessed by certified examiners trained to perform neurologic examinations at 18 months </p> </li> <li> <p>1 RCT: described as cerebral palsy associated with motor delay (diplegia, monoplegia, quadriplegia, and hemiplegia); assessed by trained nurse practitioner using detailed physical and neurologic examination at 3 years </p> </li> </ul> </p> <p>(definitions and assessment methods taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> <p>(23/252)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000 (37 to 117)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71 (95% CI 0.40 to 1.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 2 RCTs with limitations: 1 with high risk of selection bias, bias due to lack of blinding and attrition bias; 2 with unclear risk of selection bias </p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin K versus placebo prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a>) </p> <p><i>and</i> </p> <p>Phenobarbital versus placebo prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 7 years, definition not clear; method of assessment not clear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> <p>(12/151)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000 (26 to 140)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77 (95% CI 0.33 to 1.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VERY LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of selection bias, and high risk of attrition bias </p> <p>indirectness (‐1): dual intervention of vitamin K and phenobarbital</p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulphate versus placebo for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months to 2 years</p> <p> <ul id="CD012077-list-0045"> <li> <p>1 RCT: defined as abnormalities of tone and loss of motor function; assessed by developmental paediatrician at 2 years </p> </li> <li> <p>1 RCT: defined severe cerebral palsy as not walking or unlikely to walk unaided by 2 years; children screened with Ages and Stages Questionnaires; screen‐positive and a sample of screen‐negative children had clinical and neurodevelopmental assessments at 18 months (using Bayley Scales of Infant Development; Griffiths Tests; or other); if this was not possible, clinical history and examination (using the Health Status Questionnaire) was used </p> </li> <li> <p>1 RCT: used the European Cerebral Palsy Network definition; paediatricians evaluated motor function at 2 years; if examination was not possible, parent telephone interview was used </p> </li> <li> <p>1 RCT: definition not provided; assessed by neurodevelopment examinations at 4, 8, 12, and 18 months, with diagnoses made or verified by developmental paediatrician after the 18 month examination </p> </li> <li> <p>1 RCT: defined as presenting with 2 or more of the following three features: a delay of 30% or more in gross motor developmental milestones; abnormality in muscle tone, 4+ or absent deep tendon reflexes, or movement abnormality; or persistence of primitive reflexes or absence of protective reflexes; assessed by paediatrician or paediatric neurologist at 2 years </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> <p>(154/3093)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 per 1000 (27 to 43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68 (95% CI 0.54 to 0.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6145 (5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antenatal corticosteroids versus placebo for accelerating fetal lung maturation for women at risk of preterm birth (<a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 2 to 6 years</p> <p> <ul id="CD012077-list-0046"> <li> <p>1 RCT: defined as any of hemiparesis, diplegia, tetra‐, quadriplegia; assessed using detailed physical and neurologic examination (including of motor co‐ordination) at 3 years </p> </li> <li> <p>1 RCT: defined as pathological muscle tonus, pre‐existing primitive reflexes and delay in motor coordination; assessed using neurological examination by trial author (including evaluation of gross and fine motor) at 2 years </p> </li> <li> <p>3 RCTs: definition not clear</p> </li> </ul> </p> <p>(definitions and assessment methods taken, where possible, from RCT manuscripts as not detailed in review) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 per 1000</p> <p>(28/414)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000 (23 to 70)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.60 (95% CI 0.34 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>904 (5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 2 RCTs with unclear and 1 RCT with inadequate allocation concealment</p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Repeat doses of corticosteroids versus single course for women at risk of preterm birth (<a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months to 3 years</p> <p> <ul id="CD012077-list-0047"> <li> <p>1 RCT: defined as abnormalities of muscle tone as well as loss of motor function; assessed by developmental paediatrician using neurological examinations at 2 years </p> </li> <li> <p>1 RCT: defined as non‐progressive motor impairment characterised by abnormal muscle tone and decreased range of movements; assessed (by neonatologists, general paediatricians, developmental paediatricians, and trained nurses) using a standardised neurological assessment at 18 months to 2 years </p> </li> <li> <p>1 RCT: definition as described by <a href="./references#CD012077-bbs2-0110" title="RosenbaumP , PanethN , LevitonA , GoldsteinM , BaxM , DamianoD , et al. A report: the definition and classification of cerebral palsy April 2006. Developmental Medicine and Child Neurology Supplement2007;109:8‐14. ">Rosenbaum 2007</a>; assessed by paediatric neurologist or paediatrician using specific neurological examination at 2 years </p> </li> <li> <p>1 RCT: defined as severe delay in gross motor milestones, failure to walk by 17 months of corrected age; abnormality of tone or reflexes; and aberration of primitive reflexes or postural reactions; assessed by paediatricians or paediatric neurologists using neurologic examination between 2 and 3 years </p> </li> </ul> </p> <p>(definitions and assessment methods taken from RCT manuscripts as not all detailed in review) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> <p>(52/1891)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000 (20 to 41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03 (95% CI 0.71 to 1.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3800 (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the management of preterm fetalcompromise</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immediate versus deferred delivery of the preterm baby with suspected fetal compromise (<a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at or after 2 years</p> <p>definition not clear; assessed by family practitioner or paediatrician using short questionnaire </p> <p>(assessment method taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> <p>(2/251)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1000 (11 to 207)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.88 ( CI 95% 1.33 to 26.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT at high risk of performance bias and other bias (did not account for non‐independence of data for twin pregnancies) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: CI: confidence intervals; IA: intermittent auscultation; RCT: randomised controlled trial; RR: risk ratio; CI: confidence interval </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Summary of findings: all comparisons measuring cerebral palsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012077-tbl-0007"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Summary of findings: subgroup or sensitivity analyses of select comparisons for cerebral palsy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention and comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Subgroup or sensitivity analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk with intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants (trials)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test for subgroup differences</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b> Interventions for the diagnosis and prevention of fetalcompromise in labour</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>Continuous cardiotocography (CTG) versus intermittent auscultation (IA) for fetal assessment during labour (<a href="./references#CD012077-bbs2-0002" title="AlfirevicZ , DevaneD , GyteGML . Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD006066.pub2] ">Alfirevic 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>Cerebral palsy at 18 months to 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pregnancy risk status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195 per 1000 (85 to 451)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.54 (95% CI 1.10 to 5.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 1.52, df = 1 (P = 0.22), I² = 34%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mixed or not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20 (95% CI 0.52 to 2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13079 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Onset of labour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 (2 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.74 (95% CI 0.97 to 3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,252 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gestational age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Preterm labour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195 per 1000 (85 to 451)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.54 (95% CI 1.10 to 5.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 1.52, df = 1 (P = 0.22), I² = 34%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both or gestation not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20 (95% CI 0.52 to 2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,079 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of babies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Singleton</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195 per 1000 (85 to 451)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.54 (95% CI 1.10 to 5.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 1.52, df = 1 (P = 0.22), I² =34%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both or not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20 (95% CI 0.52 to 2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,079 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Access to fetal blood sampling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 (2 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.74 (95% CI 0.97 to 3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,252 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both or not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 (2 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.74 (95% CI 0.97 to 3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,252 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20 (95% CI 0.52 to 2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,079 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 1.52, df = 1 (P = 0.22), I² = 34%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195 per 1000 (85 to 451)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.54 (95% CI 1.10 to 5.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b> Interventions for the prevention of preterm birth</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prenatal administration of progesterone versus placebo for preventing preterm birth in women with a previous history spontaneous preterm birth (singletons) (<a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Route of administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (0 to 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.14 (95% CI 0.01 to 3.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Prophylactic antibiotics versus no antibiotics for inhibiting preterm labour with intact membranes (<a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Cerebral palsy at 7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Type of antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta‐lactam antibiotics alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1000 (6 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 1.22 (95% CI 0.41 to 3.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1049 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Chi² = 1.41, df = 2 (P = 0.49), I² = 0.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Macrolide antibiotics alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 per 1000 (7 to 65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 1.42 (95% CI 0.48 to 4.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1073 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Macrolide and beta‐lactam antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 per 1000 (16 to 123)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 2.83 (95% CI 1.02 to 7.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1052 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any macrolide versus no macrolide for inhibiting preterm labour with intact membranes (<a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Any macrolide versus no macrolide antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1000 (21 to 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.90 (95% CI 1.20 to 3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3173 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any beta‐lactam versus no beta‐lactam for inhibiting preterm labour with intact membranes (<a href="./references#CD012077-bbs2-0011" title="FlenadyV , HawleyG , StockOM , KenyonS , BadawiN . Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD000246.pub2] ">Flenady 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Any beta‐lactam versus no beta‐lactam antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000 (20 to 49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.67 (95% CI 1.06 to 2.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3173 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b> Interventions prior to preterm birth for fetal maturation or neuroprotection</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenobarbital versus placebo prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 18 months to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Excluding trials with non‐concealment at randomisation (C quality)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000 (37 to 117)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71 (95% CI 0.40 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin K versus placebo prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0004" title="CrowtherCA , CrosbyDD . Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] ">Crowther 2010</a>) </p> <p>and</p> <p>Phenobarbital versus placebo prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebral palsy at 7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Excluding trials with inadequate concealment of allocation of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000 (26 to 140)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77 (95% CI 0.33 to 1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="20" valign="top"> <p>Magnesium sulphate versus placebo for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="20" valign="top"> <p>Cerebral palsy between 18 and 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>neuroprotective intent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 per 1000 (36 to 59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71 (95% CI 0.55 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4446 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Chi² = 1.69, df = 2 (P = 0.43), I² = 0%</p> <p>(Performed by overview authors)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maternal neuroprotective (pre‐eclampsia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000 (1 to 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.40 (95% CI 0.08 to 2.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1593 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tocolytic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000 (1 to 148)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.13 (95% CI 0.01 to 2.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single or multiple pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 per 1000 (16 to 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.92 (95% CI 0.57 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2321 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 1.28, df = 1 (P = 0.26), I² = 22.1%</p> <p>(Performed by overview authors)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000 (11 to 67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.52 (95% CI 0.21 to 1.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>527 (2 RCTs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gestational age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less than 34 weeks at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 per 1000 (30 to 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.69 (95% CI 0.54 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5357 (5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not applicable (subgroups not exclusive)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less than 30 weeks at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000 (31 to 73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.86 (95% CI 0.56 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1537 (2 RCTs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Loading dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 g (any or no maintenance)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 per 1000 (24 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.79 (95% CI 0.56 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3595 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 1.33, df = 1 (P = 0.25), I² = 24.6%</p> <p><i>(Performed by overview authors)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 g (any or no maintenance)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000 (24 to 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.59 (95% CI 0.40 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2444 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maintenance dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No maintenance (any loading)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113 per 1000 (15 to 879)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.37 (95% CI 0.18 to 10.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>747 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chi² = 0.44, df = 1 (P = 0.51), I² = 0%</p> <p><i>(Performed by overview authors)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any maintenance (any loading)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 per 1000 (23 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68 (95% CI</p> <p>0.51 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5292 (3 RCTs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Loading and maintenance dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loading dose (4 g) and no maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113 per 1000 (15 to 879)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>average RR 1.37 (0.18, 10.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>747 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Chi² = 2.94, df = 3 (P = 0.40), I² = 0%</p> <p><i>(Performed by overview authors)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loading dose (4 g) and lower‐dose maintenance (1 g/hour)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 per 1000 (18 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>average RR 0.81 (95% CI 0.54 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2848 (2 RCTs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loading dose (4 g) and higher‐dose maintenance (2 to 3 g/hour)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000 (1 to 148)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.13 (95% CI 0.01 to 2.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loading dose (6 g) and higher‐dose maintenance (2 to 3 g/hour)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000 (24 to 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.59 (95% CI 0.40 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2444 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Retreatment permitted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000 (24 to 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.59 (95% CI 0.40 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2444 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Chi² = 1.26, df = 2 (P = 0.53), I² = 0%</p> <p><i>(Performed by overview authors)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1000 (24 to 46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.76 (95% CI 0.55 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3536 (3 RCTs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000 (8 to 170)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94 (95% CI 0.20 to 4.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High antenatal corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 per 1000 (35 to 56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67 (95% CI 0.53 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4493 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Studies with lowest risk of bias only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 per 1000 (32 to 56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68 (95% CI 0.52 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3699 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Antenatal corticosteroids versus placebo for accelerating fetal lung maturation for women at risk of preterm birth (<a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Cerebral palsy at 2 to 6 years</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>In babies born from pregnancies complicated by hypertension syndromes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000 (2 to 177)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.28 (95% CI 0.03 to 3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Main decade of recruitment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In babies from trials conducted in 1970s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 per 1000 (7 to 97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95 (95% CI 0.26 to 3.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Chi² = 1.05, df = 2 (P = 0.59), I² = 0%</p> <p>(Performed by overview authors)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In babies from trials conducted in 1980s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 per 1000 (20 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.62 (95% CI 0.28 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406 (1 RCT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In babies from trials conducted in 1990s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 1000 (22 to 149)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.42 (95% CI 0.16 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176 (2 RCTs)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Abbreviations: CI: confidence intervals; RCT: randomised controlled trial; RR: risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Summary of findings: subgroup or sensitivity analyses of select comparisons for cerebral palsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012077-tbl-0008"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Summary of findings: all comparisons measuring cerebral palsy or death</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention and comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions prior to preterm birth for fetalmaturation or neuroprotection</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulphate versus placebo for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or cerebral palsy between 18 months and 2 years (as above under cerebral palsy)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> <p>(583/3093)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177 per 1000 (147 to 211)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 0.94 (95% CI 0.78 to 1.12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6145 (5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: CI: confidence intervals; RCT: randomised controlled trial; RR: risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Summary of findings: all comparisons measuring cerebral palsy or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012077-tbl-0009"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Summary of findings: all comparisons measuring severity of cerebral palsy</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention and comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the treatment of pre‐eclampsia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulphate versus placebo for women with pre‐eclampsia (<a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe cerebral palsy at 18 months (definition: not walking or unlikely to walk unaided by 24 months) </p> <p>(definition taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> <p>(9/1464)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000 (1 to 8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.34 (95% CI 0.09 to 1.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2895 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of attrition bias for this outcome (2895 of 6922 children in original RCT included) </p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions prior to preterm birth for fetalmaturation or neuroprotection</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Magnesium sulphate (neuroprotective intent) versus placebo for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild cerebral palsy at 2 years</p> <p> <ul id="CD012077-list-0048"> <li> <p>1 RCT: definition: walking at 2 years; assessed by developmental paediatrician at 2 years </p> </li> <li> <p>1 RCT: definition: Gross Motor Function Classification System of level 1; assessed by paediatrician or paediatric neurologist at 2 years </p> </li> <li> <p>1 RCT: definition not clear; paediatricians evaluated motor function at 2 years; if examination was not possible, parent telephone interview was used </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> <p>(74/2218)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 per 1000 (17 to 35)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.74 (95% CI 0.52 to 1.04)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4387 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate cerebral palsy at 2 years</p> <p> <ul id="CD012077-list-0049"> <li> <p>1 RCT: definition: not walking at 2 years but likely to do so; assessed by developmental paediatrician at 2 years </p> </li> <li> <p>1 RCT: definition not clear; paediatricians evaluated motor function at 2 years; if examination was not possible, parent telephone interview was used </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> <p>(21/962)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 per 1000 (7 to 28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.66 (95% CI 0.34 to 1.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1943 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe cerebral palsy at 2 years</p> <p> <ul id="CD012077-list-0050"> <li> <p>1 RCT: definition: not walking at 2 years but likely to do so (moderate); not likely to walk (severe); assessed by developmental paediatrician at 2 years </p> </li> <li> <p>1 RCT: definition: Gross Motor Function Classification System level of 2 or 3 (moderate), or level 4 or 5 (severe); assessed by paediatrician or paediatric neurologist at 2 years </p> </li> <li> <p>1 RCT: definition not clear; paediatricians evaluated motor function at 2 years; if examination was not possible, parent telephone interview was used </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> <p>(72/2218)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 per 1000 (14 to 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64 (95% CI 0.44 to 0.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4387 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe cerebral palsy at 2 years</p> <p> <ul id="CD012077-list-0051"> <li> <p>1 RCT: definition: not likely to walk; assessed by developmental paediatrician at 2 years </p> </li> <li> <p>1 RCT: definition not clear; paediatricians evaluated motor function a 2 years; if examination was not possible, parent telephone interview was used </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> <p>(13/962)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 (5 to 25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.82 (95% CI 0.37 to 1.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1943 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: CI: confidence intervals; RCT: randomised controlled trial; RR: risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Summary of findings: all comparisons measuring severity of cerebral palsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012077-tbl-0010"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Summary of findings: all comparisons measuring other composite outcomes that include cerebral palsy as a component</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention and comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants (trials)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the treatment of pre‐eclampsia</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Magnesium sulphate versus placebo for women with pre‐eclampsia (<a href="./references#CD012077-bbs2-0010" title="DuleyL , GülmezogluAM , Henderson‐SmartDJ , ChouD . Magnesium sulphate and other anticonvulsants for women with pre‐eclampsia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD000025.pub2] ">Duley 2010</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurosensory disability at 18 months (definition: functional blindness (binocular visual acuity &lt; 6/60), deafness (severe enough to need a hearing aid), severe cerebral palsy, or DQ &lt; 2 SD below the mean) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> <p>(17/1648)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000 (4 to 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77 (95% CI 0.38 to 1.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3283 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of attrition bias for this outcome (3283 of 6922 children in original RCT included) </p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or neurosensory disability at 18 months (definition as above for 'neursensory disability at 18 months') </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 per 1000</p> <p>(233/1648)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 per 1000 (127 to 177)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06 (95% CI 0.90 to 1.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3283 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of attrition bias for this outcome (3283 of 6922 children in original RCT included) </p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b> Interventions for the prevention of preterm birth</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulphate versus other tocolytic agents for preventing preterm birth in threatened preterm labour (<a href="./references#CD012077-bbs2-0006" title="CrowtherCA , BrownJ , McKinlayCJD , MiddletonP . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD001060.pub2] ">Crowther 2014</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious infant outcome (definition: total perinatal and infant mortality; IVH 3/4 or PVL; cerebral palsy at 18 months; assessment method as above under 'cerebral palsy') </p> <p>(1 RCT included cerebral palsy in composite outcome)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> <p>(3/51)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 per 1000 (41 to 518)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.47 (95% CI 0.69 to 8.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VERY LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of selection, attrition, and reporting bias and high risk of performance bias </p> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b> Interventions prior to preterm birth for fetalmaturation or neuroprotection</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Magnesium sulphate versus placebo for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any neurologic impairment at 18 months or 2 years (definition: any of cerebral palsy, blindness, deafness, or developmental delay or intellectual impairment (DQ or IQ less than 1 SD below the mean)) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 per 1000</p> <p>(200/1421)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 per 1000 (121 to 167)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01 (95% CI 0.86 to 1.19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2848 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major neurological disability at 18 months or 2 years (definition: any of moderate or severe cerebral palsy, blindness, deafness, or an MDI less than 70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 per 1000</p> <p>(91/1421)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 per 1000 (53 to 90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07 (95% CI 0.82 to 1.40)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2848 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐1): wide confidence intervals crossing the line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or any neurologic impairment at 18 months or 2 years (definition as above for 'any neurological impairment') </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348 per 1000</p> <p>(495/1421)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348 per 1000 (317 to 387)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (95% CI 0.91 to 1.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2848 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or major neurological disability at 18 months or 2 years (definition as above for 'major neurological disability') </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272 per 1000</p> <p>(386/1421)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277 per 1000 (244 to 312)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02 (95% CI 0.90 to 1.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2848 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antenatal corticosteroids versus placebo for accelerating fetal lung maturation for women at risk of preterm birth (<a href="./references#CD012077-bbs2-0014" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurodevelopmental delay at 2 years (definition: severe disability: tetraplegic cerebral palsy and/or mental retardation (Bayley's mental index &lt; 70)) </p> <p>(definition taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> <p>(3/32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 per 1000 (13 to 279)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64 (95% CI 0.14 to 2.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VERY LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear allocation concealment</p> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Repeat doses of corticosteroids versus single course for women at risk of preterm birth (<a href="./references#CD012077-bbs2-0007" title="CrowtherCA , McKinlayCJD , MiddletonP , HardingJE . Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD003935.pub4] ">Crowther 2015</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Survival free of any disability 18 months to 2 years, defined as:</p> <p> <ul id="CD012077-list-0052"> <li> <p>1 RCT: definition: survival free of severe, moderate or mild neurosensory disability: severe neurosensory disability defined as severe cerebral palsy (child considered permanently non‐ambulant), severe developmental delay (MDI score, &gt; 3 SD below the mean), or blindness; moderate disability defined as moderate cerebral palsy (child non‐ambulant at 2 years but likely to walk), moderate developmental delay (MDI score, &gt; 2 SD to 3 SD below the mean), or deafness; mild disability defined as either mild cerebral palsy (walking at 2 years) or mild developmental delay (MDI score, &gt; 1 SD to 2 SD below the mean) </p> </li> <li> <p>1 RCT: definition: survival free of neurological impairment (cerebral palsy or cognitive delay (2 SD below the normative value)) </p> </li> </ul> </p> <p>(definitions taken from RCT manuscripts as not clearly detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>773 per 1000</p> <p>(1215/1571)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>781 per 1000 (750 to 812)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01 (95% CI 0.97 to 1.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3155 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Survival free of major neurosensory disability at 2 to 3 years, defined as:</p> <p> <ul id="CD012077-list-0053"> <li> <p>1 RCT: definition: survival being ambulant by 2 years of age and not having blindness, deafness, a developmental index score of more than 2 SD below the mean, or cerebral palsy </p> </li> <li> <p>1 RCT: definition: survival without severe neurodevelopmental impairment (cerebral palsy, MDI &lt; 70, DQ &lt; 70, deafness, or blindness) </p> </li> </ul> </p> <p>(definitions taken from RCT manuscripts as not clearly detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>847 per 1000</p> <p>(572/675)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>856 per 1000 (780 to 941)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 1.01 (95% CI 0.92 to 1.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1317 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of selection bias, attrition bias and high risk of other bias </p> <p>inconsistency (‐1): substantial heterogeneity (I² = 88%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major neurosensory disability at 2 to 3 years, defined as:</p> <p> <ul id="CD012077-list-0054"> <li> <p>1 RCT: definition: severe or moderate neurosensory disability: severe neurosensory disability defined as severe cerebral palsy (child considered permanently non‐ambulant), severe developmental delay (MDI score &gt; 3 SD below the mean), or blindness; moderate disability defined as moderate cerebral palsy (child non‐ambulant at 2 years but likely to walk), moderate developmental delay (MDI score &gt; 2 SD to 3 SD below the mean), or deafness </p> </li> <li> <p>1 RCT: definition: severe neurodevelopmental impairment (cerebral palsy, MDI &lt; 70, DQ &lt; 70, deafness, or blindness) </p> </li> </ul> </p> <p>(definitions taken from RCT manuscripts as not clearly detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 per 1000 (71/643)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 per 1000 (34 to 415)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 1.08 (95% CI 0.31 to 3.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1256 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>study limitations (‐1): 1 RCT with unclear risk of selection bias, attrition bias, and high risk of other bias </p> <p>imprecision (‐1): wide confidence intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability at 2 years, defined as:</p> <p> <ul id="CD012077-list-0055"> <li> <p>1 RCT: definition: severe, moderate, or mild neurosensory disability: severe neurosensory disability defined as severe cerebral palsy (child considered permanently non‐ambulant), severe developmental delay (MDI score &gt; 3 SD below the mean), or blindness; moderate disability defined as moderate cerebral palsy (child non‐ambulant at 2 years but likely to walk), moderate developmental delay (MDI score &gt; 2 SD to 3 SD below the mean), or deafness; mild disability was defined as either mild cerebral palsy (walking at 2 years) or mild developmental delay (MDI score &gt; 1 SD to 2 SD below the mean) </p> </li> </ul> </p> <p>(definition taken from RCT manuscript as not clearly detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361 per 1000 (182/504)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354 per 1000 (300 to 419)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98 (95% CI 0.83 to 1.16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>999 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Composite serious outcome at 18 months to 2 years, defined as:</p> <p> <ul id="CD012077-list-0056"> <li> <p>1 RCT: definition: death or any neurosensory disability: severe, moderate or mild neurosensory disability: severe neurosensory disability defined as severe cerebral palsy (child considered permanently non‐ambulant), severe developmental delay (MDI score &gt; 3 SD below the mean), or blindness; moderate disability defined as moderate cerebral palsy (child non‐ambulant at 2 years but likely to walk), moderate developmental delay (MDI score &gt; 2 SD to 3 SD below the mean), or deafness; mild disability defined as either mild cerebral palsy (walking at 2 years) or mild developmental delay (MDI score &gt; 1 SD to 2 SD below the mean) </p> </li> <li> <p>1 RCT: definition: death or neurologic impairment (cerebral palsy or cognitive delay (cognitive delay was defined as 2 SD below the normative value)) </p> </li> </ul> </p> <p>(definitions taken from RCT manuscripts as not clearly detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 per 1000</p> <p>(356/1571)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224 per 1000 (197 to 254)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99 (95% CI 0.87 to 1.12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3164 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the management of preterm fetalcompromise</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Immediate versus deferred delivery of the preterm baby with suspected fetal compromise (<a href="./references#CD012077-bbs2-0015" title="StockSJ , BrickerL , NormanJE . Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD008968.pub3] ">Stock 2016</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or disability at or after 2 years (definition: cerebral palsy, little or no vision, requirement for hearing aid, or Griffiths DQ of 70 or less) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155 per 1000</p> <p>(44/283)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190 per 1000 (132 to 272)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.22 (95% CI 0.85 to 1.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>573 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study limitations (‐1): 1 RCT at high risk of performance bias and other bias (did not account for non‐independence of data for twin pregnancies) </p> <p>imprecision (‐1): wide intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurodevelopmental impairment at or after 2 years (definition: cerebral palsy, little or no vision, requirement for hearing aid, or Griffiths DQ of 70 or less) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> <p>(12/251)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 per 1000 (41 to 163)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.72 (95% CI 0.86 to 3.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study limitations (‐1): 1 RCT at high risk of performance bias and other bias (did not account for non‐independence of data for twin pregnancies) </p> <p>imprecision (‐1): wide intervals crossing line of no effect</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or severe disability at 6 to 13 years (definition: classified severe blindness, severe deafness, cerebral palsy, or Kaufman Mental Processing Component &lt; 70 points) </p> <p>(definition taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168 per 1000</p> <p>(25/149)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 per 1000 (81 to 235)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.82 (95% CI 0.48 to 1.40)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>302 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study limitations (‐1): 1 RCT at high risk of performance, attrition and other bias</p> <p>imprecision (‐1): wide intervals crossing line of no effect</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: CI: confidence intervals; DQ: developmental quotient; IQ: intelligence quotient; IVH: intraventricular haemorrhage; MDI: mental development index; PVL: periventricular leukomalacia; RCT: randomised controlled trial; RR: risk ratio; SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Summary of findings: all comparisons measuring other composite outcomes that include cerebral palsy as a component</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012077-tbl-0011"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Summary of findings: all comparisons measuring motor dysfunction</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention and comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk with intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants (trials)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of the evidence (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions for the prevention of preterm birth</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prenatal administration of progesterone versus placebo for preventing preterm birth in women with a previous history spontaneous preterm birth (singletons) (<a href="./references#CD012077-bbs2-0008" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Motor impairment at 4 years (definition: overall activity problems or co‐ordination problems) </p> <p>(age and definition taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> <p>(2/82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000 (3 to 92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.64 (95% CI 0.11 to 3.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOW</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; one small RCT with few events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b> Interventions prior to preterm birth for fetal maturation or neuroprotection</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenobarbital versus control prior to preterm birth for preventing neonatal periventricular haemorrhage (<a href="./references#CD012077-bbs2-0005" title="CrowtherCA , CrosbyDD . Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2] ">Crowther 2010a</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other neuromotor impairment at 3 years (definition: tonal abnormalities with no delay in ambulation or other motor milestones) </p> <p>(definition taken from RCT manuscript as not detailed in review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> <p>(4/55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 per 1000 (9 to 254)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67 (95% CI 0.13 to 3.49)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VERY LOW</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study limitations (‐2): 1 RCT with high risk of selection bias, bias due to lack of blinding, and attrition bias </p> <p>imprecision (‐2): wide confidence intervals crossing line of no effect; 1 small RCT with few events </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Magnesium sulphate versus no placebo for women at risk of preterm birth for neuroprotection of the fetus (<a href="./references#CD012077-bbs2-0009" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Substantial gross motor dysfunction between 18 months and 2 years (definition: motor dysfunction such that the child was not walking at age 2 years or later, or the inability to grasp and release a small block with both hands) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> <p>(94/3013)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1000 (14 to 27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61 (95% CI 0.44 to 0.85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5980 (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIGH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or substantial gross motor dysfunction between 18 months and 2 years (definition as above for 'substantial gross motor dysfunction') </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174 per 1000</p> <p>(523/3013)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 per 1000 (130 to 194)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average RR 0.92 (95% CI 0.75 to 1.12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5980 (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MODERATE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>inconsistency (‐1): substantial heterogeneity (I² = 65%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: CI: confidence intervals; RCT: randomised controlled trial; RR: risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Summary of findings: all comparisons measuring motor dysfunction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012077.pub2/full#CD012077-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012077.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012077-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012077-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012077-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD012077-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD012077-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012077-note-0015">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012077\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012077\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012077\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012077\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012077\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012077.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012077.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012077.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012077.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012077.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728165102"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012077.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728165105"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012077.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebdd1bc7af498',t:'MTc0MDcyODE2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 